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General Introduction and Outline of this Thesis
 
In 1905 Ernest Starling used the word “hormone” (derived from the ancient Greek word 
óρμαω, “to set in motion”) for the first time to describe the recently discovered “internal 
chemical messengers that are carried from the organ they are produced to the organ 
they affect by the blood stream” 1. Nowadays we know that hormones are essential for 
the wellbeing of every human being. Moreover, human life would be impossible without 
hormones. 
This thesis focuses on the treatment and long-term effects of two diseases that are 
caused by overproduction of two very important hormones: acromegaly caused by 
growth hormone (GH) overproduction and Cushing’s syndrome (CS) caused by cortisol 
overproduction. In both diseases the pituitary gland plays a key role.
The pituitary gland
Anatomy and function
The pituitary gland (or hypophysis) is an endocrine gland, about the size of a pea and 
approximately 0.6 grams in weight, which is located in the midline of the base of the 
skull 2. It is frequently called “the master gland” as it orchestrates the complex regula-
tory functions of many other endocrine glands.
The pituitary gland (Figure 1) consists of 2 lobes: the anterior pituitary gland (or adeno-
hypophysis) and the posterior pituitary gland (or neurohypophysis). The anterior pitu-
itary gland, which is of endodermal origin, produces six major hormones: 1) prolactin, 
2) GH, 3) adrenocorticotropic hormone (ACTH), 4) luteinizing hormone (LH), 5) folli-
cle-stimulating hormone (FSH), and 6) thyroid-stimulating hormone (TSH). These 
hormones are secreted in a pulsatile manner, in response to specific hypothalamic 
releasing and inhibiting factors and each of these hormones exerts specific responses 
in its peripheral target tissues. The hormonal products of peripheral target glands, in 
turn, have feedback control at the level of the hypothalamus and pituitary gland.
The posterior pituitary gland consists of pituicytes, modified glial cells, and axons whose 
cell bodies are located in the hypothalamus. It stores and releases hormones such as 
antidiuretic hormone (ADH) and oxytocin. 
The pituitary gland lies outside the dura, below the optic chiasm and the hypothalamus 
(Fig 3). It rests in the sella turcica, which is part of the sphenoid bone.
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Figure 1) Anatomy of the pituitary gland. (www.medscape.com)
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Figure 2) Anatomy of structures surrounding the pituitary gland. (www.medscape.com)
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Anteroinferior to the sella turcica lies the sphenoid sinus. Bilateral to the sella turcica 
(thus in the parasellar region) lie the cavernous sinuses (Fig 2). The cavernous sinuses 
are built up by a multi-loculated venous structure containing a part of the internal 
carotid artery, the oculomotor  nerve (cranial nerve III), the trochlear nerve (cranial nerve 
IV), the abducens nerve (cranial nerve VI) and the V1 and V2 branches of the trigeminal 
nerve. Thus, one can imagine that large expanding pituitary tumors may cause signifi-
cant morbidity. 
The blood supply of the pituitary gland originates from the superior and inferior hypoph-
yseal arteries (Figure 1). The hypothalamic-pituitary portal plexus provides the major 
blood source for the anterior pituitary gland, so pulses of hypothalamic hormones can 
directly be transmitted without significant systemic dilution.
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Figure 3)  Anatomy of the normal pituitary gland. 
 (From Williams Textbook of endocrinology, Melmed et al, 2011, Figure 7,2., published with 
 permission from Elsevier) PP, posterior pituitary gland; AP, anterior pituitary gland; oc, optic 
 chiasm; cc, corpus callosum; MB, mammillary body; pc, posterior commissure; ac; anterior 
 commissure.
The somatotropic axis
GH is the most abundant anterior pituitary hormone. It is secreted by somatotroph cells, 
which account for up to 50% of the total anterior pituitary cell population2. GH secre-
tion is controlled by both hypothalamic and peripheral factors (Figure 4). In short, GH is 
secreted under dual hypothalamic control: GH–releasing hormone (GHRH) induces and 
somatostatin suppresses GH secretion. In healthy individuals GH is released in approxi-
mately 10 intermittent pulses per 24 hours, mostly during the night, with GH levels unde-
tectable during most of the day 3. 
A
B
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The peripheral action of GH is mediated via the GH receptor, which is expressed mainly 
in the liver and cartilage. GH induces the production of insulin-like growth factor type-1 
(IGF-1) in the liver. IGF-I directly causes proliferation and inhibition of apoptosis of virtu-
ally all cell types and has negative feedback control on GHRH and GH production. Besides 
GHRH and IGF-1 many other factors have a significant influence on the somatotropic 
axis. For example: secretion of both GH and IGF-1 is influenced by available nutrients: 
GH production increases during fasting and IGF-1 levels are suppressed in malnourished 
patients. Furthermore GH production diminishes during aging and in obesity and IGF-I is 
suppressed in patients with liver disease, hypothyroidism, or poorly controlled diabetes 4 . 
Hypothalamic–pituitary–adrenal (HPA) axis 
ACTH producing cells (corticotropic cells) account for about 20% of the pituitary cell 
population2. Corticotropin-releasing hormone (CRH), which is produced in the hypothal-
amus, is the most important stimulator of ACTH production. ACTH stimulates the adrenal 
glands to produce cortisol. In healthy individuals ACTH secretion has a classic circadian 
rhythm: levels peak early in the morning and reach a nadir at midnight. Furthermore 
cortisol inhibits the synthesis of CRH and ACTH via negative feedback 5. 
Figure 4) The Hypothalamic–pituitary–adrenal axis and somatotropic axis.
 (Adapted from Williams Textbook of endocrinology, Melmed et al, 2011, Figure 8,4., published 
 with permission from Elsevier)
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The major function of the HPA axis is to mediate the neuroendocrine stress response 
and maintain metabolic homeostasis and it has important anti-inflammatory effects 
and catabolic effects to provide substrates for gluconeogenesis. In conditions of stress 
the secretion of CRH and thus also of cortisol are stimulated. The peripheral actions of 
cortisol are mediated via glucocorticoid receptors (GR) and mineralocorticoid receptors 
(MR). GRs are ubiquitously expressed, but MRs are expressed only in selected tissues 6. 
Disorders of the pituitary gland 
Disorders of the pituitary gland have 3 classical manifestations: 1) symptoms related 
with pituitary insufficiency, 2) symptoms related with hormonal excess, and 3) symp-
toms associated with mass effects of the pituitary lesion. Although especially pituitary 
insufficiency can have multiple causes (for example genetic or congenital disorders, 
infiltrative diseases, infection, trauma, surgery or irradiation7) all three manifestations 
of pituitary gland disorders are most frequently caused by a pituitary tumor. 
Pathological processes arising from both the gland itself or from the surrounding struc-
tures are relatively common, but often asymptomatic. In adults who undergo cranial 
imaging studies for reasons other than suspected pituitary disease, an unsuspected 
pituitary lesion (a so called incidentaloma) can be found on CT-scans in 4–20% of all 
patients and on MRI-scans in 10–38% of all patients 8. During autopsy an unsuspected 
pituitary adenoma is found in >10%. Indeed, pituitary adenomas, which are benign 
neoplasms that arise from adenohypophysial cells 2, are by far the most prevalent pitu-
itary lesions (± 85% of all pituitary lesions9) and they account for 6-10% of all symptom-
atic intracranial tumors10. Pituitary adenomas are classified according to size: they are 
called a microadenoma if they are < 10 mm in diameter and a macroadenoma if they are 
≥ 10 mm in diameter9. Although they are benign they can invade surrounding structures 
relatively easily. Pituitary carcinomas are rare. About one third of all pituitary adenomas 
are clinically non-functioning and do not cause a clinically distinct hypersecretory 
syndrome 2. The majority of these adenomas arise from gonadotroph cells. All other 
types of pituitary adenomas can produce one or more pituitary hormones that cause 
clinical signs and symptoms of hormonal excess. The most common hormone producing 
adenoma is the prolacting (PRL)-producing adenoma (or prolactinoma) that arises from 
lactotroph cells. TSH-producing adenomas are rare. GH-producing adenomas (which 
arise from somatotroph cells and cause acromegaly) and ACTH-producing adenomas 
(which arise from corticotroph cells and cause Cushing’s syndrome) account for 10-15 % 
of all adenomas each 2. 
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Adenomas of the adenohypophysis are monoclonal neoplasms, which suggests that 
somatic mutations precede clonal expansion11. However pituitary adenomas rarely occur 
in the setting of hereditary syndromes (like multiple endocrine neoplasia type 1 and 
Carney’s complex) or as familial isolated pituitary adenomas (FIPAs). More than 95% of pitu-
itary adenomas are sporadic, meaning there is no family history of pituitary adenomas 11. 
Over the past decade, due to technical advances in genetic research, a number of muta-
tions that are associated with pituitary adenomas have been found. For example germline 
mutations in the aryl-hydrocarbon receptor-interacting protein (AIP, a tumor suppressor 
gene that acts via the cAMP pathway) have been identified in 20% of FIPA families. 
Germline AIP mutations have also been found in 8-18% of selected seemingly sporadic 
cases of young adults with macroadenomas or gigantism11. Microduplication on chromo-
some Xq26.3 has been found in a number of children with GH secreting macroadenomas, 
causing X-linked acrogigantism 12,13. Furthermore somatic mutations in the ubiquitin-spe-
cific protease USP8 gene have been found in 36% of patients with an ACTH-producing 
adenoma 14,15. Although much progress has been made in the understanding of the patho-
physiology of pituitary adenomas, many factors still need to be elucidated. 
Acromegaly
Acromegaly is the rare clinical syndrome (incidence of 3-4 cases/1 million people/year, 
prevalence of 60 per million) that is caused by prolonged exposure to excessive amounts 
of GH 3. The GH excess causes proliferation of many tissues including connective tissue, 
cartilage and bone. This causes characteristic changes of the face (e.g frontal bossing, 
mandibular prognatism, hypertrophy of the tongue, lower lip and nose) and enlargement 
of the hands and feet (the acra). Furthermore, if the GH excess is already present in 
childhood or adolescence, before the closure of the epiphyseal growth plates, it causes 
gigantism. The term “acromegaly” (from ancient Greek: ακροσ = extremity and µεγαλοσ 
= large) was used for the first time in 1886 by the French neurologist Dr. Pierre Marie, 
although he was not the first to give an accurate clinical description of this disease. 
Most people without a medical training will probably never have heard of the term “acro-
megaly”, but everybody will, at least unconsciously, know certain cases. Especially 
acromegalic giants have been famous since ancient times: Goliath probably suffered 
from acromegaly, as did the Egyptian Pharaoh Akhenaten (± 1358 BC, Fig. 5). During the 
17th century giants were recruited for the Prussian army for the “Potsdammer Riesen-
garde” (2 battalions of 600 men each!, Fig. 6) and as bodyguards for the king of England, 
solely because of their height. From the 18th century until the Second World War it was 
common that people with physical abnormalities were used as show objects in circus 
shows and expositions and giants were a popular attraction 16,17. Even nowadays, people 
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who suffer(ed) from acromegaly can still become very popular because of their appear-
ance: nearly everybody knows the famous actors Carel Struyken (“Lurch” in the “Adams 
Family”, Fig. 7) and Richard Kiel (“Jaws” in the “James Bond” series, Fig. 8).
Besides the typical changes in appearance, acromegaly also influences many other 
organ systems. At diagnosis the majority of the patients have arthropathy, with joint 
complaints in up to 70% of patients 18. This may cause major functional disability. Many 
patients have respiratory dysfunction due to soft tissue swelling, with obstructive 
sleep apnea syndrome (OSAS) documented in more than 50% of patients at diagnosis. 
Furthermore the excess amount of GH can cause growth of many organs including the 
heart, resulting in major structural and functional alterations. This may cause arrhyth-
mias, cardiac valve disease and myocardial hypertrophy, which may eventually result in 
congestive heart failure. Furthermore GH has many metabolic effects which may result 
in overt diabetes mellitus (DM, present in 10-25% of all patients at diagnosis), hyperten-
sion (present in 25-35% of all patients at diagnosis) and dyslipidaemia 19. Thus, it is not 
Figure 5) Statue of the Egyptian Pharaoh Akhenaten.
Figure 6) Drawing of the “Potsdammer Riesengarde”.
Figure 7) Carel Struyken as “Lurch” in the “Adams Family”.
Figure 8) Richard Kiel as “Jaws” in the “James Bond”series.
5
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surprising that acromegaly is associated with a markedly decreased quality of life (QoL) 
20-22 and an increased overall mortality rate, with an overall standardized mortality rate 
of more than 3.0 in inadequately treated patients 23,24, mainly because of cardiovascular 
disease.
Acromegaly is caused by a GH secreting pituitary adenoma (of which 25% co-secrete 
PRL) in nearly all cases. Mean age at diagnosis is 45 years and males and females seem 
to be affected equally 25. Overall, younger patients have more aggressive tumors that 
secrete higher amounts of GH. Because the signs and symptoms of acromegaly develop 
insidiously there is often a delay in diagnosis for up to 10 years. At diagnosis more than 
70% of all GH secreting adenomas are macrodenomas. Acromegaly is rarely caused by a 
pituitary carcinoma, a hypothalamic tumor secreting GHRH or ectopic GH or GHRH secre-
tion from a neuroendocrine tumor 3.
Cushing’s syndrome
Cushing’s syndrome (CS) is caused by prolonged exposure to supraphysiological levels 
of glucocorticoids. Although iatrogenic CS, caused by the use of exogenous gluco-
corticoids, is quite common, endogenous CS, like acromegaly, is a rare disorder with a 
reported incidence of 2-3 cases per 1.000.000 people per year 26. CS is named after the 
American neurosurgeon Harvey Cushing. Cushing’s life-long interest in CS was triggered 
by his encounter in 1910 with a patient who has become known as Minnie G (Fig 9.) 27,28. 
Twenty-two years later Cushing published his seminal report “The basophil adenomas 
of the pituitary gland and their clinical manifestations (pituitary basophilism)”. In this 
classic work, he reported in detail the cases of 12 patients with CS, resulting in a descrip-
tion of CS that has not yet been improved upon. He believed that an abnormality in the 
pituitary gland was the cause of the syndrome.
Unlike in acromegaly, none of the signs and symptoms of CS is pathognomonic. Common 
symptoms of CS are weight gain (the most common symptom, present in 95% of all 
patients) fatigue, depression, insomnia, irritability, decreased memory and concentra-
tion, decreased libido, menstrual irregularities and back pain. However, these symp-
toms are also common in the general population and are not very discriminatory. The 
same accounts for common signs of CS: obesity (mostly centripetal), a dorsocervical 
fat pad (the so called buffalo hump), supraclavicular fat pads, facial fullness (or moon 
face), peripheral edema, acne, hirsutism or balding in females, a thin skin and poor skin 
healing, hypertension (present in up to 90% of all patients!), DM (present in up to 50%), 
dyslipidaemia, osteoporosis, hypokalemia, kidney stones and recurrent infections 26, 29. 
Many of these symptoms and signs are also present in people with morbid obesity or 
1)  Introduction
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the metabolic syndrome 30, conditions that are very common in our present society 
where bad eating habits and a sedentary lifestyle are the norm. Signs that are more 
discriminatory for CS (thus having a higher sensitivity) are peripheral muscle atrophy or 
muscle weakness, easy bruising, striae (especially when reddish/purple in color and > 1 
cm wide), facial plethora and, in children, weight gain with decreasing growth velocity 26. 
When CS is full blown, the diagnosis is straightforward. However, because none of the 
signs and symptoms are pathognomonic the diagnosis may be very challenging in milder 
cases. This often causes a delay in diagnosis. This delay is problematic since CS causes 
a significantly impaired quality of life 20, 31-33 and, in untreated cases, the 5-year survival 
has been reported to be as low as 50% 24, 34, 35. Cardiovascular disease is the major cause 
of mortality. 
CS can be either ACTH dependent, with high levels of plasma ACTH that stimulate the 
adrenal glands to secrete excessive amounts of cortisol, or ACTH independent, with 
excessive autonomous production of cortisol by abnormal adrenocortical tissue which 
suppresses CRH and ACTH secretion. ACTH dependent causes of CS account for 80-85% 
of all cases of endogenous CS. An ACTH secreting pituitary adenoma (also called 
Figure 9) Harvey Cushing and “Minnie G.”
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Cushing’s disease (CD), usually caused by a microadenoma) is the cause of CS in 80% of 
the patients with ACTH dependent CS. In the remaining 20% an ectopic ACTH secreting 
tumour (frequently a neuroendocrine tumor of the lung) is the cause. ACTH indepen-
dent CS is most frequently caused by a unilateral adrenal tumour, which is a benign 
adenoma in 60% of the cases and a carcinoma in 40% of the cases 36. Both CD and 
cortisol producing adrenal adenomas are more frequently present in women (male to 
female ratio 1:3). Mean age at diagnosis is 40 years 34.
 
PART I
Treatment of acromegaly and Cushing’s disease by 
transsphenoidal surgery
Up till now transsphenoidal surgery (TS) of the pituitary gland is the treatment of choice 
for virtually all patients with acromegaly and CD 37-40.
The transsphenoidal route to access the brain leads through the sphenoid sinus (either 
via the nose or upper lip) within the constraints of nasal/sinus anatomy, which provides 
a narrow but relatively noninvasive corridor to the skull base and has been known since 
ancient times. Egyptian embalmers used this route during the mummification process 
to remove the brain without disfiguring the face and head 41. 
Until the end of the 19th century the transsphenoidal route was not used. At that time 
pituitary tumors were already recognized, but were considered rare and the function 
of the pituitary gland was still completely unknown (although it had been noticed that 
patients with acromegaly almost always had an enlarged sella). Attempts to remove 
pituitary tumors had been made, but were always performed transcranially 42. 
The transsphenoidal route to access the sella turcica was rediscovered by Giordano 
during anatomical studies with cadavers at the end of the 19th century. At the begin-
ning of the 20th century a number of European and American investigators, including 
Schloffer (who performed the first transsphenoidal operation on a large pituitary tumor 
in 1906) and Harvey Cushing, found that TS was feasible in living patients and it was 
successfully performed in a few patients with nonfunctional macroadenomas or acro-
megaly (which ended the long debate about the etiology of acromegaly 42). However, at 
that time the illumination of the operating field during TS was inadequate and the risk of 
meningitis was high since there were no antibiotics, so nearly all neurosurgeons aban-
doned the transsphenoidal route in favor of the transcranial route. Pituitary surgery 
was restricted for patients with mass effect of the pituitary tumor who needed decom-
1)  Introduction
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pression. Patients with acromegaly without mass effects were treated with radiation 
therapy or sometimes with medical therapy 43.
It took until the second half of the 1950s before the French neurosurgeon Guiot intro-
duced the use of intraoperative fluoroscopy and reinstated TS as an important thera-
peutic option for patients with pituitary tumors. When Jules Hardy (a Canadian neuro-
surgeon who learned TS from Guiot) added the use of the operating microscope, which 
provided state of the art optics in combination with a binocular vision 44, in 1963, TS with 
the aid of a microscope became the gold standard for pituitary surgery. 
Because of the excellent visualization of the pituitary gland with the microscope Hardy 
could recognize adenomas within the pituitary gland, enabling him to perform a selec-
tive adenomectomy.
At that time there was still uncertainty about the etiology of CD although a pituitary 
origin had been suggested several times (first by Harvey Cushing). This was due to a 
number of reasons: many patients with adrenal tumors had similar symptoms, the 
first attempts to attack the pituitary gland in patients with CD (either with transcranial 
surgery or with radioactive seeds) had been unsuccessful and because patients with 
CD usually have a microadenoma, they often did not have an enlarged sella and/or pitu-
itary gland. Hardy finally proved that CS could be caused by a pituitary adenoma when he 
successfully performed a selective adenomectomy in a patient with CD in 1963 45. This 
was in fact the first time TS was performed in a patient with CD. However, bilateral adre-
nalectomy remained the treatment of choice for CD until the first successful series on 
TS in CD had been published in the 1980s. Thereafter microscopic TS became the primary 
treatment option for CD.
In the 1990s a major change was introduced in the field of TS: the purely endoscopic 
technique of TS (that is, using the endoscope as the only visualizing tool) was intro-
duced as an alternative to the microscopic technique thanks to the collaboration 
between neurological and otorhinolaryngological surgeons 46. Although many groups 
were experimenting with the endoscopic technique of TS, Jho and Carrau, a neurosur-
geon and otorhinolaryngologist of the University of Pittsburgh School of Medicine, are 
widely recognized as the pioneers of the purely endoscopic endonasal approach for the 
treatment of pituitary adenomas. They were the first to report upon the results of endo-
scopic TS in a series of 50 patients with pituitary adenomas in 1997 47. Thereafter Cappa-
bianca and de Divitiis, from Naples, reported on their experience with the endoscopic 
technique 48 and they made major contributions to the technique by developing dedi-
cated endoscopic instrumentation and suggesting technical improvements. From then 
onwards many neurosurgeons have adopted the procedure (Figure 10).
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The endoscopic technique of TS has theoretical advantages and disadvantages 
compared to the microscopic technique of TS. Advantages are the panoramic view with 
increased illumination of the operating field and the possibility to use different angles 
making it possible to reach the suprasellar and parasellar regions. Disadvantages are 
the two-dimensional view and the easy clouding of the lens in case of bleeding 49, 50. 
Since the introduction of the endoscopic technique of TS a vivid discussion has arisen 
about which technique should be the technique of choice for TS: the endoscopic or the 
traditional microscopic technique of TS. Important factors to take into account to answer 
this question are the abilities of the technique to achieve: 1) the primary objective of 
the surgery (in the case of pituitary adenomas: gross tumor resection in non-func-
tional adenomas and remission of the hormonal syndrome in functioning adenomas), 
2) patient safety, 3) patient comfort and, 4) cost-effectiveness. However, because both 
acromegaly and CD are rare diseases it is difficult to adequately answer these ques-
tions and it is crucial that results of both microscopic and endoscopic TS are reported 
systematically. 
Our center introduced the endoscopic technique of TS in 1998 and entirely switched to 
this technique within a year. Thus our center was among the first centers in the world 
that adopted the endoscopic technique of TS and the first center in the Netherlands. 
Over the years we have gained a lot of experience with the endoscopic technique of TS 
but so far results had not been analyzed adequately.
The first aim of this thesis is to gain more insight in the role of endoscopic TS for the 
treatment of both acromegaly and CD. To do so we systematically analyzed the results 
of endoscopic TS in our hospital in patients with acromegaly and CD (Part 1 of this thesis). 
Figure 10) Endoscopic transsphenoidal pituitary surgery in the Radboud university 
 medical center, Nijmegen, the Netherlands. 
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In chapter 2 we describe the outcome of endoscopic TS (as the primary treatment 
modality for acromegaly) in 40 patients with acromegaly caused by a macroadenoma 
treated in our hospital between 1998 and 2007. 
In chapter 3 we evaluate the results of endoscopic TS (as the primary treatment) in 86 
patients with CD treated in our hospital between 1998 and 2011. Furthermore, we evalu-
ated the recurrence rates after initial remission.
In chapter 4 we report on the results of repeated endoscopic TS in 14 patients with 
persistent or recurrent CD after an initial TS treated at our hospital between 1998 and 2007. 
Other treatment modalities in acromegaly and Cushing’s syndrome
Acromegaly
Medical therapy
Three forms of medical therapy are currently used to treat patients with acromegaly: 
1) somatostatin receptor ligands (SRL, octreotide and lanreotide), 2) dopamine agonists 
(DA, cabergoline) and 3) GH receptor antagonists (GHRA, pegvisomant). Both SRL and 
DA target the pituitary adenoma itself and reduce GH secretion. GHRA are directed at 
blocking GH effects in the periphery 38. 
Long-term studies have shown that SRL can lower GH values to < 2.5 ng/ml and can 
normalize IGF-1 in up to 70% of all patients 37. However, these studies have been 
performed in preselected patient groups. In unselected patients with acromegaly, acro-
megaly will be controlled with SRLs only in approximately 25% 38. However, shrinkage 
of the adenoma (of > 20%) occurs in 75% of the patients with acromegaly treated with 
SRLs and these drugs have proven to be safe on the longterm. However the costs asso-
ciated with the use of SRLs are high 51: in the Netherlands lanreotide-autosolution 60 mg 
each 28 days costs about €12,000 annually and Sandostatin LAR 20 mg each 28 days 
costs about € 15,000 annually (Farmacotherapeutisch Kompas, 2015).
Cabergoline is the DA that is most effective for treatment of acromegaly, but mono-
therapy with this drug controls acromegaly in less than 10% of patients. The best 
response can be expected in patients with mildly elevated IGF-1 levels. However, it is 
a safe drug and far cheaper than SRLs and the GHRA pegvisomant, amounting only 
€ 1000 a year.
The GHRA pegvisomant (which has been approved by the USA Food and Drug Administra-
tion (FDA) since 2003) is very effective in normalizing IGF-1 levels, provided that a suffi-
ciently high dosage is given, and the medication is well tolerated. Normalisation of IGF-1 
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can be achieved in virtually all patients treated with GHRA. The first long-term safety 
reports are reassuring, showing a low incidence of adverse effects such as increase in 
pituitary tumor size, elevations of liver enzymes, and lipodystrophy at the injection site 52. 
Pegvisomant is by far the most costly medication used for treatment of acromegaly 
51: in the Netherlands treatment with 20 mg/day has an annual cost of approximately 
€ 55.000,-.
Because medical therapy cannot cure acromegaly and therefore requires life-long use 
of costly medication the current recommendation is to restrict primary medical therapy 
to patients in whom surgery is not feasible (e.g. because of comorbidities or refusal by 
the patient) or if surgical cure is not possible to achieve because of extensive growth 
of the tumor. For all other patients it is considered a second-line therapy. SRLs are the 
medical treatment of choice. If the response on SRL monotherapy is inadequate, pegvi-
somant and/or cabergoline can be added. If there is no response to a SRL, pegvisomant 
monotherapy is an option as well 38. Pretreatment with SRL for 3-6 months before TS 
with the aim to reduce the size of the adenoma and improve the condition of the patient 
should be considered 53. 
Radiation therapy (RT) 
The general consensus is that RT, which was the primary therapy for acromegaly before 
the 1960s, is nowadays the third-line treatment, i.e. when TS and medical therapy have 
failed 37. This is mainly because of limited effectiveness and safety issues.
Conventional fractionated RT can achieve remission of acromegaly in over 60% of 
patients, but its usefulness is limited by the delay between therapy and disease control, 
with a median time to complete remission between 6 and 10 years. More recently 
stereotactic RT has been introduced. In stereotactic RT a higher dosage of RT is given in 
usually a single dosage on a smaller area. This limits its value for larger adenomas that 
cannot be safely separated from surrounding normal radiosensitive tissues. Remis-
sion of acromegaly (usually after surgical debulking) can be achieved in approximately 
50% of all patients with stereotactic RT and median time to remission is 3-10 years 54. 
Control of tumor growth is excellent (>90%) with both stereotactic and conventional RT. 
However, hypopituitarism is observed in over 50% of patients 5–10 years after RT for 
acromegaly. There seems to be no difference between stereotactic and conventional 
RT in this respect. There is also a small risk of damage of the optic nerves, especially 
with stereotactic RT. After conventional RT there may be a small increased risk of devel-
oping secondary tumors or cerebrovascular events due to radiation vasculopathy, but 
results are conflicting 37, 54-56. 
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Cushing’s disease/syndrome
When CS is caused by an adrenal adenoma the therapy of choice is unilateral adrenalec-
tomy, which results in remission in virtually all cases.
In case of CD, the recommended second-line therapy, after TS has been unsuccessful 
(and if a repeated TS is not feasible or has also failed) is either bilateral adrenalectomy 
or RT. The choice should be made taking into account the wishes of the patient, the 
function of the pituitary gland after TS and whether a patient tolerates medical therapy, 
which will be necessary in case of RT. 
Billateral adrenalectomy (ADX)
Traditionally, open procedures of adrenalectomy were associated with considerable 
morbidity and mortality. Nowadays the minimally invasive laparoscopic approach, which 
has reduced perioperative morbidity significantly, is the technique of choice. The major 
advantage of a bilateral ADX is that hypercortisolism is permanently cured in virtually 
all cases 57. However, adrenalectomized patients require life-long substitution of gluco-
corticoids and mineralocorticoids, with the permanent risk of an adrenal crisis. A severe 
complication of bilateral ADX, which develops in approximately 20% of all patients, is 
Nelson’s syndrome: an expanding invasive macroadenoma of the pituitary gland as a 
consequence of the lack of glucocorticoid feedback to control adenoma cells 58.
Radiotherapy
Radiotherapy in CD has the same advantages and disadvantages as in acromegaly 
(see above), although hypopituitarism may be more prevalent in CD in the long-term. 
Remission rates after conventional fractionated radiation therapy for CD range from 
56% to 84% 59, 60. The median time to remission ranges between 18 and 42 months 54. 
The benefit of stereotactic RT seems to be a faster biochemical response to treatment 
with a median time to remission between 7.5 and 33 months 54. However, the remission 
rates after stereotactic RT are still unclear. Recent literature of stereotactic RT series 
suggests that they lie between 35 and 80% 54.
Medical therapy
Various types of medication can be used for the treatment of CS: 1) Adrenal directed 
therapy. With steroidogenesis inhibitors (metyrapone, ketoconazole or mitotane). These 
drugs are all reasonably effective, and normalize urinary cortisol values in 70-80%, but 
they have major side effects and toxicity and availability is not always guaranteed 40. 
2) Pituitary targeted therapy including SRL (pasireotide) and dopamine agonists (caber-
goline). Although these drugs are generally well tolerated, they only normalize cortisol 
excretion in 15-30% of patients 40, 61. 3) The glucocorticoid receptor antagonist mifepri-
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stone, which has recently been approved for CS by the FDA, induces significant clinical 
and metabolic improvement in patients with CS 62, 63. However, as cortisol values rise 
during therapy it is unclear how one should assess adequate response and long-term 
safety still needs to be determined. 
So unfortunately, in contrast to acromegaly, no drug that is currently available for the 
treatment of CS is both effective and well tolerated on the long-term. Furthermore, 
there is a lack of high-quality studies on medical therapy for CS 64. Therefore currently, 
medical therapy in CS still has only an adjunctive role 61. It can be prescribed to control 
severe hypercortisolism and improve the general condition of the patient prior to TS or 
when radiotherapy has not yet reached its full effect, and in the occasional patients 
that are not fit for or refuse other treatment modalities 61. 
PART 2
Long-term Quality of Life after treatment of acromegaly 
and Cushing’s syndrome
Over the past decade the interest in QoL of patients with pituitary adenomas has expo-
nentially increased 65. General health related questionnaires that had been developed 
for other patient categories, showed that QoL is decreased in all patients with (both 
functional and nonfunctional) pituitary adenomas 32, 65. To adequately measure QoL 
in a specific patient group it is recommended that a general health questionnaire is 
used in combination with a disease-specific questionnaire 65. To gain further insight in 
the specific problems in patients with different types of adenomas, disease-specific 
health questionaires have been developed like the ACROQoL for acromegaly 22, 66, the 
CushingQoL and the Tuebingen CD-25 for CS 33, 67.
Meanwhile a multitude of studies have investigated QoL after successful treatment 
of pituitary adenomas. All patient groups seem to have a decreased QoL compared to 
healthy matched control subjects 65, 68. Patients that have successfully been treated 
for a non-functional pituitary adenoma perform best: the total patient group has a 
slightly impaired QoL 68, 69, but if comorbidities or hormonal deficiencies are adequately 
controlled it may be possible to achieve a normal or near normal QoL 70. Even though QoL 
significantly improves after remission, patients in long-term remission of CD and acro-
megaly generally have a more impaired QoL than patients treated for other pituitary 
adenomas 65, 70, 71. 
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In order to understand why QoL remains more impaired in patients in long-term remis-
sion of CS and acromegaly compared to patients adequately treated for other pituitary 
adenomas, it is essential to determine which patient or disease-specific characteristics 
negatively influence QoL. 
Therefore, the second aim of this thesis is to get more insight in patient — or 
disease-specific — characteristics that negatively influence QoL in patients in long-
term remission of CS and acromegaly (Part 2 of this thesis). 
Acromegaly
In patients in remission of acromegaly, the following factors have been found to nega-
tively influence the QoL: the use of SRLs 72, previous treatment with radiotherapy 73, 74, 
persisting joint complaints or musculoskeletal pain 18, presence of clinical osteoarthritis 
75 and presence of deficiency of growth hormone 76 but not of other pituitary hormones. 
Furthermore, as can be expected, most studies reported the negative effect on QoL of 
female gender and older age. 
Because changes in appearance are highly prevalent in acromegaly and seem to persist, 
at least partially, after long-term remission, it is likely that this will also have a negative 
influence on QoL. However, this has not been adequately investigated, despite the fact 
that the appearance subscale was the most affected subscale in studies that used 
the AcroQoL to investigate QoL. Moreover, patients in remission of acromegaly had only 
slightly better results on this subscale than patients with active disease 21, 22, 77-79. 
In chapter 5 we investigate whether patients in long-term remission of acromegaly 
suffer from more psychological distress and psychological and social dysfunctioning 
related to self-consciousness of appearance than a gender-, age- and bosy mass index 
(BMI)-matched control group, and whether this negatively affects QoL. To do so, we 
use the Derriford appearance scale 59 (DAS59), which is a psychological questionnaire 
developed for research in plastic surgery and oncology. It also identifies the anatom-
ical source of self-consciousness. This questionnaire has not been used previously in 
patients with acromegaly.
Cushing’s syndrome
In patients in remission of CS, a number of studies reported that QoL remains impaired 
after treatment 31, 68, 80-87. However most of these studies have major limitations and/or 
only investigated QoL in patients in remission of CD. The presence of hypopituitarism, 
female gender, older age and glucocorticoid deficiency seemed to negatively influence 
QoL . Furthermore, it has been suggested that a persisting effect of the previous period 
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of hypercortisolism might negatively influence QoL but this has never been adequately 
investigated.
In chapter 6 we report on the QoL of 123 patients in long-term remission of CS, compared 
to a sex- and age-matched healthy control group. We also investigate the influence of 
the aetiology of CS, the treatment strategy and coexisting hormonal deficiencies on QoL.
PART 3
Long-term physical sequelae after treatment of acromegaly 
and Cushing’s syndrome
As stated before, both acromegaly and CS have a great impact on the physical health of 
patients. If the signs and symptoms of the disease are not totally reversible after remis-
sion, this will most likely have a negative impact on QoL. 
The third aim of this thesis is to gain more insight in the long term effects of the 
previous period of growth hormone or cortisol hypersecretion on physical health of 
patients in long-term remission (Part 3 of this thesis). 
Acromegaly
Because acromegaly is a rare disease, only little is known about the long-term physical 
consequences of the previous period of GH hypersecretion in patients in remission 88. In 
the few studies that have been performed, most patients received medical therapy to 
control disease, so no conclusions can be made about patients that are really in remis-
sion of acromegaly. Furthermore, the studies that were performed had limitations, such 
as the lack of a control group or a very small sample size. Therefore, up to date, very little 
is known about the long-term physical effects of a longstanding period of GH excess in 
patients that are cured. 
In general, the previous studies indicate that, by adequately controlling GH and IGF-1 
levels, glucose-related metabolic abnormalities seem to improve and may even nor- 
malize 19 (although this may not account for the long-term 89), lipid abnormalities seem to 
improve 88, 90, OSAS seems to be at least partially reversible 91, 92, cardiovascular disease 
(hallmarked by left ventricular dysfunction) improves 19, 93 and even arthropathy may 
be partially reversible 94. However it is still unclear to what extent these abnormalities 
recover. 
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As stated before, craniofacial disproportions are highly prevalent in patients with active 
acromegaly and they affect QoL. However no study has investigated to what extent the 
craniofacial disproportions persist after long-term remission. In the past decade ceph-
alometry using 3D imaging technology has rapidly evolved 95. Because 3D cephalometry 
is much more accurate than traditional techniques to perform cephalometry, it offers 
new opportunities to accurately quantify craniofacial disproportions in patients with 
acromegaly. 
In chapter 7 we evaluate the differences in craniofacial dimensions of soft and bony 
tissues between patients in long-term remission of acromegaly and control subjects 
matched for gender, age, BMI and ethnicity, using 3D cephalometry and 3D image fusion 
head models.
Cushing’s syndrome
Over the past few years a number of groups started to investigate the long-term phys-
ical effects of the previous period of hypercortisolism in patients in remission of CS 34, 
96. Most studies have only focused on the long term effects of CS on the brain. They all 
found that structural abnormalities, like a smaller hippocampal volume and enlarged 
ventricles, persist even after long-term remission 96. 
As previously stated, active CS is hallmarked by centripetal obesity and an increased 
cardiovascular risk. Only a limited amount of research has been performed to investi-
gate if these changes persist after long-term remission of CS. 
Centripetal obesity, with excess visceral adipose tissue (VAT), causes a state of systemic 
low-grade inflammation 97-99. This process is triggered when macrophages infiltrate the 
VAT in response to microhypoxia and rupturing of adipocytes. As a result the secretion of 
adipocytokines by the VAT changes, leading to an adverse adipocytokine profile, which 
is associated with insulin resistance, endothelial dysfunction and eventually macro-
vascular cardiovascular disease. A small number of studies investigated if centrip-
etal obesity and systemic low-grade inflammation persist after remission of CS 100-103. 
However, these studies have methodological limitations (e.g. small numbers of patients, 
patients with untreated hormonal deficiencies included, patients included shortly after 
remission), and the results are conflicting. 
In chapter 8 we investigate the adipose tissue distribution and adipocytokine profiles of 
patients in long-term remission of CS, and compared the results with a healthy gender-, 
age- and BMI-matched control group.
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Only a small number of studies have previously investigated vascular health during 
remission of CS, using different (surrogate) markers of vascular function 101, 104-109 and 
these studies report contradicting results. Vascular health may theoretically be 
affected in patients in long-term remission of CS by two different mechanisms: 1) 
through persisting centripetal obesity or comorbidities like impaired glucose tolerance, 
systemic hypertension and dyslipidaemia or 2) via a persisting effect of the previous 
period of hypercortisolism itself on vascular health 6, 110. 
In chapter 9 we investigate whether micro- and macrovascular health is impaired in 
a well-selected group of patients in long-term remission of CS compared to healthy 
matched controls. To do so we use a broad spectrum of techniques: we measured serum 
biomarkers associated with endothelial dysfunction, performe gold standard measure-
ments of endothelial function and investigate the presence of overt atherosclerosis.
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Abstract
Objective: Transsphenoidal pituitary surgery (TS) is the primary treatment of choice 
for patients with acromegaly. Macroadenomas (>1 cm) are more difficult to resect than 
microadenomas (remission rate ± 50% compared to ± 90%). Besides the conven-
tional microscopic TS, the more recently introduced endoscopic technique is nowa-
days frequently used. However, no large series reporting on its results have yet been 
published. We evaluated the outcome of endoscopic TS in 40 patients with a growth 
hormone (GH) secreting macroadenoma, treated in our hospital between 1998 and 2007.
Methods: Medical records were retrospectively reviewed. Remission was defined as 
disappearance of clinical symptoms of acromegaly, normal serum Insulin-like Growth 
Factor 1 levels (≤2 SD) and serum GH levels suppressed to < 2 mU/L after an oral glucose 
tolerance test within the first 4 months after TS.
Results: In four patients TS aimed at debulking of the tumor. In the remaining 36 patients, 
remission was achieved in 20 patients. In the first five years remission was achieved in 6 
out of 18 patients (33%) compared to 14 out of 22 patients (63%) in the following 5 years 
(p=0.06). Thirteen patients had a mild perioperative complication. Before TS 15 patients 
received hormonal substitution therapy compared to 12 patients (33%) after TS. 
Conclusion: Endoscopic TS is a good primary therapeutic option for patients with a GH 
secreting macroadenoma, resulting in a remission rate of up to 63% in experienced 
hands. This technique can potentially improve the outcome of TS in these patients.
2)  Endoscopic transsphenoidal surgery in acromegaly
2
41
Introduction
Untreated acromegaly causes significant morbidity, and is associated with a two- to 
threefold increase in mortality. When acromegaly is treated successfully and “safe” 
growth hormone (GH) and Insulin Growth Factor 1 (IGF-1) values are achieved, the mortality 
rate normalises 32. Therefore, appropriate treatment of acromegaly is crucial. However, 
symptoms and signs of acromegaly develop insidiously, and there is often a delay in 
diagnosis for up to 10 years. Therefore, approximately 70% of GH secreting adenomas 
are ≥ 1cm (macroadenomas) at the time acromegaly is diagnosed 32. 
According to experts, transsphenoidal pituitary surgery (TS) is the treatment of choice 
for acromegaly 28,31, potentially rapidly restoring normal physiology by a single interven-
tion. Macroadenomas however are difficult to remove by TS, especially when invasive. 
This may explain the relatively low remission rate of about 50% reported after TS in 
macroadenomas, while remission rates up to 90% are achieved by TS in microadenomas 
(< 1 cm) [34]. Since more recently developed medical therapies achieve good results in 
controlling acromegaly, some authors have recommended medical therapy as a primary 
treatment option instead of TS for patients with a GH secreting macroadenoma that 
does not cause mass effects 13,25.
Nowadays, the endoscopic technique of TS is increasingly used by many neurosur-
geons instead of the conventional microscopic technique. This technique, offering a 
panoramic wide angle view with increased illumination, was first developed in the 
1990s. Different angles can be used, making it possible to effectively reach supra- and 
parasellar portions of the lesion and work around the corner 10,14. Due to these advan-
tages it has been suggested that the endoscopic technique may be preferable to the 
conventional technique, especially in patients with invasive macroadenomas 14,28,39. 
However, due to the recent introduction of this technique, no large series reporting on 
the results of endoscopic TS in acromegaly have yet been published.
To gain insight in the role of endoscopic TS as a primary treatment option for patients 
with GH secreting macroadenomas, we evaluated the results of endoscopic TS in 
40 consecutive patients with a GH secreting macroadenoma, treated in our hospital 
between 1998 and 2007. 
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Patients and methods
Patients
Between 1998 and 2007 40 patients with acromegaly and a macroadenoma on a preop-
erative Magnetic Resonance Imaging (MRI) scan underwent endoscopic TS in our centre. 
The medical records of these patients (19 males and 21 females, Table 1) were retrospec-
tively reviewed. Age at time of TS was 47.4 ± 11.4 (mean ± SD) years and BMI was 29.0 ± 
4.9 kg/m2. We collected data on preoperative as well as early postoperative evaluation, 
complications that occurred during TS or in the early postoperative period and data on 
the follow-up of these patients.
Preoperative evaluation and perioperative treatment
The initial diagnosis of acromegaly was based on clinical grounds and biochemical tests, 
including assessment of serum GH levels (basal and after oral administration of glucose) 
and serum IGF-1 levels. Furthermore the thyrotropic, gonadotropic and pituitary-adrenal 
axes were assessed, as well as the prolactin blood level. Preoperative pituitary imaging 
by MRI was performed in all patients.
Long-acting somatostatin analogues (SA) were given preoperatively in 34 patients for a 
median period of 7 months (range 1-28), one patient received 10 mg/4 weeks, 20 patients 
received 20 mg/4 weeks and 13 patients received 30 mg/4 weeks.
One hour before surgery, administration of glucocorticoids (prednisolone, 25 mg i.v. every 
8 h) was started. Two days after surgery glucocorticoid administration was changed 
from i.v. to oral and the dose was tapered rapidly. 
Surgical technique
The endoscopic technique of TS was introduced in our hospital in 1994, and first used for 
acromegaly in 1998. From 1998 onward practically all TS (n=365) were performed endo-
scopically. The surgeries were exclusively performed by two neurosurgeons. The tech-
nique is very similar to the technique Jho et al. and Cappabianca et al. have described 
previously 7,8,21,22. However, a binostril transsphenoidal approach to the sella turcica was 
used, during which the endoscope was handheld. 
For the endoscopic transnasal TS 0º and 30° rigid endoscopes with a lens diameter of 4 
mm with a separate shaft were used, which allow easy and comfortable holding, while 
offering a suction-irrigation-system for cleaning the lens (Karl Storz GmbH, Tuttlingen, 
Germany). The instruments used are principally the same as used with the microsurgical 
technique. Because an adenoma was visible on preoperative MRI a selective adenomec-
tomy was performed in all patients. 
2)  Endoscopic transsphenoidal surgery in acromegaly
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Postoperative evaluation
A complication of TS was defined as any event occurring during or after TS which required 
treatment. As intraoperative cerebrospinal fluid (CSF) leakage is inherent to the surgical 
procedure and is closed during TS with a fat graft it was not regarded as a complication, 
whereas postoperative CSF leakage was considered a complication.
On the seventh day postoperatively, at least 48 hours after the last dose of glucocor-
ticoids, early biochemical evaluation was carried out, by measuring the serum concen-
trations of IGF-1, fasting cortisol, adrenocorticotropic hormone (ACTH), thyrotropin (TSH), 
free thyroxine (FT4), gonadotropines (LH and FSH), testosterone, estradiol and prolactin. 
Patients were re-evaluated every 2 to 4 weeks during the first 3 months after surgery. 
Serum GH and IGF-1 were measured at each visit. Four months after surgery a new MRI 
of the pituitary was performed to check for tumour remnants. An oral glucose tolerance 
test (OGTT; 100 g of glucose 36) was performed if IGF-1 was normalised or was marginally 
elevated. Thereafter patients who were in remission were evaluated at least once a year 
or earlier in case of clinical suspicion of a relapse.
Criteria for remission and relapse
Remission was defined as disappearance of clinical symptoms of active GH hypersecre-
tion with in addition normal serum IGF-1 levels (≤ mean + 2 standard deviations for age) 
and suppression of serum GH levels to < 2 mU/L during OGTT within the first 4 months 
after surgery 19,20. Relapse was defined as development of clinical signs of active GH 
hypersecretion with elevated serum IGF-1 levels (> mean + 2 standard deviations for age) 
and serum GH levels ≥ 2 mU/L during OGTT 19,20.
Imaging
All preoperative and postoperative MRI-scans were evaluated by the same neurosur-
geon to prevent bias. Maximal diameter of the adenoma was defined as the largest 
distance that could be measured in any direction of the adenoma. Invasion was defined 
as suspected growth of the adenoma beyond the sella into the cavernous sinus or the 
sphenoid sinus.
Analysis of factors influencing outcome and statistics
Data were analysed using SPSS 16.0. Characteristics of patients operated in the first and 
second 5 years were compared using unpaired T-test and Pearson’s Chi-square test. The 
influence of various factors on the chance to achieve remission by TS was analysed 
by binary logistic regression. The factors analysed were: date of operation (as a surro-
gate measure for experience of the neurosurgeons), age, gender, the level of preop-
erative IGF-1 and GH, the diameter of the adenoma on preoperative MRI, evidence of 
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 Figure 1)  Results of endoscopic pituitary surgery in patients with a growth hormone 
 (GH) secreting macroadenoma (1998-2007).
Endoscopic pituitary surgery    
N=40 
Remission 
N=20 
Failure 
N=16 
 2
nd pituitary 
surgery 
N=2
 
  
Medication 
N=7 
Radiotherapy 
N=3 
γ-knife 
N=2 
Medication 
N=3 
Medication 
N=1 
Remission 
N=1 
Medication 
N=1   
Relapse 
N=2 
Debulking
N=4 
Intention cure 
N=36 
Radiotherapy & medication 
N=2 
Medication 
N=2 
No further 
therapy 
N=2  
 
Radiotherapy &
Medication
N=1 
 
 
2)  Endoscopic transsphenoidal surgery in acromegaly
2
45
invasion on the preoperative MRI, occurrence of perioperative complications and the 
need for hormonal substitution therapy after TS. The influence of dichotomous vari-
ables (gender, substitution therapy before TS, evidence of invasion on the preoperative 
MRI, TS in the first or second five years, occurrence of perioperative complications and 
the need for hormonal substitution therapy after TS) on the chance of remission were 
also analysed using Pearson’s Chi-square test. Statistical significance was defined as 
p = <0.05 (two-sided).
Results
Remission rates after TS 
The results of endoscopic TS in the 40 patients with a GH secreting macroadenoma are 
shown in figure 1. The individual data per patient are presented in Table 1. Histological 
investigation of the removed tissue showed evidence of a GH producing adenoma in all 
cases. The overall remission rate in our series is 50%. However, four patients (patients 
21, 30, 33 and 34, Table 1) had an invasive adenoma of more than 30 mm in diameter 
and suffered from local mass effects. The intention of the TS in these patients was 
to debulk the adenoma, as it was appreciated that cure could not be achieved by TS. In 
the remaining 36 patients, in whom the intent was cure, remission was achieved in 20 
patients. In this group the remission percentage thus was 56%. Median follow-up was 56 
months (range 6-126). Recently, 2 patients (patients 12 and 35) developed a mild relapse. 
Patient 12 is now treated with octreotide, while the relapse of patient 35 is very mild and 
no treatment had yet been initiated.
The date of TS significantly influenced the chance of remission after TS. If a patient 
was operated at a later date, the chance of achieving remission after TS was higher 
(p=0.04). If the results of TS during the first five year interval after the introduction of 
the endoscopic technique are compared with the second five year interval, remission 
was achieved in 6 out of 18 patients (33%) during the first 5 years, whereas in the next 
five years 14 out of 22 patients (63%) were in remission after TS (p=0.06). However, the 
four patients who only underwent debulking were all operated on in the last 5 years. 
If these patients are excluded, the remission rate achieved in the last 5 years is 77%, 
which is significantly better than the remission rate over the first 5 years (p=0.01). Table 
2 shows that baseline characteristics of patients operated during the first 5 years do 
not significantly differ with baseline characteristics of patients operated during the last 
5 years, except for preoperative IGF-1 levels which were significantly higher in de second 
group. This does not change if the four patients who underwent debulking are excluded. 
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Table 1)  Results of endoscopic transsphenoidal pituitary surgery in patients 
 with acromegaly (1998-2007). (page 48-51)
Patient number, 
gender, age (y)
Preoperative
octreotide
MRI
(mm)
Invasion on
preoperative MRI
Year of TS Postoperative
IGF-1
nmol/L      SD
Postoperative
oGTT
TS
result
Additional
therapy
Last
IGF-1
nmol/L         SD
Follow-up
(months)
1.f, 52 Y 20 sc r 1998 50.3 >2 - F RT + cab 19.0 1 127
2.m, 43 N 25 - 1999 24.0 1 38 F octr 32.8 >2 38
3.f, 27 N 18 sc r 2000 92.7 >2 9 F GK 10.6 -2 109
4.m, 40 Y 10 - 2000 23.1 1 <2 R - 12.9 -1 106
5.f, 24 Y 17 - 2000 77.0 >2 - F octr + cab 41.0 >2 78
6.f, 59 Y 20 ssphen,sc l 2001 64.5 >2 - F TS, RT + peg 15.6 0 76
7.f, 54 N 11 sc l 2001 62.8 >2 - F RT+ octr 23.5 1 73
8.m, 39 N 14 - 2001 73.6 >2 - F RT+ octr, cab 28.1 2 68
9.m, 49 Y 43 ssphen, sc l + r 2001 60.5 >2 - F TS+ octr, cab 21.6 1 91
10.f, 50 Y 12 - 2001 10.2 -2 <2 R - 15.4 0 74
11. f, 49 Y 13 - 2001 38.4 >2 - F octr 14.0 0 91
12.m, 37 Y 20 - 2001 28.3 1 <2 R octr 15.6 0 87*
13.m, 44 Y 10 sc r 2001 83.6 >2 - F GK + octr, peg 27.9 2 86
14.f, 34 Y 16 - 2002 10.5 -2 <2 R - 11.4 -2 70
15.f, 55 Y 18 - 2002 30.9 >2 3 F octr 9.8 -2 86
16.f, 56 Y 11 sc r 2002 12.7 -1 <2 R - 13.6 0 79
17.m, 56 Y 14 - 2002 16.8 0 <2 R - 15.2 0 77
18.m, 64 Y 12 - 2002 18.0 1 2 F octr 18.3 1 57
19.f, 66 Y 16 ssphen, sc r 2003 27.1 2 <2 R - 25.0 2 65
20.f, 45 Y 30 sc l 2003 24.7 1 <2 R - 29.0 2 48
21.m, 35 Y 39 ssphen 2003 66.3 >2 - F octr 14.1 -1 69
22.f, 56 Y 15 sc r 2003 15.3 0 <2 R - 16.5 0 47
23.f, 41 Y 15 - 2003 28.0 1 <2 R - 22.7 1 66
24.m, 54 Y 13 - 2004 19.8 1 <2 R - 16.6 0 44
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Table 1)  Results of endoscopic transsphenoidal pituitary surgery in patients 
 with acromegaly (1998-2007). (page 48-51)
Patient number, 
gender, age (y)
Preoperative
octreotide
MRI
(mm)
Invasion on
preoperative MRI
Year of TS Postoperative
IGF-1
nmol/L      SD
Postoperative
oGTT
TS
result
Additional
therapy
Last
IGF-1
nmol/L         SD
Follow-up
(months)
1.f, 52 Y 20 sc r 1998 50.3 >2 - F RT + cab 19.0 1 127
2.m, 43 N 25 - 1999 24.0 1 38 F octr 32.8 >2 38
3.f, 27 N 18 sc r 2000 92.7 >2 9 F GK 10.6 -2 109
4.m, 40 Y 10 - 2000 23.1 1 <2 R - 12.9 -1 106
5.f, 24 Y 17 - 2000 77.0 >2 - F octr + cab 41.0 >2 78
6.f, 59 Y 20 ssphen,sc l 2001 64.5 >2 - F TS, RT + peg 15.6 0 76
7.f, 54 N 11 sc l 2001 62.8 >2 - F RT+ octr 23.5 1 73
8.m, 39 N 14 - 2001 73.6 >2 - F RT+ octr, cab 28.1 2 68
9.m, 49 Y 43 ssphen, sc l + r 2001 60.5 >2 - F TS+ octr, cab 21.6 1 91
10.f, 50 Y 12 - 2001 10.2 -2 <2 R - 15.4 0 74
11. f, 49 Y 13 - 2001 38.4 >2 - F octr 14.0 0 91
12.m, 37 Y 20 - 2001 28.3 1 <2 R octr 15.6 0 87*
13.m, 44 Y 10 sc r 2001 83.6 >2 - F GK + octr, peg 27.9 2 86
14.f, 34 Y 16 - 2002 10.5 -2 <2 R - 11.4 -2 70
15.f, 55 Y 18 - 2002 30.9 >2 3 F octr 9.8 -2 86
16.f, 56 Y 11 sc r 2002 12.7 -1 <2 R - 13.6 0 79
17.m, 56 Y 14 - 2002 16.8 0 <2 R - 15.2 0 77
18.m, 64 Y 12 - 2002 18.0 1 2 F octr 18.3 1 57
19.f, 66 Y 16 ssphen, sc r 2003 27.1 2 <2 R - 25.0 2 65
20.f, 45 Y 30 sc l 2003 24.7 1 <2 R - 29.0 2 48
21.m, 35 Y 39 ssphen 2003 66.3 >2 - F octr 14.1 -1 69
22.f, 56 Y 15 sc r 2003 15.3 0 <2 R - 16.5 0 47
23.f, 41 Y 15 - 2003 28.0 1 <2 R - 22.7 1 66
24.m, 54 Y 13 - 2004 19.8 1 <2 R - 16.6 0 44
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Patient number, 
gender, age (y)
Preoperative
octreotide
MRI
(mm)
Invasion on
preoperative MRI
Year of TS Postoperative
IGF-1
nmol/L       SD
Postoperative
oGTT
TS
result
Additional
therapy
Last
IGF-1
nmol/L         SD
Follow-up
(months)
25.f, 43 Y 11 - 2004 29.5 2 <2 R - 22.8 1 43
26.m, 48 N 12 - 2005 35.8 >2 - F octr 23.6 1 31
27.f, 29 Y 10 sc l 2005 25.6 1 <2 R - 23.5 1 37
28.f,51 Y 13 - 2005 11.7 -1 <2 R - 15.6 0 49
29.m, 64 Y 14 sc r 2005 30.0 >2 - F cab 21.4 1 36
30.m, 68 Y 30 sc l + r, ssphen 2005 31.5 > 2 - F octr 16.8 1 30
31.m, 46 Y 21 - 2005 43.1 > 2 <2 F - 36.2 >2 32
32.m, 45 N 15 - 2005 46.0 >2 <2 F - 31.3 >2 38
33.m,35 Y 42 sc l + r 2005 163.8 > 2 595 F RT + octr,cab 56.9 >2 33
34.f, 28 Y 45 sc l + r 2006 98.7 >2 - F RT+ octr 33.3 >2 15
35.f, 67 Y 11 - 2006 21.5 1 <2 R - 27.4 >2 31*
36.m, 40 Y 21  sc r 2007 22.9 0 <2 R - 21.3 1 14
37.m, 62 Y 20 - 2007 18.4 1 <2 R - 18.4 1 6
38.f, 41 Y 24  sc re 2007 31.7 2 <2 R - 12.0 -1 15
39.f, 46 Y 18 - 2007 16.2 0 <2 R - 21.3 1 8
40.m, 54 Y 27 sc r 2007 26.6 2 <2 R - 26.6 2 6
f: female; m: male; Preoperative octreotide Y: treated with octreotide before surgery; Preoperative 
octreotide N: not treated with octreotide before surgery; MRI: magnetic resonance imaging results given 
as maximal diameter of the visualized tumor in mm; sc r: cavernous sinus right; sc l: cavernous sinus left; 
ssphen: shenoid sinus; ssphen: sphenoid sinus; TS: transsphenoidal surgery; IGF-1 nmol/l: value of insu-
lin-like growth factor-1; IGF-1 SD: standard deviation of insulin-like growth factor-1 compared to normal 
There were no statistically significant differences between the patients who under-
went successful or unsuccessful TS with respect to age, gender, occurrence of periop-
erative complications, preoperative IGF-1 levels or need for hormonal substitution 
therapy after TS. There was a trend that if the diameter of the adenoma was larger the 
chance to achieve remission was smaller (p= 0.06 in all patients), however if the four 
patients who underwent only debulking were excluded this trend was no longer present 
(p= 0.56). Eight of 19 patients (42%) with evidence of invasion on preoperative MRI, and 
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Patient number, 
gender, age (y)
Preoperative
octreotide
MRI
(mm)
Invasion on
preoperative MRI
Year of TS Postoperative
IGF-1
nmol/L       SD
Postoperative
oGTT
TS
result
Additional
therapy
Last
IGF-1
nmol/L         SD
Follow-up
(months)
25.f, 43 Y 11 - 2004 29.5 2 <2 R - 22.8 1 43
26.m, 48 N 12 - 2005 35.8 >2 - F octr 23.6 1 31
27.f, 29 Y 10 sc l 2005 25.6 1 <2 R - 23.5 1 37
28.f,51 Y 13 - 2005 11.7 -1 <2 R - 15.6 0 49
29.m, 64 Y 14 sc r 2005 30.0 >2 - F cab 21.4 1 36
30.m, 68 Y 30 sc l + r, ssphen 2005 31.5 > 2 - F octr 16.8 1 30
31.m, 46 Y 21 - 2005 43.1 > 2 <2 F - 36.2 >2 32
32.m, 45 N 15 - 2005 46.0 >2 <2 F - 31.3 >2 38
33.m,35 Y 42 sc l + r 2005 163.8 > 2 595 F RT + octr,cab 56.9 >2 33
34.f, 28 Y 45 sc l + r 2006 98.7 >2 - F RT+ octr 33.3 >2 15
35.f, 67 Y 11 - 2006 21.5 1 <2 R - 27.4 >2 31*
36.m, 40 Y 21  sc r 2007 22.9 0 <2 R - 21.3 1 14
37.m, 62 Y 20 - 2007 18.4 1 <2 R - 18.4 1 6
38.f, 41 Y 24  sc re 2007 31.7 2 <2 R - 12.0 -1 15
39.f, 46 Y 18 - 2007 16.2 0 <2 R - 21.3 1 8
40.m, 54 Y 27 sc r 2007 26.6 2 <2 R - 26.6 2 6
f: female; m: male; Preoperative octreotide Y: treated with octreotide before surgery; Preoperative 
octreotide N: not treated with octreotide before surgery; MRI: magnetic resonance imaging results given 
as maximal diameter of the visualized tumor in mm; sc r: cavernous sinus right; sc l: cavernous sinus left; 
ssphen: shenoid sinus; ssphen: sphenoid sinus; TS: transsphenoidal surgery; IGF-1 nmol/l: value of insu-
lin-like growth factor-1; IGF-1 SD: standard deviation of insulin-like growth factor-1 compared to normal 
12 of 21 patients (57%) without invasion achieved remission after TS (p=0.34). If the four 
patients in whom the intention of the TS was to debulk the adenoma were not taken 
into account the remission rate in patients with suspected invasion was 53%, indicating 
that in this study invasion did not significantly influence the chance to achieve remis-
sion (p=0.82).
values in people of the same age and sex; oGTT: Minimal value of growth hormone achieved during the 
postoperative oral glucose tolerance test; GTT -: no oral glucose tolerance test performed after surgery; TS 
result R: remission; TS result F: failure; RT: conventional radiotherapy; octr: octreotide; cab: cabergoline; GK: 
gamma knife radiosurgery; peg: pegvisomant *: relapse at last follow-up
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Additional treatment and benefits of TS in patients with persistent 
acromegaly after TS.
Although remission was not achieved via TS in 20 patients, the maximal diameter of 
the adenoma was reduced from median 18 mm (range 10-45) on the preoperative MRI to 
median 7 mm (range 0-35) on the MRI performed four months after surgery. The adenoma 
was reduced in size in all cases, and in 6 cases no residual adenoma was visible on the 
postoperative MRI. In three patients (patients 11, 15 and 18) normal IGF-1 levels could be 
achieved with a dose of octreotide which was the same or even lower than the dose 
prescribed before the operation and which had been insufficient to suppress IGF-1 to 
normal levels before TS. 
Figure 1 shows how the 20 patients with persisting acromegaly after TS were treated. 
A second TS was attempted in two patients but failed to result in cure. Of the eight 
patients receiving additional conventional radiotherapy none is presently in remission 
and all still receive medical treatment to control the acromegaly. Radiosurgery (γ-knife) 
was performed in 2 patients and resulted in remission in one of them. Of the remaining 
patients not cured by the TS, all patients except patient 32 and 33 were exclusively 
treated with medication. Patient 32 and 33 did not receive any further treatment. In 
patient 32 IGF-1 is only slightly elevated with no symptoms of active acromegaly, GH is 
suppressed to < 2 mU/L after OGTT and mean GH values are below 6.5 mU/L. Patient 33 
refused to be tested or treated further after TS, because the symptoms of acromegaly 
had disappeared. 
Complications of TS and influence of TS on deficiencies of pituitary 
hormones.
Only mild complications occurred in our series. Fourteen patients developed a very mild 
transient diabetes insipidus (DI), for a maximum of 2 to 3 days. This was not regarded as 
a complication. Only patient (patient 33) had a more severe transient DI. Five patients, 
of whom two had had mild transient DI early after the operation, were treated with fluid 
restriction when they developed a mild hyponatremia due to inappropriate ADH secre-
tion. Four patients had mild epistaxis, controlled with nasal tampons. Three patients had 
cerebrospinal fluid (CSF) leakage postoperatively. They were treated successfully with 
an external lumbar drain. 
Fifteen patients (38%) already received substitution therapy for deficiency of one or 
more hormones before TS. After TS 33% of all patients receive long-term hormonal 
substitution. Twenty percent of the patients receive substitution with levothyroxine, 
12.5% receive androgens, 12.5% receive glucocorticoids, 2.5% receive GH therapy and 
2.5% receive desmopressin (Table 3). 
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Table 2) Comparison of baseline characteristics of the patients operated during the 
 first 5 years and the patients operated during the second 5 years.
First 5 years (n = 18) Second 5 years (n = 22) Significance
Gender (% male) 8 (44%) 11 (50%) p = 0.76
Age (years) 46.2 (± 11.0) 48.4 (± 11.9) p = 0.56
BMI (kg/m2) 29.8 ( ± 4.4) 26.6 (± 5.3) p = 0.32
Preoperative medication 13 (72%) 20 (91%) p = 0.12
Adenoma diameter (cm) 16.9 (± 7.8) 20.9 (10.4) p = 0.18
Invasion on preoperative MRI 7 (39%) 12 (54%) p = 0.32
Preoperative IGF-1 value (nmol/L) 93.3 (± 23.5) 116.6 ( ±36.9) p = 0.03*
Data are expressed as means and standard deviations in case of continuous variables and as exact 
numbers and percentages in case of nominal or ordinal variables. BMI: Body mass index; IGF-1 : insu-
lin-like growth factor-1; MRI: magnetic resonance imaging
Table 3) Influence of transsphenoidal surgery on substitution therapy in 40 patients 
 with acromegaly caused by a macroadenoma.
Substitution 
therapy
Levothyroxine  Androgen Glucocorticoid GH Desmopressin Total
Discontinued after 
TS
5 5 1 11
Started after TS 4 2 2 1 1 10
Continued after TS 4 3 3 10
TS: transsphenoidal surgery, GH: growth hormone.
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Discussion
In this study we report on the results of endoscopic TS in 40 consecutive patients 
with acromegaly and a pituitary macroadenoma on preoperative MRI, operated on in 
our hospital between 1998 and 2007. Although some results of endoscopic TS in small 
numbers of patients with acromegaly have been mentioned in large series of patients 
with different pituitary tumours 6,11 ,26,42, no series focusing on results of endoscopic TS 
in patients with acromegaly have yet been published. All previous published series on 
results of TS in patients with GH-secreting macroadenomas used the conventional 
technique of TS. 
Remission rates after conventional TS reported in these larger series of patients with 
GH-secreting macroadenomas (including giant macroadenoma) vary widely, from 15 to 
71% (Table 4) 1,2,4,15,18,23,29,34,40,41,43,45. The overall remission rate of 50% in this study is in 
concordance with these results. However, not all series have used the same criteria 
to describe remission. The studies which used the criteria for remission formulated by 
Giustina et al. in 2000 19,20, as we did in our series, reported remission rates in patients 
with macroadenomas of maximally 50%. Therefore the remission rate of 50% reported 
in our series is comparable to the best previously published remission rates achieved in 
patients operated on by the conventional microscopic method of TS.  
However, the remission rate of 63% (or 77% if the patients who underwent debulking are 
excluded) we achieved in the last 5 years, compared to a remission rate of 33% in the 
first 5 years is very promising for the future. The characteristics of patients operated 
in the first 5 years and second 5 years were comparable (Table 2).The only significant 
difference was that the patients operated upon in the second 5 years had a significantly 
higher IGF-1 level. Therefore we believe that the higher remission rate achieved in the last 
5 years is not biased by patients that were easier to operate on. So, it is more likely that 
the large difference between the remission rate achieved in the first 5 years and the 
second 5 years after introduction of the endoscopic technique of TS can be explained 
by the increasing experience of the two neurosurgeons who performed all endoscopic 
TS in our hospital. Strong evidence exists indicating that success rates of microscopic 
TS critically depend on the skills and experience of the neurosurgeon 3,15,18. Our data indi-
cate that this is no different for endoscopic TS. This argues in favour of concentrating 
endoscopic TS for acromegaly in a limited number of experienced centres.
Previously published series on conventional microscopic TS in patients with acromegaly 
and a macroadenoma found that the chance of remission after TS could be predicted 
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Table 4) Review of the criteria to define remission of acromegaly and remission 
 percentages in macroadenomas reported in the most recently published 
 series (1997-2005).
Author N Criteria of remission Remission %
v Lindert (1997)
Abosch (1998)
Swearingen (1998)
Gittoes (1999)
Laws (2000)
Kaltsas (2001)
Abe (2001)
Shimon (2001)
Beauregard (2003)
Trepp (2005)
Erturk (2005)
Nomikos (2005)
40
254
129
45
51
50
126
44
77
64
19
364
GH<2 ng/ml after OGTT, IGF1 N
basal GH<5 ng/ml
GH<2 ng/ml after OGTT or IGF1 N or basal GH<2.5ng/ml
GH<2 mU/l after OGTT or basal GH<5mU/l
GH<1 ng/ml after OGTT or IGF1 N or basal GH<2.5ng/ml
basal GH<2.5 ng/ml, IGF1 N
basal GH<2.5 ng/ml, IGF1 N
GH<2 ng/ml basal or after OGTT, IGF1 N
GH<1 ng/ml after OGTT or IGF1 N or basal GH<2.5ng/ml
GH<1 ng/ml after OGTT or IGF1 N or basal GH<2.5ng/ml
GH<2 ng/ml basal or after OGTT
GH<1 ng/ml after OGTT or IGF1 N or GH<2.5ng/ml
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71
48
51
51
26
68
64
49
39
15
50
N: number of patients included; GH: Growth hormone; OGTT: oral glucose tolerance test; IGF1: insulin-like 
growth factor type 1.
by the suspected invasiveness of the macroadenoma on the preoperative MRI scan 2,4,18. 
However, in this study, although we observed a non-significant trend towards a lower 
chance of successful TS if tumour invasion was suspected, remission was still achieved 
in 42% of patients with suspected invasion. This may be explained by the fact that the 
endoscopic technique enables the use of different angles to operate, making it possible 
to effectively reach suprasellar and parasellar portions of the lesion 10,14. If this is the case, 
the endoscopic technique might be preferable in case of invasive macroadenomas.
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Due to the good results that have been achieved by medical therapy in patients with acro-
megaly and the relatively low remission rates after TS for patients with a GH secreting 
macroadenoma, some authors have recommended medical therapy as a primary treat-
ment option instead of TS for patients with a GH secreting macroadenoma not causing 
mass effects 13,25,39. Nowadays long-acting somastatin analogues (SA) have the poten-
tial to normalize IGF-1 levels in two thirds of patients, additionally controlling tumour size 
[17]. The more recently developed GH receptor antagonist pegvisomant can normalise 
IGF-1 in up to 97% of patients 44. Furthermore, studies on combination therapies with SA 
and pegvisomant or SA and dopamine agonists have shown that combination therapy 
may be successful when monotherapy has failed 16,33,38. Although medical treatment 
can result in long-term remission, it cannot cure acromegaly. Moreover, pegvisomant, 
which is effective by preventing GH action in the target tissues (organs), lacks a direct 
effect on the tumour to control long-term tumour growth. This might limit its use as 
primary therapy for patients with macroadenomas, until more long-term data on safety 
are available. Last but not least, lifelong use of expensive medication is required with 
the risk of serious side effects. 
Studies have shown that surgical debulking can improve control of acromegaly by SA 
12,24,35. So even if a patient cannot be cured by TS, TS should still be considered, especially 
if acromegaly cannot be controlled by SA before TS. In this study TS reduced the size of 
the adenoma in all patients who were not cured by TS and improved the response to SA 
treatment in at least 5 of these patients. Unfortunately, a preoperative IGF-1 value during 
SA therapy was not available in all patients, so possibly more patients benefited from 
the TS to control their acromegaly. 
Preoperative treatment with SA has been associated with improved results of TS, espe-
cially in macroadenomas 1,5,9,30. This could possibly be explained by adenoma shrinkage 
or change in consistency of the adenoma 9. However, most published studies have 
limitations. They are retrospective, have poor remission rates or small numbers of 
patients. Furthermore, other studies have not confirmed this positive effect 27,37. A nega-
tive effect of preoperative treatment with SA on the outcome of TS results, however, 
has never been found. Therefore and because pretreatment with SA improves meta-
bolic control, we prescribed preoperative therapy with octreotide in all but 6 patients. 
Of these 6 patients, none achieved remission after TS. However, because of the small 
number of patients who did not receive preoperative treatment and the retrospective 
character of this study it was not possible to evaluate whether preoperative treatment 
had an effect on the results of TS.
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Thirteen patients in our study had a perioperative complication. All complications were 
mild and no serious complications occurred. This is in concordance with the incidence 
of complications associated with TS via the microscopic technique 1,2,4,15,18,23,29,34,40,41,43,45. 
However, the endoscopic technique is probably more comfortable for the patients as 
the nose septum is almost left intact and usually no nasal packing is required after 
surgery. Besides the four patients with mild epistaxis, no rhinologic/local complications 
occurred, which seems to be less than those reported with the conventional technique. 
However, most patients that are operated upon via the microscopic technique do not 
need nasal packaging, but receive it because of a longstanding surgical habit.
In this series the number of hormonal deficiencies caused by TS was equal to the number 
of deficiencies cured by TS. All patients had a macroadenoma, which frequently causes 
a hormonal deficiency by itself before surgery. If the adenoma is selectively removed, 
normal pituitary function can potentially be restored 45. Therefore in macroadenomas, 
the fear of creating new hormonal deficiencies should probably not be a reason to 
restrain from TS.
Conclusion
Endoscopic TS is a treatment which should be considered as a primary therapeutic 
option for patients with a GH secreting macroadenoma. In this series of patients oper-
ated on by experienced surgeons, it resulted in a remission rate of at least 50%, with 
only mild complications. The relatively high remission rate of 63% (or 77% excluding the 
patients who underwent primary debulking) we achieved in the last 5 years indicates 
that operation results can improve further if experience is gained. Because the endo-
scopic technique enables the surgeon to use different angles this technique can poten-
tially improve the outcome of TS in macroadenomas, especially in patients with inva-
sive macroadenomas. However, a randomized clinical trial, comparing endoscopic and 
conventional TS in patients with a GH secreting macroadenoma, is needed to determine 
the exact pros and cons of both techniques.
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Endoscopic transsphenoidal 
pituitary surgery: 
a good and safe primary 
treatment option for Cushing’s 
disease, even in case of 
macroadenomas or invasive 
adenomas
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Abstract 
Context: Although the endoscopic technique of transsphenoidal pituitary surgery (TS) 
has been widely adopted, reports on its results in Cushing’s disease (CD) are still scarce 
and no studies have investigated long-term recurrence rates. This is the largest endo-
scopic series published until now.
Objective: To gain insight in the role of endoscopic TS as a primary treatment option for 
CD, especially in patients with MRI-negative CD and (invasive) macroadenomas.
Design: retrospective cohort study. 
Patients and methods: The medical records of 86 patients with CD who underwent 
endoscopic TS were examined. Data on preoperative and postoperative evaluation, 
perioperative complications and follow-up were collected. Remission was defined as 
disappearance of clinical symptoms with a fasting plasma cortisol level ≤ 50 nmol/l 
either basal or after 1 mg dexamethasone. 
Results: The remission rate in different adenoma subclasses varied significantly: 60% in 
MRI-negative CD (n=20), 83% in microadenomas (n=35), 94% in non-invasive macroade-
nomas (n=16) and 40% in macroadenomas that invaded the cavernous sinus (n=15). The 
rate of recurrence was 16% after 71 ± 39 months follow-up (mean ± SD, range 10-165). 
Conclusions: Endoscopic TS is a safe and effective treatment for all patients with CD. 
Recurrence rates after endoscopic TS are comparable to those published for micro-
scopic TS. Our data suggest that in patients with non-invasive and invasive macroade-
nomas, the endoscopic technique of TS should be the technique of choice, as remission 
rates seem to be higher than remission rates reported for microscopic TS, although no 
comparative study has been performed. 
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Introduction
Persisting Cushing’s disease (CD) after unsuccessful treatment is associated with a 
four- to five fold increased standardized mortality ratio and substantial morbidity 
1-3. Successful treatment of CD is therefore crucial. Since Hardy introduced the oper-
ating microscope to selectively remove adrenocorticotropic hormone (ACTH) secreting 
microadenomas via the transsphenoidal route in 1963, transsphenoidal surgery (TS) has 
become the treatment of choice for CD 4. Over the years a large number of reports on 
the results of microscopic TS in patients with CD have been published. These reports 
show that, in experienced hands, excellent remission rates of over 80% can be achieved 
if a microadenoma is visualized on preoperative imaging 5-16. However, if no adenoma is 
visualized on preoperative imaging (Magnetic Resonance Imaging (MRI) negative CD), or 
if a macroadenoma is the cause of CD, remission rates are substantially lower 5-10, 13-16. 
Furthermore CD relapses in up to 25% of the patients. Therefore it has been suggested 
that TS is the optimal primary treatment for only a subset of patients with CD 17. 
In the 1990s the purely endoscopic technique of TS has been introduced as an alter-
native to the conventional microscopic technique. The endoscopic technique offers a 
panoramic view with increased illumination of the operating field. Furthermore different 
angles can be used making it possible to reach the supra- and parasellar regions. Due to 
these advantages the endoscopic technique has been widely adopted 18-22. Compared 
to historical microscopic series the endoscopic technique seems to result in improved 
outcome rates in macroadenomas 18-22. However, reports on the results of endoscopic 
TS in CD are still scarce and in the studies that have been published (including our own 
report on the results in the first 35 patients) all patients have a short follow-up period 
so no statements about recurrences can be made 23-25. Furthermore it is still unclear if 
the endoscopic technique has advantages or disadvantages in patients with very small 
microadenomas (<5 mm), which occur frequently in patients with CD 26, 27. Therefore some 
neurosurgeons are reluctant to use this technique in patients with CD 27. 
To gain more insight in the role of endoscopic TS as a primary treatment option for 
patients with CD, especially in patients with MRI-negative CD or (invasive) macroade-
nomas, we evaluated the results of endoscopic TS in the first 86 patients treated in our 
centre. Furthermore we evaluated the rates of recurrence after initial remission. 
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Patients and methods
Patients
From 1998 onwards all TS in our hospital were performed endoscopically. All patients 
who underwent endoscopic TS as primary treatment for CD between January 1998 
and December 2011 (n=86) were identified for this retrospective cohort study. The 
medical records of these 86 consecutive patients were examined. Data on preopera-
tive and early postoperative evaluation, perioperative complications and follow-up were 
collected according to the guidelines of our local medical ethical committee. Seven-
ty-two percent of all patients were female. At the time of TS the age of the patients was 
42.3 ± 14.9 years (mean ± SD) and body mass index (BMI) was 30.5 ± 7.2 kg/m2. The initial 
results of the first 35 TS have been published previously 23.
Diagnostic evaluation
At presentation all patients had symptoms of active hypercortisolism. The clinical 
diagnosis of hypercortisolism was confirmed by standard biochemical investigations 
(elevated 24-h urinary free cortisol (UFC) excretion, loss of diurnal variation of plasma 
and/or salivary cortisol levels and failure to suppress plasma cortisol after 1 mg dexa-
methasone overnight) 28. ACTH dependency was confirmed by normal or elevated ACTH 
values. The diagnosis of pituitary-dependent CD was established as follows: pituitary 
imaging by MRI scanning with intravenous contrast (gadolinium) was performed in all 
patients. If no adenoma was seen on the MRI scan (MRI-negative CD, n=20) or if the 
adenoma was < 6 mm (n=21) inferior petrosal sinus sampling (IPSS) was performed (n=22) 
or (in case IPSS could not be performed because of technical reasons, comorbidity or 
refusal by the patient) a corticotrophin-releasing hormone (CRH) test (100 µg human CRH 
i.v.) and a high dose dexamethasone suppression test (DST) (7 mg dexamethasone in 
7 h i.v.) were performed (n=19). 
Perioperative treatment
Eighty-seven percent of all patients received cortisol lowering medication (keto-
conazole in 48 patients, metyrapone in 22 patients and a combination of these drugs 
in 8 patients) before TS for 3.6 ± 1.8 months. One hour before surgery, administration of 
glucocorticoids (prednisolone, 25 mg i.v. every 8 h) was started and after surgery the 
dose was tapered rapidly. 
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Surgical procedures
The endoscopic technique of TS was introduced in our hospital in 1994 and was first 
used for CD in 1998 (n=2). Thereafter an increasing number of patients with CD were oper-
ated endoscopically, reaching an average of 8 patients per year from 2003 onwards. The 
technique of endoscopic TS has been described before 22, 23, 29. In short: a binostril, trans-
sphenoidal, endoscopic approach to the sella turcica during which the endoscope is 
handheld was used. Until 2010 endoscopic TS was exclusively performed by two neuro-
surgeons and thereafter by three neurosurgeons.
A selective adenomectomy was performed if an adenoma could be localized during 
TS (n=76). In 5 patients no adenoma could be localized peroperatively and a hemihy-
pophysectomy was performed (based on the results of IPSS). In one patient the whole 
pituitary gland seemed abnormal and a resection of the total anterior pituitary gland 
was performed. In 4 patients only debulking of the adenoma was performed, because 
it was clear that it was impossible to remove the total adenoma based on preoperative 
imaging. However, these patients required an operation because of local mass effects 
of the adenoma. 
All material removed during TS was examined histopathologically and immunohisto-
chemical staining for pituitary hormones was performed to confirm the diagnosis of 
ACTH-secreting pituitary adenoma.
A complication of TS was defined as any event occurring during or in the month after 
TS that required treatment. As intraoperative cerebrospinal fluid (CSF) leakage, which 
occurred in eleven patients and was closed with a fat graft peroperatively, is inherent to 
the surgical procedure this was not regarded as a complication. 
Postoperative evaluation
On the fourth day postoperatively biochemical evaluation was carried out (after gluco-
corticoid substitution had been stopped for at least 24 hours), by measurement of 
fasting (08:00 h) plasma cortisol, ACTH, thyrotropin, free thyroxine, gonadotropins, 
testosterone or estradiol and insulin-like growth factor type 1. 
If basal plasma cortisol was lower than 200 nmol/l substitution therapy with hydrocor-
tisone, 30 mg a day, was prescribed. Patients were reevaluated every 2–4 weeks during 
the first 3 months after TS and thereafter at two- to three months intervals during the 
first year. The fasting plasma cortisol concentration was measured at each visit. In addi-
tion, a 1 mg overnight DST was carried out 1 and 3 months postoperatively and there-
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after in patients who were in remission, once a year. If a patient received glucocorticoid 
substitution therapy postoperatively, the dose was reduced and stopped, if possible, 
between 3 and 12 months after TS. Thereafter the integrity of the hypothalamic–pitu-
itary–adrenal axis was assessed by an insulin tolerance test (ITT). The thyrotrophic, 
gonadotrophic and somatotrophic axes were checked regularly. If growth hormone defi-
ciency was suspected a growth hormone (GH) stimulation test was performed (prefer-
ably an ITT, but in case of contraindications a GHRH-Arginine test).
Additional procedures for this study
All preoperative MRI scans were reviewed by one neurosurgeon (H.B.). The diameter 
of the adenoma was measured in 3 orthogonal planes. The volumes of the adenomas 
were estimated using the following formula: 4/3π (a/2 • b/2 • c/2) (30). Furthermore 
the adenomas were divided into four groups, based on the modified Hardy criteria 31 : 
1) MRI-negative CD (23.3% of all patients), 2) microadenomas without cavernous sinus 
invasion (< 1 cm, 40.7% of all patients), 3) macroadenomas with or without suprasellar 
extension but no cavernous sinus invasion (noninvasive macroadenomas, ≥ 1cm, 18.6% 
of all patients) and 4) macroadenomas with invasion in the cavernous sinus (invasive 
macroadenomas, 17.4% of all patients). Invasion in the cavernous sinus was subclassi-
fied according to the KNOSP classification 32. 
In all patients who were assumed to be in remission, a new 1 mg DST was performed to 
exclude a mild recurrence. Data on postoperative substitution therapy were collected at 
the last follow-up visit for the patients who were in remission. For patients with persistent 
or recurrent disease data on postoperative substitution therapy were collected at the 
last visit before additional therapy was initiated.
Criteria of remission and recurrence
Remission was defined as disappearance of clinical symptoms of hypercortisolism with 
basal plasma cortisol level ≤ 50 nmol/l after glucocorticoid withdrawal for 24–48 h and/
or suppression of plasma cortisol level ≤ 50 nmol/l after a 1 mg overnight DST within the 
first 3 months after surgery 28, 33. 
Recurrence after initial remission was defined as inadequate suppression of plasma 
cortisol levels after a 1 mg overnight DST (> 50 nmol/l) in combination with elevated 
midnight salivary cortisol levels and/or elevated 24-h UFC levels. 
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Statistics
Data are presented as mean ± standard deviation and range for continuous vari-
ables, and as frequency for categorical variables. Categorical variables were analyzed 
with Chi-square tests or Fisher’s exact tests. Continuous variables were analyzed 
with unpaired Mann-Whitney U tests. A stepwise forward logistic regression analysis 
was performed to determine possible independent predictors of remission using the 
following variables: gender, age, BMI, mean preoperative cortisol levels, treatment with 
cortisol lowering agents, adenoma volume on preoperative MRI, adenoma classification 
and operation date (as a surrogate marker for the experience of the neurosurgeons). 
Kaplan–Meier analysis was used to estimate the probability of recurrence-free survival 
for the patients who were initially in remission after TS (both for the total group as sepa-
rately for the different adenoma classes). Statistical significance was defined as P≤0.05 
(two sided). Data were analyzed using SPSS 20.0.
Results
Remission and recurrence rates after endoscopic TS
The results of endoscopic TS in the 86 patients with CD are shown in Figure 1. The remis-
sion rates between the adenoma classes were significantly different (Figure 2, p<0.01). 
Remission was achieved in 12 of 20 patients with MRI-negative CD (60%), 29 of 35 
patients with a microadenoma (83%), 15 of 16 patients with a noninvasive macroade-
noma (94%) and 6 of 15 patients with an invasive macroadenoma (40%). In all patients 
with invasive macroadenomas the invasion of the cavernous sinus was classified as a 
KNOSP grade of ≥ 2. Remission was achieved in 2 of the 4 patients with KNOSP grade 2 
invasion, 3 of the 8 patients with KNOSP grade 3 invasion and one of the 3 patients with 
KNOSP grade 4 invasion. Two patients with KNOSP grade 3 invasion developed a relapse 
after initial remission.
The proportion of the different adenoma classes varied significantly over the years, 
with a higher percentage of patients with MRI-negative CD in the first 5 years and a 
higher percentage of invasive macroadenomas in the last 5 years (p<0.01). As investi-
gated with a stepwise logistic regression analysis, adenoma classification was the only 
preoperative variable that significantly influenced the chance of remission (p<0.01). 
Evidence of an ACTH-producing pituitary adenoma was found during immunohisto-
chemical investigation in 79% if the patients were in remission of CD after TS compared 
to 54% of the patients with persistent CD (p=0.02).
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Figure 1) Results of endoscopic pituitary surgery in 86 patients with Cushing’s 
 disease (1998-2011). ADX: adrenalectomy; RT: radiation therapy; †: deceased. 
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Figure 3) Kaplan Meier survival analysis demonstrating recurrence-free survival of 
 Cushing’s disease after endoscopic pituitary surgery for A) the total patient 
 group and B) the different adenoma classes.
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Figure 2) Overview of the remission rates of Cushing’s syndrome after endoscopic 
 pituitary surgery for the different adenoma classes.
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The follow-up period of the total patient group was 71 ± 39 months (5-164). After 42 ± 27 
months (10-98) CD recurred in 10 of the 62 patients who were initially in remission (16%).
The probability of recurrence-free survival, as estimated with a Kaplan-Meier anal-
ysis, was 98% one year after successful primary TS, 84% after 5 years and 73% after 
8 or more years (Figure 3a). The chance of recurrence significantly increased with a 
larger adenoma classification: probability of recurrence-free survival after successful 
primary TS was 91.7% after a mean of 100 months in the MRI-negative CD group, 66.8% 
after 45 months in the microadenoma group, 60.9% after 43 months in the noninvasive 
macroadenoma group and 37.5% after 35 months in the invasive macroadenoma group 
(p=0.04, Figure 3b). 
Complications of endoscopic TS and influence on pituitary hormone 
secretion
In this series all complications of endoscopic TS were relatively mild and did not cause 
any permanent damage. The most severe complication, which occurred in one patient, 
was postoperative bleeding originating from the sphenopalatine artery. This directly 
required reoperation. One patient with persistent CD after TS developed a pulmonary 
embolism two weeks after surgery. Ten patients (11.6% of all patients) had mild epistaxis 
controlled with nasal tampons. Four patients (4.6%) had postoperative CSF leakage, 
which was successfully treated with an external lumbar drain (ELD). Four patients (4.6%) 
developed transient diabetes insipidus (polyuria for more than two days and less than 6 
months requiring desmopressin substitution), which resolved spontaneously in the first 
few weeks after surgery. Ten patients (11.6%) developed transient hyponatremia of < 130 
mmol/L postoperatively, caused by inappropriate ADH secretion and/or (relative) gluco-
corticoid deficiency. Three patients (3.4%) had an infection postoperatively and were 
treated with antibiotic therapy: 2 patients because of a local urinary tract infection and 
one patient because of a local infection at the entry point of the ELD. 
Table 1) Influence of transsphenoidal surgery on hormonal substitution therapy in 
 86 patients with Cushing’s disease.
Substitution therapy Levothyroxine  Androgen Glucocorticoid GH Total
Discontinued after TS 5 3 0 0 8
Continued after TS 6 2 0 0 8
Started after TS 13 1 12 5 31
TS: transsphenoidal surgery, GH: growth hormone.
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Table 2) Remission and recurrence rates of Cushing’s disease in micro- and macro- 
 adenomas after primary transsphenoidal pituitary surgery: a selection† of 
 recently published single centre series. (page 71-72)
Author N Remission criteria Remission percentage Recurrence %
Microscopic series
Swearingen
(1999) [16]
154 • Basal cortisol <138 
nmol/L and
• UFC < 55 nmol/L
Overall 87%
Microadenomas (n=137) 90%
Macroadenomas (n=17) 65%
7%
follow-up mean 8.7 y
Rees
(2002) [13]
54 • Basal cortisol < 50 
nmol/L
Overall 70%
MRI-negative CD (n=16) 69%
Microadenomas (n=23) 100%
Macroadenomas (n=10) 40%
5%
follow-up mean 7 y
Shimon
(2002) [15]
77 • Normal UFC and
• Cortisol < 138 
nmol/L after 48h 
DST
Overall 78%
MRI-negative CD (n=10) 80%
Microadenomas (n=42) 79%
Macroadenomas (n=3) 33%
5%
follow-up mean 4.2 y
Yap
(2002) [34]
97 • Basal cortisol < 50 
nmol/L
Overall 68,5%
MRI-negative CD n=34
Microadenomas n=45
Macroadenomas n=10
11.5%
follow-up mean 7.6 y
Chen
(2003) [6]
174 • Cortisol <83nmol/L 
after a 1mg DST
Overall 79%
Microadenomas (n=133) 92%
Macroadenomas (29) 17%
6.5%
follow-up mean 5 y
Hammer
(2004) [9]
200* • Basal cortisol  
< 140nmol/L or
• Cortisol <140 nmol/L 
after a 1mg DST 
Overall 85%
Microadenomas (n=140) 86%
Macroadenomas (n=52) 83%
Invasive adenomas (n=8) 63%
9%
follow-up median 
11.1 y
Esposito
(2006) [8]
39* • Basal cortisol < 140 
nmol/L
Overall 79%
MRI-negative CD (n=8) 50%
Microadenomas (n=23) 91%
Macroadenomas (n=8) 75%
6%
follow-up mean 2.8 y
Rollin
(2007) [14] 
108 • Glucocorticoid 
dependence and
• Cortisol <82,8 
nmol/L after a 1mg 
DST
Overall 85%
MRI-negative CD (n=21) 71% 
Microadenomas (n=59) 95%
Macroadenomas (n=23) 74%
7%
follow-up mean 6 y
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Author N Remission criteria Remission percentage Recurrence %
Fomekong
(2009) [35]
40 • Normal UFC or
• Glucocorticoid 
dependence
Overall 65%
MRI-negative CD (n=3) 0%
Microadenomas (n=25) 64%
Macroadenomas (n=12) 83%
11.5%
follow-up mean 7 y
Alwani
(2010)[5]
79 • Normal UFC and
• Cortisol <50 nmol/L 
after a 1mg DST
Overall 65%
MRI-negative CD (n=14) 57% 
Microadenomas (n=44) 77% 
Macroadenomas (n=21) 43%
21%
follow-up
median 7 y
Ciric
(2012)[7]
136 • Basal cortisol < 
138nmol/L
Overall 85%
Microadenomas (n=123) 90%
Macroadenomas (n=13) 31%
9.7%
follow-up mean 5.7 y
Honegger
(2012)[10]
83 • Normal UFC and
• Cortisol <55 nmol/L 
after a 1mg DST
Overall 84%
MRI-negative CD (n=20) 77% 
Microadenomas (n=46) 93%
Macroadenomas (n=5) 100%
Invasive macroad. (n=7) 43%
7%
follow-up mean 3.2 y
Endoscopic series
Dehdashti
(2007)[25]
25 • Basal cortisol < 100 
nmol/L and
• Suppression of 
cortisol after 1mg 
DST and
• Normal UFC
Overall 80%
MRI-negative CD (n=5) 60%
Microadenomas (n=13) 100%
Macroadenomas (n=5) 80%
Invasive macroad. (n=2) 0%
0%
follow-up
median 1.4 y
Starke
(2012)[24]
62 • Basal cortisol < 138 
nmol/L or
• Decreased UFC
Overall 95%
MRI-negative CD (n=16) 100%
Microadenomas (n=30) 97%
Macroadenomas (n=15) 87%
10%
follow-up
mean 2.3 y
This series 86 • Basal cortisol < 50 
nmol/L or
• Cortisol, 50 nmol/L 
after 1mg DST
Overall remission 72%
MRI-negative CD (n=20) 60%
Microadenomas (n=35) 83%
Macroadenomas (n=16) 94%
Invasive macroad. (n=15) 40%
16%
follow-up mean 5.6 y
†: Only single centre studies with clear criteria for remission and relapse and in which remission rates 
were mentioned or could be calculated for different adenoma subclasses were included in this litera-
ture overview. N: number of patients; *: for a few patients the operation was the second operation; DST: 
dexamethasone suppression test; UFC: 24 hour urinary free cortisol; y: years; MRI: magnetic resonance 
imaging scan; CD: Cushing’s disease.
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Thirteen patients (15%) already received substitution therapy for deficiencies of one or 
more pituitary hormones before surgery. After TS, six patients who received hormonal 
substitution before TS did not need any hormonal substitution anymore and 22 patients 
started with substitution therapy. So at last follow-up (or at the follow-up visit before 
additional treatment was initiated) 35% of all patients received one or more hormonal 
substitution therapies. Twenty-two percent of all patients received substitution with 
levothyroxine, 14% received long-term glucocorticoid substitution (for a minimum dura-
tion of 2 years), 6% received GH and 3.5% received androgens (Table 1). 
Additional treatment for persistent and recurrent CD
Figure 1 shows how the patients with persistent and recurrent CD were treated. Four 
of the 24 patients with persistent CD did not receive any additional treatment. The 
persisting CD is subclinical in three of these patients and the fourth patient refused 
further treatment. Eleven patients with persistent CD were treated with repeat endo-
scopic TS which was only successful in 3 patients. Seven patients with persistent CD 
were treated with radiation therapy (RT), which was successful in 6 patients. In the 
seventh the pituitary tumor turned out to be a pituitary carcinoma. The patient died of 
metastatic disease. Two patients with persistent CD were treated with a bilateral ADX.
Five of the ten patients with recurrent CD were treated with a second endoscopic TS which 
was successful in 4 patients. In the fifth patient the intention of the repeat TS was to 
debulk the adenoma which had grown very rapidly in a short period of time and also turned 
out to be a pituitary carcinoma. Three patients with recurrent CD (30%) were treated 
with radiation therapy and two patients have not yet received additional treatment. 
Discussion
This study reports on the results of endoscopic TS in 86 patients with CD treated at the 
Radboud University Nijmegen Medical Centre between 1998 and 2011. To our knowledge 
this is the largest series on the results of endoscopic TS in CD published till now, with the 
longest follow-up time. In addition, in contrast to most previously published series on 
results of both endoscopic and microscopic TS, we included a relatively large number of 
patients with macroadenomas, including invasive macroadenomas. 
The most important finding of our study is the high remission rate of 94% achieved 
in patients with noninvasive macroadenomas. This compares favourably to previously 
published remission rates after microscopic TS in patients with ACTH secreting macroad-
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enomas which are on average 60%, despite the fact that most studies used less strict 
criteria for remission than we used (Table 2) 5, 7-10, 13-16, 34-36. In line with our results, Starke 
et al. recently reported a high remission rate of 87% in patients with ACTH secreting 
macroadenomas (n=15, of which 6 were invasive) achieved with endoscopic TS. Further-
more, the remission rates after endoscopic TS also seem to be higher in patients with 
a GH secreting or a non-functioning macroadenoma 18-22. We therefore believe that the 
endoscopic technique of TS should be the treatment of choice in patients with an ACTH 
secreting macroadenoma.
It is of interest that in the previously published series on microscopic TS only a few 
patients with ACTH secreting macroadenomas that invaded the cavernous sinus were 
included, probably because it was believed to be virtually impossible to achieve remis-
sion in these patients. Remission was nevertheless achieved in 40% of the patients with 
an invasive macroadenoma in the current series, of whom one patient even had a total 
encasement of the intracavernous carotid artery (KNOSP grade 4). This relatively good 
result can be explained by the fact that compared to the microscopic technique of TS, 
the endoscopic technique enables the use of different operating angles which makes it 
possible to effectively reach suprasellar and parasellar portions of the lesion, including 
the cavernous sinus 37. In our opinion invasion of the adenoma in the cavernous sinus 
should therefore not be a reason to refrain from surgery, especially because at present 
TS remains the only treatment that potentially restores normal physiology and all other 
treatment options for CD have major disadvantages.
In patients with an intrasellar ACTH secreting microadenoma we achieved a remis-
sion rate of 83% which is in concordance with remission rates previously reported in 
both conventional microscopic and endoscopic series (Table 2). Thus in patients with a 
microadenoma the technique of TS is probably equivocal, as long as the TS is performed 
by an experienced neurosurgeon. Furthermore, the number and type of complications, 
the complication rates and the rates of postoperative hormonal deficiencies that are 
reported are similar with both techniques 18, 19. The preference of the neurosurgeon and/
or the patient should therefore determine the technique of TS that is used in patients 
with a microadenoma.
In MRI-negative CD the remission rate we achieved was 60%, which is significantly lower 
than the remission rate achieved in microadenomas that could be visualized on preop-
erative MRI. This is in concordance with most conventional microscopic series, that 
also report lower remission rates in MRI-negative CD (Table 2). Interestingly Starke et al 
achieved remission in 100% of the patients with MRI-negative CD with the endoscopic 
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technique 21 . More data are needed in order to determine the real value of endoscopic TS 
in patients with MRI-negative CD. 
This is the first study that reports on long-term recurrence rates after endoscopic TS 
in CD. We found that, after a mean of 5.6 years of follow-up, 16% of the patients who 
were initially in remission after endoscopic TS developed a recurrence. All patients were 
actively investigated for recurrence and a strict definition of recurrence was used in 
order to obtain a good insight in actual recurrence rates. There are only few previously 
published microscopic series that carefully analyzed patients for recurrence 3, 5, 38, 39 and 
these series also report relatively high recurrence rates varying between 13 and 21%. 
Therefore recurrence rates of CD after endoscopic TS seem to be comparable to recur-
rence rates after microscopic TS. Because most recurrences occur in the first 5 years 
after TS and more recurrences occur in larger/invasive adenomas (Figure 3), the cause 
of a recurrence is most likely a small adenoma remnant left behind during TS. 
We previously reported that endoscopic TS seems to be a good therapeutic option for 
recurrent or persistent CD, after analyzing the outcome in 14 patients 29. At the time we 
did not separately analyze the results of persistent and recurrent CD, but remission was 
achieved in 7 out of 8 patients with recurrent CD and 3 out of 6 patients with persistent 
CD. This study confirms that repeated endoscopic TS seems to a good therapeutic 
option for patients with recurrent CD with remission achieved in 4 out of 5 patients. 
However, repeated endoscopic TS seems to be of less value for patients with persistent 
CD as remission was only achieved in 3 out of 11 patients. 
A limitation of this study is that, although the total patient group is relatively large, the 
number of patients in the different adenoma subclasses is relatively small. Another 
limitation of this study is its retrospective nature. Ideally a comparison between the 
microscopic and endoscopic technique of TS in CD would be made via a randomized 
controlled trial, with one or two neurosurgeons performing both operations. However, 
because CD is a rare disease, such a trial is very difficult to organize. Furthermore only 
a few neurosurgeons have extensive experience with both techniques of TS. Thus the 
only way that the results of the microscopic and endoscopic technique of TS in CD can 
currently be compared in a large number of patients is via a meta-analysis. However, at 
present remission rates between different studies are difficult to compare as remis-
sion criteria vary immensely between different studies (Table 2). It is therefore of the 
greatest importance that a good consensus statement is established about the defini-
tion of remission and recurrence of CD after TS for future research purposes.
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In conclusion, endoscopic TS is a safe and effective treatment for all patients with CD. 
Recurrence rates after endoscopic TS are comparable to those published for micro-
scopic TS. Our data suggest that in patients with non-invasive and invasive macroade-
nomas the endoscopic technique of TS should be the technique of choice as remission 
rates seem to be higher than remission rates reported for microscopic TS, although no 
formal comparative study has been performed. In MRI-negative CD or microadenomas 
the preference of the neurosurgeon and/or the patient should determine the technique 
of TS that is used, because remission and complication rates that are reported in micro-
scopic TS and endoscopic TS are comparable.
77
3)  Endoscopic transsphenoidal surgery in Cushing’s disease
Reference list
1  Dekkers OM, Biermasz NR, Pereira AM et al. 
Mortality in patients treated for Cushing’s 
disease is increased, compared with pa-
tients treated for nonfunctioning pituitary 
macroadenoma. Journal of Clinical Endocri-
nology and Metabolism 2007; 92: 976-981.
2  Lindholm J, Juul S, Jorgensen JO et al.. Inci-
dence and late prognosis of cushing’s syn-
drome: a population-based study. Journal of 
Clinical Endocrinology and Metabolism 2001; 
86: 117-123.
3   Hassan-Smith ZK, Sherlock M, Reulen RC et 
al. Outcome of Cushing’s disease following 
transsphenoidal surgery in a single center 
over 20 years. Journal of Clinical Endocrinol-
ogy and Metabolism 2012; 97: 1194-1201.
4  Mehta GU, Lonser RR, Oldfield EH. The histo-
ry of pituitary surgery for Cushing disease. 
Journal of Neurosurgery 2012; 116: 261-268.
5  Alwani RA, de Herder WW, van Aken MO et al. 
Biochemical predictors of outcome of pitu-
itary surgery for Cushing’s disease. Neuro-
endocrinology 2010; 91: 169-178.
6   Chen JC, Amar AP, Choi S, Singer P, Couldwell 
WT, Weiss MH. Transsphenoidal microsurgi-
cal treatment of Cushing disease: postop-
erative assessment of surgical efficacy by 
application of an overnight low-dose dexa-
methasone suppression test. Journal of 
Neurosurgery 2003; 98: 967-973.
7  Ciric I, Zhao JC, Du H et al. Transsphenoidal 
surgery for Cushing disease: experience 
with 136 patients. Neurosurgery 2012; 70: 
70-80.
8  Esposito F, Dusick JR, Cohan P et al. Clinical 
review: Early morning cortisol levels as a 
predictor of remission after transsphenoi-
dal surgery for Cushing’s disease. Journal 
of Clinical Endocrinology and Metabolism 
2006; 91: 7-13.
9  Hammer GD, Tyrrell JB, Lamborn KR et al. 
Transsphenoidal microsurgery for Cushing’s 
disease: initial outcome and long-term re-
sults. Journal of Clinical Endocrinology and 
Metabolism 2004; 89: 6348-6357.
10  Honegger J, Schmalisch K, Beuschlein F et 
al. Contemporary microsurgical concept for 
the treatment of Cushing’s disease: endo-
crine outcome in 83 consecutive patients. 
Clinical Endocrinology 2012; 76: 560-567.
11  Patil CG, Prevedello DM, Lad SP et al. Late re-
currences of Cushing’s disease after initial 
successful transsphenoidal surgery. Journal 
of Clinical Endocrinology and Metabolism 
2008; 93: 358-362.
12  Prevedello DM, Pouratian N, Sherman J et al. 
Management of Cushing’s disease: outcome 
in patients with microadenoma detected on 
pituitary magnetic resonance imaging. Jour-
nal of Neurosurgery 2008; 109: 751-759.
13  Rees DA, Hanna FW, Davies JS, Mills RG, Va-
fidis J, Scanlon MF. Long-term follow-up re-
sults of transsphenoidal surgery for Cush-
ing’s disease in a single centre using strict 
criteria for remission. Clinical Endocrinology 
2002; 56: 541-551.
14.  Rollin G, Ferreira NP, Czepielewski MA. Pro-
spective evaluation of transsphenoidal pi-
tuitary surgery in 108 patients with Cushing’s 
disease. Arquivos Brasileiros de Endocrinolo-
gia and Metabologia 2007; 51: 1355-1361.
15  Shimon I, Ram Z, Cohen ZR, Hadani M. Trans-
sphenoidal surgery for Cushing’s disease: 
endocrinological follow-up monitoring of 82 
patients. Neurosurgery 2002; 51: 57-61.
16  Swearingen B, Biller BM, Barker FG et al.. 
Long-term mortality after transsphenoidal 
surgery for Cushing disease. Annals of Inter-
nal Medicine 1999; 130; 821-824.
17  Feelders RA, Hofland LJ, de Herder WW. 
Medical treatment of Cushing’s syndrome: 
adrenal-blocking drugs and ketaconazole. 
Neuroendocrinology 2010; 92 Suppl 1: 111-115.
18  Tabaee A, Anand VK, Barron Y et al. Endo-
3
78
scopic pituitary surgery: a systematic re-
view and meta-analysis. Journal of Neuro-
surgery 2009; 111: 545-554.
19  DeKlotz TR, Chia SH, Lu W, Makambi KH, Auli-
si E, Deeb Z. Meta-analysis of endoscopic 
versus sublabial pituitary surgery. Laryngo-
scope 2012; 122: 511-518.
20  Dehdashti AR, Ganna A, Karabatsou K, Gentili 
F. Pure endoscopic endonasal approach for 
pituitary adenomas: early surgical results in 
200 patients and comparison with previous 
microsurgical series. Neurosurgery 2008; 
62: 1006-1015.
21  Jane JA, Jr., Starke RM, Elzoghby MA et al. 
Endoscopic transsphenoidal surgery for ac-
romegaly: remission using modern criteria, 
complications, and predictors of outcome. 
Journal of Clinical Endocrinology and Metab-
olism 2011; 96: 2732-2740.
22  Wagenmakers MA, Netea-Maier RT, van 
Lindert EJ, Pieters GF, Grotenhuis AJ, Hermus 
AR. Results of endoscopic transsphenoi-
dal pituitary surgery in 40 patients with a 
growth hormone-secreting macroadenoma. 
Acta Neurochirurgica 2011; 153: 1391-1399.
23.  Netea-Maier RT, van Lindert EJ, den Heijer 
M et al. Transsphenoidal pituitary surgery 
via the endoscopic technique: results in 35 
consecutive patients with Cushing’s dis-
ease. European Journal of Endocrinology 
2006; 154: 675-684.
24  Starke RM, Reames DL, Chen CJ, Laws ER, 
Jane JA, Jr. Pure Endoscopic Transsphenoidal 
Surgery for Cushing’s Disease: Techniques, 
Outcomes, and Predictors of Remission. 
Neurosurgery 2013; 72: 240-247. 
25  Dehdashti AR, Gentili F. Current state of the 
art in the diagnosis and surgical treatment 
of Cushing disease: early experience with 
a purely endoscopic endonasal technique. 
Neurosurgical Focus 2007; 23: E9.
26  Jagannathan J, Sheehan JP, Jane JA, Jr. Eval-
uation and management of Cushing syn-
drome in cases of negative sellar magnetic 
resonance imaging. Neurosurgical Focus 
2007; 23: E3.
27  Oldfield EH. Editorial: Unresolved issues: 
radiosurgery versus radiation therapy; 
medical suppression of growth hormone 
production during radiosurgery; and endo-
scopic surgery versus microscopic surgery. 
Neurosurgical Focus 2010; 29: E16.
28  Nieman LK, Biller BM, Findling JW et al. The 
diagnosis of Cushing’s syndrome: an En-
docrine Society Clinical Practice Guideline. 
Journal of Clinical Endocrinology and Metab-
olism 2008; 93: 1526-1540.
29  Wagenmakers MA, Netea-Maier RT, van 
Lindert EJ, Timmers HJ, Grotenhuis JA, Her-
mus AR. Repeated transsphenoidal pituitary 
surgery (TS. via the endoscopic technique: 
a good therapeutic option for recurrent or 
persistent Cushing’s disease (CD.. Clinical 
Endocrinology 2009; 70: 274-280.
30.  Levy MJ, Jager HR, Powell M, Matharu MS, 
Meeran K, Goadsby PJ. Pituitary volume and 
headache: size is not everything. Archives 
of Neurology 2004; 61: 721-725.
31  Hardy J. Transphenoidal microsurgical treat-
ment of pituitary tumours. In Recent ad-
vances in the diagnosis and treatment of 
pituitary tumours., pp 375–388. New York: 
Raven Press, 1979.
32  Knosp E, Steiner E, Kitz K, Matula C. Pituitary 
adenomas with invasion of the cavernous 
sinus space: a magnetic resonance imaging 
classification compared with surgical find-
ings. Neurosurgery 1993; 33: 610-617.
33  Biller BM, Grossman AB, Stewart PM et al. 
Treatment of ACTH-dependent Cushing’s 
syndrome: a consensus statement. Journal 
of Clinical Endocrinology and Metabolism 
2008; 93: 2454-62.
34  Yap LB, Turner HE, Adams CB, Wass JA. Un-
detectable postoperative cortisol does not 
always predict long-term remission in Cush-
ing’s disease: a single centre audit. Clinical 
Endocrinology 2002; 56: 25-31.
79
3
3)  Endoscopic transsphenoidal surgery in Cushing’s disease
35  Fomekong E, Maiter D, Grandin C, Raftopou-
los C. Outcome of transsphenoidal surgery 
for Cushing’s disease: a high remission rate 
in ACTH-secreting macroadenomas. Clinical 
Neurology and Neurosurgery 2009; 111: 442-
449.
36  De Tommasi C, Vance ML, Okonkwo DO, Diallo 
A, Laws ER, Jr. Surgical management of ad-
renocorticotropic hormone-secreting mac-
roadenomas: outcome and challenges in 
patients with Cushing’s disease or Nelson’s 
syndrome. Journal of Neurosurgery 2005; 
103: 825-830.
37  Ceylan S, Koc K, Anik I. Endoscopic endona-
sal transsphenoidal approach for pituitary 
adenomas invading the cavernous sinus. 
Journal of Neurosurgery 2010; 112: 99-107.
38  Atkinson AB, Kennedy A, Wiggam MI, Mc-
Cance DR, Sheridan B. Long-term remission 
rates after pituitary surgery for Cushing’s 
disease: the need for long-term surveil-
lance. Clinical Endocrinology 2005; 63: 549-
559.
39 Chee GH, Mathias DB, James RA, Kendall-Tay-
lor P. Transsphenoidal pituitary surgery in 
Cushing’s disease: can we predict outcome? 
Clinical Endocrinology 2001; 54: 617-626.
80
4
481
M.A.E.M. Wagenmakers1, R.T. Netea-Maier1, E.J. van Lindert2, H.J.L.M. Timmers1, J.A. Grotenhuis2 and 
A.R.M.M. Hermus1
Affiliations: Pituitary Centre Nijmegen, 1Department of Endocrinology and 2Department of 
Neurosurgery, Radboud University Nijmegen Medical Centre, Geert Grooteplein 8, 6500 HB, Nijmegen, 
The Netherlands
Clinical Endocrinology, 2009. 70(2): p. 274-280.
Repeated transsphenoidal 
pituitary surgery via the 
endoscopic technique: 
a good therapeutic option 
for recurrent or persistent 
Cushing’s disease4
82
Abstract
 
Background: No data on results of repeated transsphenoidal surgery via the endoscopic 
technique for patients with persistent or recurrent Cushing’s disease are available. 
Design and patients: We retrospectively evaluated the remission rates and complica-
tions of repeated transsphenoidal surgery via the endoscopic technique in 14 patients 
with persistent (N=6) or recurrent (N=8) Cushing’s disease treated in our centre between 
1999 and 2007. 
Main Outcomes: Remission was defined as disappearance of symptoms of hypercor-
tisolism with basal plasma cortisol level ≤ 50 nmol/L 24-48 hours after glucocorticoid 
withdrawal and/or suppression of plasma cortisol level ≤ 50 nmol/L after 1 mg dexa-
methasone overnight within the first 3 months after transsphenoidal surgery.
Results: With repeated endoscopic transsphenoidal surgery a remission rate of 10/14 
(71%) was achieved. No patient had a relapse during a median follow-up of 24 months. 
Cerebrospinal fluid leakage was the most frequent complication (6 patients) and 11 
patients required hormonal substitution after surgery. The success of repeated trans-
sphenoidal surgery could not be predicted by visualisation of an adenoma on MRI before 
first or second surgery, histopathological confirmation of an ACTH secreting adenoma 
after first or second surgery, treatment with cortisol lowering agents before first or 
second surgery, the operation technique used during the first surgery, persistent versus 
recurrent disease after the first surgery, age, gender and interval between the two 
surgeries.
Conclusion: Repeated transsphenoidal surgery via the endoscopic technique is a good 
treatment option for selected patients with recurrent or persistent Cushing’s disease 
following primary pituitary surgery. 
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Introduction
Cushing’s disease (CD) is a potentially life threatening condition that requires aggressive 
treatment 1,2. At present transsphenoidal pituitary surgery (TS) is the primary treatment 
of choice. Remission rates vary from 50 to 90%. However, CD persists in the remaining 
patients, and 5-25% of the patients who are initially in remission develop a recurrence 
3-8. Treatment options for persistent or recurrent CD include radiation therapy, bilateral 
adrenalectomy, medical therapy and repeated TS. Thus far, no consensus exists on 
which therapy is preferable 5,9,10. 
Pituitary radiotherapy has been used to treat persistent or recurrent CD for several 
decades. Remission rates after conventional fractionated radiation therapy range 
from 56 to 84% 5,9. However, its usefulness is limited by the delay between therapy 
and disease control and the 50% to 100% incidence of hypopituitarism several years 
after treatment. Additional complications include radiation necrosis, cerebral vascu-
lopathy, damage to surrounding structures and the development of radiation-induced 
neoplasms. Stereotactic radiosurgery, which was introduced more recently, may lead to 
faster normalisation of hormone levels with a lower complication risk than conventional 
radiotherapy, but long-term follow-up is needed to determine its real value 5,9,11,12. 
Bilateral adrenalectomy has a very high success rate of reversing hypercortisolism, 
ranging from 88% to 100%. Traditionally, open procedures of adrenalectomy were asso-
ciated with considerable morbidity and mortality 13,14. Nowadays the minimally inva-
sive laparoscopic approach is preferred, which has reduced perioperative morbidity 
significantly 9,15. However, adrenalectomised patients require lifelong glucocorticoid 
and mineralocorticoid replacement. The major concern is the development of Nelson’s 
syndrome in 15 to 46% of the patients 5,16,17. 
Medical therapy in CD mostly serves an adjunctive role after unsuccessful TS. At present 
only steroidogenesis inhibitors have been proven effective. Furthermore, discontinu-
ation of medical treatment will invariably result in recurrence of CD and all available 
medicaments have significant side effects 18. 
Repeated TS may be a good treatment option for persistent or recurrent CD. It has the 
potential to instantly cure CD, while adrenal and pituitary function may remain intact. 
However, few investigators have addressed the results of repeated TS and the reported 
risk of hypopituitarism and other complications is higher than after the first TS 19-26. 
Furthermore all previous studies operated patients via the conventional microscopic 
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technique of TS. Cappabianca et. al. have suggested that the endoscopic technique 
of TS might be considered the procedure of choice in recurrent or residual pituitary 
adenomas, as the wider and direct visual control of the surgical field provides an advan-
tage if the anatomy has been distorted by previous surgery 27. No results on repeated TS 
via the endoscopic technique in CD have been published until now 27,28. 
In order to gain insight into the role of repeated TS as a treatment option for persistent 
or recurrent CD, we evaluated the remission rates and complications of repeated TS in 
14 patients, treated in our hospital between 1999 and 2007. All patients had surgery via 
the endoscopic technique.
Patients and methods
Patients
Between 1999 and 2007, 68 endoscopic TS were carried out for CD in our hospital. Four-
teen of these operations were repeated TS, for persistent CD in 6 patients and recurrent 
CD in 8 patients. The medical records of these patients were retrospectively reviewed. 
There were 5 males and 9 females and age at time of the second surgery was 37.2 ± 10.3 
years (Table 1).
Between 1999 and 2007 a total of 24 patients were treated for persistent or recurrent 
CD. Besides the fourteen patients that underwent an endoscopic repeated TS, 5 patients 
underwent conventional pituitary radiotherapy, 4 patients underwent stereotactic 
radiosurgery and 1 patient underwent a bilateral adrenalectomy. A multidisciplinary 
team of neurosurgeons, endocrinologists and a radiotherapist decided which therapy 
for persistent or recurrent CD was the optimal therapy for each individual patient, taking 
into account the invasiveness of the adenoma, findings at previous surgery, the physical 
condition of the patient and the patient’s preference.
Diagnostic evaluation before the first and second TS
The initial diagnosis of hypercortisolism was based on clinical symptoms and biochem-
ical tests, including 24-hour urinary free cortisol measurements, assessment of the 
plasma cortisol and ACTH circadian rhythm and an overnight low dose dexamethasone 
suppression test (1 mg at 23.00) 29. A  CRHtest (100 µg human CRH i.v.) 30and a high-dose 
dexamethasone suppression test 31 were performed in most patients. In addition pitu-
itary imaging by contrast enhanced magnetic resonance imaging (MRI) was performed 
in all patients, except in patient one, in whom contrast enhanced computed tomography 
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(CT) scanning was used to search for a pituitary adenoma. Eight patients underwent 
bilateral inferior petrosal sinus sampling with i.v. stimulation with 100 µg human CRH, 
which confirmed the pituitary origin of hypercortisolism in all 8 patients 32. 
To document the persistence of hypercortisolism after TS or relapse of hypercortisolism 
in patients who were in remission for some time after TS, 24-hour urinary free cortisol 
was measured, an overnight 1 mg dexamethasone suppression test was performed, 
and midnight plasma cortisol was assessed. A new MRI scan was performed before the 
second TS in all patients.
Surgical procedures
All repeated pituitary operations in this series were performed via an endoscopic binos-
tril endonasal transsphenoidal technique. This technique was introduced in our hospital 
in 1994, and first used for CD in 1997. From 1998 onward practically all TS were performed 
endoscopically. The surgeries were exclusively performed by two neurosurgeons. 
The technique is very similar to the technique Jho et al. and Cappabianca et al. have 
described previously 33-36. However, a binostril transsphenoidal endoscopic approach to 
the sella turcica during which the endoscope is handheld was used.
For endoscopic transnasal TS, 0º and 30º rigid endoscopes with a lens diameter of 4 
mm with a separate shaft were used, which allow easy and comfortable holding, while 
offering a suction-irrigation-system for cleaning the lens (Karl Storz GmbH, Tuttlingen, 
Germany). The instruments used are principally the same as with the microsurgical tech-
nique. The technique of repeated surgery is in no way different from primary surgery. In 
two recent cases electromagnetic neuronavigation was used for orientation and local-
ization of a very small tumor.
In patients with recurrent CD a selective adenomectomy was performed if MRI identi-
fied the tumor. In case of negative MRI investigations a hemihypophysectomy was 
performed based on intraoperative findings. In patients with persistent CD after first 
TS, a total hypophysectomy was performed during repeated TS. Although this term 
suggests complete removal of all contents of the sella, it is never the intention to 
remove all pituitary tissue. Total hypophysectomy indicates the surgical exploration 
of the complete contents of the sella and removal of all anterior pituitary tissue that 
might harbor adenoma tissue. As soon as this goal seems to be achieved, further 
surgery is discontinued and thus pituitary tissue may be left in place.
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Perioperative treatment
Cortisol lowering agents (metyrapone and/or ketoconazole) were given for a period of 
4 months preoperatively in 9 patients before the first TS and in 7 patients before the 
second TS.
Administration of glucocorticoids i.v. (prednisolone, 25 mg every 8 h) was started one 
hour before surgery. After two days glucocorticoids were given orally and the dose was 
tapered rapidly. There was an interval of at least 48 hours between the last dose of 
glucocorticoids and the first postoperative measurement of fasting plasma cortisol on 
the seventh day postoperatively.
Postoperative evaluation after first and second TS
On the seventh day postoperatively, early biochemical evaluation was carried out, 
consisting of measurement of fasting (0800 h) plasma cortisol. If it was lower than 200 
nmol/L, substitution therapy with hydrocortisone 30 mg a day, or cortisone acetate, 37.5 
mg daily, was prescribed. Patients were re-evaluated every 2 to 4 weeks during the first 
3 months after surgery and then at 2-3 months intervals during the first year. Thereafter 
they were evaluated at least once a year.
The fasting plasma cortisol concentration was measured at each visit. In addition an 
overnight 1 mg dexamethasone suppression test was carried out 1 and 3 months post-
operatively, and thereafter in patients who were in remission once yearly or earlier in 
case of clinical suspicion of relapse. If a patient received glucocorticoid substitution 
postoperatively, the dose was reduced gradually and stopped, if possible between 3 and 
12 months after surgery. Thereafter the integrity of the hypothalamic-pituitary-adrenal 
axis was assessed by an insulin-hypoglycaemia test 37. The thyrotropic, gonadotropic 
and somatotropic axes were checked regularly.
Criteria for remission and relapse
Remission was defined as disappearance of clinical symptoms of hypercortisolism 
with basal plasma cortisol level ≤50 nmol/L after glucocorticoid withdrawal for 24-48 
hours and/or suppression of plasma cortisol level ≤ 50 nmol/L after overnight 1 mg dexa-
methasone within the first 3 months after surgery.6,7,10 Relapse was defined as develop-
ment of clinical symptoms of hypercortisolism and inadequate suppression of plasma 
cortisol level after an overnight 1 mg dexamethasone suppression test in patients who 
were in remission after the first surgery according to the previously mentioned criteria.
Statistics
Statistical analyses were performed using Pearson’s Chi-square tests (P) and Wilcoxon’s 
two sample tests (P*). Statistical significance was defined as P<0.05 (two tailed).
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Results
Remission rates after repeated TS (Figure 1)
The individual clinical data of the 14 patients are shown in Tables 1 and 2. The mean 
interval between the first and the second TS was 59 months (median 39, range 2-185).
After repeated TS remission was achieved in 10 patients. Nevertheless, patients 1 and 9 
received additional therapy. Patient 1 was concerned that hypercortisolism would recur 
and asked for additional radiotherapy. Patient 9 was the only patient with an invasive 
macroadenoma that could not entirely be removed during the second surgery. There-
fore the patient received additional gamma knife surgery, although he was clinically and 
biochemically in remission.
None of the patients who were in remission after the second TS had a relapse during 
follow-up of mean 34 months (median 24, range 4 to 97). At last follow-up plasma 
cortisol was not suppressed to ≤ 50 nmol/L after 1 mg dexamethasone overnight in 
patients 1,2,7 and 10 (table 2), but they had no clinical symptoms of hypercortisolism and 
24-hour urinary free cortisol excretion was not elevated. Four patients had persistent 
CD after the second TS. Patient 3 underwent a bilateral adrenalectomy and patients 5, 6 
and 8 received conventional radiotherapy.
There were no statistically significant differences between the patients who under-
went successful or unsuccessful repeated TS with respect to the following parameters: 
visualisation of an adenoma on MRI before first or second TS, histopathological confir-
mation of an ACTH secreting adenoma after first or second TS, treatment with cortisol 
lowering agents before first or second TS, the operation technique used during the 
first TS, persistent versus recurrent disease after the first TS, age, gender and interval 
between the two TS.
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Table 1) Clinical characteristics per patient: first and second transsphenoidal pitu- 
 itary surgery (1999-2007). (page 88-89)
1st surgery 2nd surgery
Patient number, 
Gender,
Age (years)
MRI Technique Histology Result 1st - 2nd
surgery (months)
CLA MRI Year Technique Histology Cortisol
(nmol/L)
 
Result
 Basal  After Dex
1. f, 36 < 10* TE + R 131 - < 10 1999 Endo TS + 0.50 0.02 R
2. f, 45 - Endo TS - F 2 M - 2001 Endo TS - 0.05 0.02 R
3. f, 36 - Endo TS - F 3 - - 2002 Endo TS - 0.55 0.21 F
4. m, 30 - Endo TS - R 11 M < 10 2002 Endo TS - 0.02 0.05 R
5. m, 41 < 10 TS + R 98 K < 10, in 2005 Endo TS NT 0.38 - F
6. f, 30 < 10 Endo TS - F 5 K < 10 2005 Endo TS + 0.57 0.25 F
7. m, 46 < 10 TS + F 185 K < 10 2005 Endo TS + 0.05 0.07 R
8. f, 22 < 10 Endo TS - F 38 K < 10 2006 Endo TS - 0.59 0.50 F
9. m, 27 < 10 Endo TS + R 53 - 22, in 2006 Endo TS + 0.15 0.04 R
10. f, 40 35 Endo TS - R 41 - < 10 2006 Endo TS + 0.02 0.03 R
11. m, 56 < 10 TS + R 124 - < 10 2006 Endo TS + 0.21 0.02 R
12. f, 27 - Endo TS - F 2 K < 10 2006 Endo TS - 0.01 - R
13. f, 54 - Endo TS - R 32 - - 2006 Endo TS - 0.02 - R
14. f, 31 < 10 TS - R 104 - < 10 2007 Endo TS + 0.01 - R
Age: age at second surgery; f: female; m: male; MRI: magnetic resonance imaging results given as maximal 
diameter of the visualised adenoma in mm; MRI *: Computed tomography scan was made instead of an 
MRI scan; MRI - : no adenoma identified; MRI in: invasion in cavernous sinus or other parasellar structures; 
TE: transethmoidal pituitary surgery; TS: microscopic transsphenoidal pituitary surgery; Endo TS: endo-
scopic transsphenoidal pituitary surgery; Histology +: evidence of ACTH-producing adenoma on histo-
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logical examination; Histology -: no evidence of ACTH-producing adenoma on histological examination; 
Histology NT: no tissue obtained during surgery; CLA: preoperative therapy with cortisol lowering agents; 
M: metyrapone; K: ketoconazole; Cortisol basal: fasting plasma cortisol level at 0800h on seventh day 
after surgery; Dex: plasma cortisol level at 0800h after 1 mg dexamethasone overnight; R: remission; F: 
failure.
Table 1) Clinical characteristics per patient: first and second transsphenoidal pitu- 
 itary surgery (1999-2007). (page 88-89)
1st surgery 2nd surgery
Patient number, 
Gender,
Age (years)
MRI Technique Histology Result 1st - 2nd
surgery (months)
CLA MRI Year Technique Histology Cortisol
(nmol/L)
 
Result
 Basal  After Dex
1. f, 36 < 10* TE + R 131 - < 10 1999 Endo TS + 0.50 0.02 R
2. f, 45 - Endo TS - F 2 M - 2001 Endo TS - 0.05 0.02 R
3. f, 36 - Endo TS - F 3 - - 2002 Endo TS - 0.55 0.21 F
4. m, 30 - Endo TS - R 11 M < 10 2002 Endo TS - 0.02 0.05 R
5. m, 41 < 10 TS + R 98 K < 10, in 2005 Endo TS NT 0.38 - F
6. f, 30 < 10 Endo TS - F 5 K < 10 2005 Endo TS + 0.57 0.25 F
7. m, 46 < 10 TS + F 185 K < 10 2005 Endo TS + 0.05 0.07 R
8. f, 22 < 10 Endo TS - F 38 K < 10 2006 Endo TS - 0.59 0.50 F
9. m, 27 < 10 Endo TS + R 53 - 22, in 2006 Endo TS + 0.15 0.04 R
10. f, 40 35 Endo TS - R 41 - < 10 2006 Endo TS + 0.02 0.03 R
11. m, 56 < 10 TS + R 124 - < 10 2006 Endo TS + 0.21 0.02 R
12. f, 27 - Endo TS - F 2 K < 10 2006 Endo TS - 0.01 - R
13. f, 54 - Endo TS - R 32 - - 2006 Endo TS - 0.02 - R
14. f, 31 < 10 TS - R 104 - < 10 2007 Endo TS + 0.01 - R
Age: age at second surgery; f: female; m: male; MRI: magnetic resonance imaging results given as maximal 
diameter of the visualised adenoma in mm; MRI *: Computed tomography scan was made instead of an 
MRI scan; MRI - : no adenoma identified; MRI in: invasion in cavernous sinus or other parasellar structures; 
TE: transethmoidal pituitary surgery; TS: microscopic transsphenoidal pituitary surgery; Endo TS: endo-
scopic transsphenoidal pituitary surgery; Histology +: evidence of ACTH-producing adenoma on histo-
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Table 2)  Substitution therapy and follow-up after second pituitary surgery
 (1999-2007).
Patient
number
Substitution
after
1st TS*
Substitution
after
2nd TS**
Result
2nd
surgery
Additional 
Therapy
Cortisol at last 
follow-up 
(nmol/L)
Follow-up
(months)
Basal After dex
1 - - R CR (45 Gy) 0.46 0.08 94
2. - T, GH R - 0.57 0.06 83
3. - T F ADX - - 68
4. - A, GH, G R - 0.15 0.03 61
5. - - F CR (50 Gy), K - - 30
6. T T F CR (50 Gy) - - 28
7. - T, G R - 0.13 0.09 30
8. - T F CR (45 Gy), K - - 15
9. - A R RS 0.10 <0.02 17
10. - T R - 0.18 0.08 15
11. T T, GH R - 0.26 <0.02 15
12. - - R - 0.40 <0.02 13
13. - G R - 0.06 <0.02 13
14. G,T,GH,E G,T,GH,E R - 0.04 <0.02 3
*: at last evaluation before relapse was diagnosed or in case of persistent Cushing’s disease immediately 
before second TS; **: At last follow-up; A: androgens; D: desmopressin; E: estrogens; G: glucocorticoids; GH: 
growth hormone; T: Levothyroxine; CR: conventional radiotherapy; RS: radiosurgery; ADX: bilateral adre-
nalectomy; K: ketoconazole; Cortisol at last follow-up: fasting plasma cortisol level at 0800h and plasma 
cortisol level at 0800h after 1 mg dexamethasone overnight, measured in January 2008 in patients who 
were clinically in remission after 2nd surgery.
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Table 3) Overview of previously published results of repeated TS in patients with 
 persistent or recurrent CD.
Population Criteria remission Remission (%) Relapse (%)
Friedman et al. 
(1989)
33 persistent
+ recurrent
Morning C < 6 µg/dl
 and UFC < 90 µg/day 
73 13
Ram et al. 
(1994)
17 persistent* Morning C < 5 µg/dl 
and UFC < 90 µg/dag 
71 25
Knappe et al. 
(1996) 
10 persistent * 
/ 17 recurrent
Not defined 71/ 56 24/22
Benveniste et 
al. (2005)
44 persistent
+ recurrent
Not defined 57 25
Locatteli et al. 
(2005)
12 persistent * Clinical symptoms of 
hypocortisolism and 
morning C ≤ 2µg/dl
67 0
Hofman et 
al.(2006)
16 recurrent C < 2 µg/dl after 2 mg 
dexamethasone and 
morning C 10 –21 µg/dl 
37 0
TS: transsphenoidal pituitary surgery; CD: Cushing’s disease; * : immediate reoperation; C: plasma cortisol; 
UFC: urinary free cortisol excretion.
Complications of repeated TS
Six of the 14 patients had mild transient diabetes insipidus. Six patients had cerebro-
spinal fluid (CSF) leakage, 4 intraoperatively (closed with a fat graft) and 2 postoper-
atively. All six patients with CSF leakage were treated successfully with an external 
lumbar drain. Two patients required a reoperation to close the leak. More serious compli-
cations occurred in 2 patients. Patient 5 had blood loss from the right cavernous sinus 
during second TS. Damage of the internal carotid artery was excluded via an angiogram. 
Surgery was terminated before any tissue was removed and a tampon was placed that 
was removed via reexploration one week later. A few hours after the reexploration the 
patient developed a hemiparesis, due to occlusion of the left internal carotid artery just 
above the bifurcation. This was very unlikely a direct complication of the TS because 
the site of occlusion of the internal carotid artery was lower than the operation area. 
Although the patient improved significantly during the revalidation process, perma-
nent disabilities remain. Patient 11 had postoperative bleeding from the sphenopala-
tine artery. Reexploration was required with successful coagulation of the artery. The 
patient recovered within a few days without other complications.
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Only 3 patients required hormonal substitution after the first TS. After the second TS 11 
patients required long-term hormonal substitution (Table 2). Of all patients, 8 required 
levothyroxine, 4 glucocorticoids, 4 growth hormone and 2 androgens and 1 estrogens 
after repeated TS.
Discussion
The present study is the first study to report on the outcome of repeated TS via the 
endoscopic technique in patients with persistent or recurrent CD. In 1994 the endo-
scopic technique for TS was introduced in our hospital. Because of the minimal inva-
siveness, the excellent view of the surgical field and wider working angle, practically all 
TS were done endoscopically from 1998 onward. Before the introduction of the endo-
scopic technique we regarded repeated TS as a technically difficult procedure. There-
fore, most patients with persistent and recurrent CD treated in our centre before 1999 
underwent bilateral adrenalectomy or radiotherapy, and only 4 patients underwent 
repeated TS. Only 1 of these 4 patients was cured. After the introduction of the endo-
scopic technique repeated TS became more feasible. The wider view of the endoscopic 
technique provides an advantage, during repeated TS, as the anatomy is altered due 
to the previous operation 27. A substantially higher remission rate of 71% was achieved 
in the fourteen patients operated on endoscopically and there was no relapse during 
follow-up of median 24 months.
The remission rate of 71% achieved in this study compares favourably with the remis-
sion rates previously reported after repeated TS via the conventional microscopic 
technique, which vary between 37% and 73%, with a 0-25% relapse rate 19-24 (Table 4). 
When comparing the reported remission rates, it is important to note that the studies 
were carried out in different patient groups. Three studies included patients with both 
persistent and recurrent CD 19-21, whereas other studies reported on patients with either 
persistent 22-23 or recurrent 24 CD. Criteria for remission also differed. In three studies 
immediate repeated TS was performed in case of persistent CD 21-23. However, this 
strategy ignores the fact that some patients who do not have a low early postoper-
ative basal plasma cortisol level do achieve remission, so by using this strategy some 
patients will unnecessarily undergo immediate repeated TS 8. Overall, the remission 
rates reported after second TS in persistent or recurrent CD seem to be slightly lower 
than the remission rates reported after first TS, which vary from 50-90%, but are mostly 
70-85% 3-9. Nevertheless, the majority of the patients with persistent or recurrent CD 
can still instantly be cured by repeated TS, and the remission rate we achieved via the 
93
4
4)  Repeated endoscopic transsphenoidal surgery in Cushing’s disease
endoscopic technique seems to be at least as good as the remission rate achieved by 
repeated TS via the conventional microscopic technique.
In this study 57% of the patients had a perioperative complication of the repeated 
TS. Although most complications in our series were mild and transient more serious 
complications occurred in two patients: one patient had a cerebrovascular accident 
postoperatively and another patient had postoperative bleeding from the sphenopala-
tine artery. The latter complication is not a rare complication of microscopic TS, occur-
ring in 3.4 % of all cases. Vascular complications of endoscopic TS and microscopic 
TS are identical 38. We previously reported a complication rate of 29% in our study on 
results of primary endoscopic TS in patients with CD3, which is similar to the complica-
tion rates reported in studies of primary microscopic TS in patients with CD. The studies 
on repeated TS in patients with persistent or recurrent CD report complication rates 
varying between 0 and 91% 19-24. Although complication rates are influenced substan-
tially by differences in definitions, the complication rate of repeated TS seems to be 
higher than the complication rate of primary TS.
Especially CSF leakage has been reported to occur more frequently during repeated TS 
than during the first TS, probably because of postoperative changes such as scar tissue, 
but also as a result of a more aggressive surgical procedure in a usually small sella with 
a concave diaphragm 22,28,39. CSF leakage occurred in 43% of the patients in this study, 
intraoperatively in 4 patients and postoperatively in 2 patients. Previously, we reported 
a CSF leakage rate of 8.5% in primary endoscopic TS in patients with CD operated on by 
the same neurosurgeons that operated on the patients in this study 3. When comparing 
rates of CSF leakage it is important to note that most studies only report on the rates of 
postoperative CSF leakage. The rate of postoperative CSF leakage is lower (1-4% during 
first TS) than the rate of intraoperative CSF leakage (9-25% during first TS) 39-40. Because 
intraoperative CSF leakage, which is usually not regarded as a complication, also occurs 
frequently during the first TS and the risk of meningitis is minimal if patients are given 
a lumbar drain, 41 we believe that the higher chance of CSFleakage during repeated TS 
should not be a reason to refrain from repeated TS.
The chance of hypopituitarism after repeated TS is higher than after the first TS. Reported 
percentages of hormonal deficiencies in patients with CD after the first TS vary from 
2-48%, but are mostly around 20%. Ram et al. 23 and Friedman et al. 20 reported rates of 
hormonal deficiencies after repeated TS in 41% and 50% of the patients. Locatelli et al. 
found an extremely high rate of hormonal deficiencies (100%), but all patients under-
went a total hypophysectomy 22. Hofmann et al. 24 and Knappe et al. 21 report on new 
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hormonal deficiencies in 0% and 8%. In the present series the percentage of patients 
with hormonal deficiencies was 78% after the second TS, with 6 patients having only 
one hormonal deficiency. The rate of hormonal deficiencies was 48% in our earlier study 
on results of first endoscopic TS in patients with CD 3. The higher rates of hypopituita-
rism after repeated TS compared to after the first TS can be expected because addi-
tional pituitary tissue is removed. Even so, the risk of hypopituitarism after second TS 
seems to be lower than reported rates of hypopituitarism several years after radio-
therapy 9,11 .
The success rate of repeated TS for persistent or recurrent CD depends on the correct 
selection of patients. In our opinion TS is a good treatment option if there is a reason-
able chance that it will be successful. CD can be controlled instantly with the possibility 
to normalise cortisol circadian rhythm and keep the pituitary adrenal axis intact. Radio-
therapy, however, is a good option if an adenoma is invasive.
Success rates of TS also critically depend on the skills and the experience of the neuro-
surgeons 42. Repeated TS is an even more difficult procedure than a first TS, and repeated 
TS is infrequently performed. Thus it is advised to concentrate repeated TS for CD in a 
limited number of specialised centres.
In conclusion, repeated TS is a good therapeutic option for selected patients with 
persistent or recurrent CD, with the potential to achieve remission in the majority 
of patients. The remission rate of 71% we achieved via the endoscopic technique of 
repeated TS compares favourably with the remission rate of repeated TS via the 
conventional microscopic technique previously described in the literature. The excel-
lent view of the surgical field during endoscopic TS provides an advantage in case of 
altered anatomy due to previous surgery.
However, only a randomised trial can definitively assess whether the endoscopic or the 
microscopic technique of TS is the preferred technique for repeated surgery in patients 
with persistent or recurrent CD.
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Abstract 
Context: Acromegaly is associated with impaired quality of life (QoL) and causes anatom-
ical disproportions, which may contribute to the decreased QoL after successful treat-
ment. The Derriford appearance scale 59 (DAS59) is a questionnaire measuring psycho-
logical distress and disruptions to everyday life associated with self-consciousness of 
appearance.
Objective: To investigate the psychological distress and dysfunction related to selfcon-
sciousness about appearance and its effect on - QoL in patients in long-term remission 
of acromegaly. 
Patients, design and methods: Patients (>18 years old) treated for acromegaly at the 
Department of Endocrinology of the Radboud University Medical Center Nijmegen were 
invited to participate. A gender-, age- and body mass index (BMI)- matched control group 
was provided by the patients themselves. Participants were asked to complete the 
modified DAS59-, research and development 36- (RAND-36), acromegaly quality of life 
questionnaire- (AcroQoL) and a sociodemographic questionnaire. Differences between 
patient and control groups and correlations between questionnaire scores and clinical 
characteristics collected from medical records were analyzed. 
Main outcome measures: Questionnaire scores.
Results: Of the 120 respondents, 73 agreed to participate [all cured or under biochemical 
control, median remission time 10.5 years (range 2.3-43.6 years)]. Of these, 34 (46.6%) 
reported self-consciousness about their appearance. Twenty-nine of these patients 
(85.3%) pointed out their face to be a prominent source of self-consciousness. Fifty-
seven matched control subjects were included as well. Significant correlations were 
found between the scores of the DAS59 and the AcroQoL, RAND-36 and VAS in patients.
Conclusions: Even after long-term remission of acromegaly, a large number of patients 
are self-conscious about their appearance, leading to psychological distress and disrup-
tions to everyday life and decreased QoL. Facial features were the most important 
source of self-consciousness. This stresses the importance of addressing self-con-
sciousness of appearance and the need for additional support in this regard during 
follow-up in these patients. 
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Introduction
Craniofacial disproportions due to soft tissue swelling and new bone formation are 
highly prevalent in patients with active acromegaly 1 . Although clinically there is a 
slight improvement in facial appearance after biochemical control of growth hormone 
(GH) hypersecretion, we have recently shown that significant differences in cranio-
facial characteristics persist even after long-term remission 2. It has been suggested 
that these changes in appearance can lead to self-consciousness about appearance, 
leading towards self-esteem disintegration, social withdrawal, body image distortion 
and an impaired quality of life (QoL) 3. 
Previous studies, which used the disease-specific AcroQoL questionnaire, have shown 
that patients with both active and controlled acromegaly have an impaired QoL. Remark-
ably, the appearance subscale of the AcroQoL was the most affected subscale in these 
studies 4-7. Moreover, the patients in remission of acromegaly had only slightly better 
scores on the appearance subscale than patients with active disease 4,6,8. However the 
appearance subscale of the AcroQoL is limited and does not investigate which aspect of 
appearance specifically causes the self-consciousness related distress.
The Derriford appearance scale 59 (DAS59) is a psychological questionnaire, developed 
for research in plastic surgery and oncology. It measures self-consciousness about one’s 
appearance and identifies the anatomical source of this self-consciousness. It is vali-
dated for both clinical and research settings. It has an excellent validity and reliability, 
and has been independently recommended as a measure of choice for the assessment 
of feelings about appearance 9,10. However, the DAS59 had never been used in patients 
with acromegaly. 
The primary aim of the present study was to investigate, by using the DAS59 question-
naire, whether patients in long-term remission of acromegaly suffer from more psycho-
logical distress and psychological and social dysfunction related to self-conscious-
ness of appearance than a gender-, age- and BMI- matched control group, and whether 
this affects QoL. In addition we aimed to identify the anatomical sources of self-con-
sciousness in these patients. We hypothesised that (irreversible) changes in craniofa-
cial characteristics caused by the previous period of GH hypersecretion are related to 
the distress related to appearance in patients in long-term remission of acromegaly.
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Subjects and methods
Patients
All patients (18-80 years old) treated at the Department of Medicine, Division of Endocri-
nology of the Radboud University Medical Center Nijmegen, who had been in remission 
of acromegaly for more than 2 years, were invited to participate in this study by letter. 
Exclusion criteria were active malignancy, cardiovascular disease (unstable coronary 
artery disease, heart failure NYHA III-IV), (recent) pregnancy (within 1 year prior to the 
study), depression, psychosis and personality disorder.
Because the assessment of one’s own appearance differs in relation to gender, age and 
BMI, participants were asked to find their own control subject with the same gender and 
roughly the same age and BMI 9,11,12. 
The study was approved by our institutional ethics committee and conformed to the 
declaration of Helsinki. All participants gave written informed consent for participation 
in the study.
Questionnaires
DAS59 
The DAS-59 is a self-reporting questionnaire that generates a series of valid and reliable 
measures of the specific psychological distress and disruption to everyday life that are 
associated with self-consciousness of appearance. It is intended for use in an adult 
population (> 16 years) 9. An introductory section identifies whether a subject is self-con-
scious about their appearance and the aspect of appearance that is of the greatest 
concern to the respondent. This is referred to as the respondent’s ‘feature’ in the rest 
of the questionnaire. The DAS59 contains 59 statements and questions with response 
categories in a Likert format to measure frequency of symptomatology (‘almost never’… 
‘almost always’) and levels of associated distress (‘not at all distressed’…’extremely 
distressed’). Fifty-seven items assess relevant psychological distress and dysfunc-
tion, and two items assess physical distress and physical dysfunction. The following 
subscales were examined as described by the questionnaire manual 13: general 
self-consciousness (GSC), social self-consciousness (SSC), facial self-consciousness 
(FSC), Sexual and bodily self-consciousness (SBSC) and negative self-concept (NSC). A 
higher score on the DAS59 is associated with a greater degree of self image-related 
distress and dysfunction. The format of the introductory section and a ‘not applicable’ 
response category for most items make the scale acceptable for respondents who are 
not concerned about appearance at all. 
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In this study a linguistic and cultural translation of the DAS59 from English to Dutch was 
performed following internationally accepted guidelines 14,15 and used with permission of 
the original authors 9. The translation into Dutch was successful. The backward-transla-
tion was compared to the original English version and did not show conceptual discrep-
ancies. During piloting the items were assessed as conceptually and linguistically mean-
ingful and appropriate, and in line with the original (English) items.
The DAS59 questionnaire was modified for the purpose of this study by including a self-
rated Visual Analogue Scale (VAS) for the participants to score the level of satisfaction 
with their facial appearance in general. The VAS is a 10 cm ‘ruler’ scaled 0 (not at all satis-
fied) to 10 (very satisfied) 16. 
RAND – 36: For the assessment of general QoL the Dutch translation of the RAND-36 was 
used [18]. It comprises 36 items regarding general wellbeing during the past 30 days. The 
items are formulated as statements or questions with Likert scale or yes/no response 
options to assess 9 health concepts: 1) physical functioning; 2) social functioning; 
3) role limitations because of physical health problems; 4) role limitations because of 
emotional problems; 5) mental health; 6) vitality; 7) bodily pain, 8) general health percep-
tions, 9) health change in the last year. Scores are calculated for each health aspect on 
a 0-100 scale, in which higher scores represent a better QoL. 
AcroQoL: This is a disease-specific questionnaire developed to assess health-re-
lated QoL in patients with acromegaly 17. It comprises 22 items. Responses are given 
as the frequency of occurrence (ranging from always to never) or degree of agreement 
(ranging from completely agree to completely disagree) on a five-point scale. The ques-
tionnaire includes two different scales; a physical performance scale and a psycho-
logical well-being scale. The psychological scale is further subdivided into 2 subscales 
regarding appearance and personal relationships, containing seven items each. The 
highest achievable score is 110 (100%), which is indicative of an excellent QoL, while the 
lowest score is 22 (0%) 5. 
Sociodemographical and clinical variables: Sociodemographical and clinical charac-
teristics of patients were collected by means of a sociodemographical questionnaire 
and medical chart review in the patient group. 
Definitions
Remission was subdivided into 2 groups and defined as: 1. cure: successful surgical and/
or radiotherapeutical treatment of the GH-producing adenoma followed by a normal-
ization of the IGF-1 concentration (≤ mean + 2 SD for age) and suppression of serum GH 
levels <1.0µg/l during OGTT (after surgical treatment)18 and 2. disease control: normal 
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IGF1 concentrations (≤ mean +2 S.D.S for age) during the use of somatostatin analogues, 
dopamine agonists and/or GH receptor antagonists. 
Hormonal deficiency was defined as deficiency of one or more pituitary hormones. 
Hypothyroidism was defined as the use of thyroid hormone substitution therapy. Hypo-
gonadism was defined as use of testosterone substitution in men and use of oestrogen 
in women. GH deficiency was defined as the need for GH substitution therapy as 
defined by a maximal GH response <15.3mU/l during an insulin tolerance test (ITT) or a 
maximal GH response of <12.3 mU/l during an arginine/GHRH test 19. Glucocorticoid defi-
ciency was defined as the need for glucocorticoid substitution therapy as defined by a 
plasma morning cortisol <100nmol/l, after withdrawal of glucocorticoids for 24 hours, or 
a maximal cortisol response <550nmol/l during an ITT 20.
Regarding current disease status, cure or biochemical disease control had been 
confirmed by a recent (<1 year) normal IGF-1 level in all participating patients.
Statistical analysis
All data are presented as means and standard deviations (SD) or median and range. 
Data were tested for normality of distribution by means of the Kolmogorov-Smirnov 
test. T tests or Mann-Whitney U tests depending on normality of distribution or χ2 tests 
(for categorical variables) were performed to compare the variables age, gender and 
BMI of the patient and control group. T tests or Mann-Whitney U tests were performed 
to compare the scores on the subscales of the DAS59, RAND, AcroQoL and VAS of the 
patient and control group. To investigate the presence of correlations between sociode-
mographic characteristics, clinical characteristics and outcomes of the questionnaires, 
Spearman’s rank correlation testing or point-biserial correlation was used as appro-
priate. Statistical significance was set at the 5% level (p<0.05). All statistical analyses 
were performed using SPSS software (version 20.0; SPSS Inc., Chicago, IL, USA). 
Results
Patient characteristics 
The clinical characteristics of the patients and control subjects are depicted in Table 1. 
One hundred and thirty-one patients were invited to participate. Of these, 120 subjects 
responded (response rate 91.6%). Forty-seven of the patients who responded decided 
not to participate because of a lack of time (n=6), a lack of interest (n=14), physical or 
emotional problems (n=19) or because they did not have a problem with their appear-
ance (n=5). Three of the patients who responded did not report their reason for refusal 
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to participate. No statistically significant differences were found between the partici-
pants and the subjects who refused to participate in this study with respect to clinical 
parameters, with the exception of age, with the non-participants being slightly older 
than the participants. A total of 73 patients (45.2% female, mean age 59.4 ±10.5 years 
and BMI 28.1 ± 4.7 kg/m2) agreed to participate. Mean age at diagnosis was 41.6 (11.2) 
years. Regarding current disease status, cure or biochemical disease control had been 
confirmed by a recent (<1 year) normal IGF-1 level in all participating patients. Median 
remission time was 10.5 (2.3-43.6) years. The treatment processes of all patients are 
depicted in Figure 1. Sixty-three (86.3%) patients had undergone primary pituitary 
surgery and 3 (4.1%) patients had undergone primary radiotherapy. At the time of the 
study acromegaly was controlled by medical therapy in 43.8% of the patients: 20 
patients (27.4%) used somatostatin analogues (SA) monotherapy, 4 (5.5%) dopamine 
agonists (DA) monotherapy, 2 (2.7%) GH receptor blockers (GHRB) monotherapy and 6 
were using combination therapy. The other 41 (56.2%) patients were in remission of 
acromegaly without medical therapy. In 41 (56.2%) patients no substitution of pituitary 
hormones was necessary after surgery or radiotherapy, 32 (43.8%) had some kind of 
hormonal deficiency, of whom 15 (20.5%) had a hypopituitarism. 
Fifty-seven control subjects were included in this study (47.4% female, age 58.6 ± 11.3 
years, BMI 26.4 ±3.5 kg/m2). There was no significant difference between the patient 
and the control group regarding age (p=0.510), gender (p=0.860) and BMI (p=0.050), which 
confirmed the adequate matching.
Derriford appearance scale scores
Table 2 shows the sources of self-consciousness and scores of the two groups on the 
DAS59. Thirty-four (46,6%) of the patients in long-term remission of acromegaly were 
self-conscious about their appearance compared to 13 (22.8%) of the control subjects 
(p<0.01). Twenty-nine (85.3%) of the patients indicated that their face was the most prom-
inent source of self-consciousness compared to 3 (23.1%) controls (p<0.01). Compared to 
the control group the patient group had statistically significanty higher scores on all 
subscales (p < 0.01). No statistically significant correlations were found between the 
DAS59 scores of the patient group and clinical characteristics like age, gender and BMI 
(Table 1). However a statistically significant correlation was found between the DAS59 
scores of the control group and age (r=-0.327, p=<0.05). Furthermore, in the patient group 
no correlation was found between the duration of remission and the DAS59 scores (r= 
-0.169, p=0.153) and between disease status (cure versus biochemical disease control) 
and the DAS59 scores (r=0.021, p=0.860). A slight but significant correlation was found 
between pituitary function and the DAS59 score (r=0.279, p<0.05) with patients with 
a preserved pituitary function scoring lower amounts of self image-related distress. 
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Table 1) Patient characteristics and correlation with the DAS59 score. 
Patients
treated for 
acromegaly 
 (N=73) 
Control
subjects
(N=57)
p-value  Correlation to
 DAS59 score
Spearman’s- 
rho
 p-value
Gender (n): male/ female 40/ 33 30/27 0.860 0.139 0.240
Age: mean (SD) (years) 59.4 (10.5) 58.6 (11.3) 0.510 -0.085 0.504
BMI (kg/m²): mean (SD) 28.1 (4.7) 26.4 (3.5) 0.050 0.087 0.466
Age at diagnosis: mean (SD) (years) 41.6 (11.16) -0.095 0.425
Duration since cure: median (range) (years) 12.6 (41) -0.169 0.153
2-5 years remission n (%)   8 (11.0)
5-10 years remission n (%)   27 (37.0)
10-15 years remission n (%) 20 (27.4)
> 15 years remission n (%) 18 (24.7)
Treatment modality n (n) (%):
Surgery 64 (87.7) 0.071 0.549
Medical 39 (53.4) -0.115 0.189
SA 26 (35.6)  
DA 8 (11.0)
P 5 (6.8)
Irradiation 14 (19.2) -0.111 0.351
Disease status: n (%) 0.021 0.860
Cure              41 (56.1)
Biochemical remission 32 (43.8)
Hormonal deficiencies: n (%)
Preserved pituitary function     41 (56.1) 0.279 < 0.05*
Hypothyroidism     26 (35.6) -0.249 < 0.05*
Hypocortisolism 19 (26.0) -0.106 0.372
Growth hormone deficiency 17 (23.3) -0.082 0.493
Hypogonadism 19 (26.0) -0.150 0.206
Diabetes insipidus 17 (23.3) -0.068 0.565
Panhypopituirism 15 (20.5) -0.077 0.516
Comorbidities
Hypertension 29 (39.7) -0.042 0.725
Diabetes mellitus 14 (19.2) 0.007 0.956
Joint related complaints 12 (16.4) -0.109 0.360
SA somatostatin analogues, DA dopamine agonists, GHRB growth hormone receptor antagonists
*P <0.05 by Spearman’s rho
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Figure 1) Treatment process of patients. 
 Patients biochemically controlled using drug treatment are depicted in dark green.
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Another correlation was found between hypothyroidism and the full scale DAS59 
score (r=-0.249, p<0.05) (Table 1) with patients with hypothyroidism scoring higher. More 
specifically, a significant correlation was found between hypothyroidism and the GSC- 
subscale (r=-0.262, p<0.05). In the patient group, no correlations were found between the 
DAS59 score and having a partner (r=0.040, p=0.739), education level (r=-0.038, p=0.749) 
or employment status (r= -0.037, p= 0.756). In the control group, these correlations were 
also not found to be statistically significant; having a partner (r=0.003, p=0.368), educa-
tion level (r=-0.006, p=0.963), employment status (r=-0.122. p=0.368).The scores of the 
AcroQoL and the RAND-36 are shown in Table 3. The DAS59 score correlates inversely 
with all subscales of the AcroQoL (p<0.01). The DAS59 scores were also inversely 
correlated with most of the subscales of the RAND-36. 
Figure 2 shows the VAS scores. Scores of the patients were significantly lower than the 
scores of the control-subjects (p <0.01). The total satisfaction score ranged from 0 to 10 
in the patient group (mean score = 6.2 ± 2.4). Twenty-five patients (34.2%) scored the 
satisfaction with their facial appearance below 6. Scores in the control subject group 
ranged from 6-10 (mean score 7.8 ± 0.8). In the patient group the scores on the VAS scale 
also showed an inverse correlation with the DAS59 score (r=-0.567, p<0.01). 
RAND 36 scores
Mean scores of the patients in long-term remission of acromegaly were significantly 
lower than the scores of the control group (Table 3). Subscale scores of patients and 
controls and comparisons between the groups are depicted in Table 3.
Figure 2) Visual Analogue Scale (VAS) scores.
Patients
VAS Scores
Pe
rc
en
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ge
Controls
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Table 2)  Derriford appearance scale 59.
Patient (N=73) Controls (N=57) P value
Prevalence of self-consciousness, n (%): 34 (46.6) 13 (22.8) < 0.01*
Sources of self-consciousness, n (% of 
self-conscious subjects):
Face/facial features 29 (85.3) 3 (23.1) < 0.01*
Large/coarse feet 1 (2.9) 0 (0.0)
Curved back 1 (2.9) 0 (0.0)
Unsightly skin 2 (5.9) 4 (30.8)
Overweight 3 (8.8) 1 (7.7)
Breasts 0 (0.0) 1 (7.7)
Scalp hair 0 (0.0) 1 (7.7)
General aging 0 (0.0) 1 (7.7)
Abdomen 0 (0.0) 2 (15.4)
Mean score (SD)
Patients (N=73)
Mean score (SD)
Controls (N=57)
p-value
Full-scale (FS) 66.6 (33.7) 38.3 (22.7) < 0.01*
General self-consciousness of 
appearance (GSC)
21.3 (16.3) 8.8 (8.5) < 0.01*
Social self-consciousness of 
appearance (SSC) 
15.2 (12.3) 8.2 (8.9) < 0.01*
Sexual and bodily self-consciousness
of appearance (SBSC)   
7.8 (6.8) 4.2 (5.0) < 0.01*
Negative self-concept (NSC) 14.4 (3.9) 12.2 (2.6) < 0.01* 
Facial self-consciousness of 
appearance (FSC)
2.8 (2.3) 1.7 (2.6) < 0.01*
Not loading on a specific factor
53. how irritable do you feel?           2.2 (1.0) 1.7 (0.7) < 0.01*
59. how hostile do you feel? 1.7 (1.0) 1.3 (0.8) < 0.01*
*P < 0.01, by Mann-Whitney U test 
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AcroQoL scores
In the patient group, the mean (SD) AcroQoL score was 64.0% (16.6%). The most affected 
scale was the subscale “appearance” mean (SD) 57.1% (19.5%). The AcroQoL appear-
ance subscale score was significantly correlated to the DAS59 full scale score (r=-0.597, 
p<0.01). Other mean subscale scores are further depicted in Table 3. 
Sociodemographic characteristics
Of the patients in remission 55 (75.3%) were married or engaged into a relationship 
versus 47 (82.5%) of the controls (p=0.528), 18 (24.7%) of the patients in remission had 
no relationship, were divorced or a widow/widower versus 10 (17.5%) of the controls. Two 
of the patients in remission (2.7%) had less than eight years of education versus 1 (1.8%) 
of the controls, 6 (8.2%) of the patients in remission versus 6 (10.5%) of the controls 
had 8-12 years of education, 45 (61.6%) of the patients in remission versus 21 (36.8%) of 
the controls had 12-16 years of education, 10 (13.7%) of the patients in remission versus 
19 (33.3%) of the controls had 16-21 years of education and 10 (13.7%) of the patients in 
remission versus 9 (15.8%) of the controls had a university degree. Twenty-two of the 
patients in remission (30.1%) had full- or part-time employment versus 30 (52.6%) of the 
controls (p<0.05), 29 (39.7%) of the patients in remission versus 18 (31.6%) of the controls 
were retired, and 22 (30.1%) of the patients in remission versus 9 (15.8%) of the controls 
were unemployed. 
Discussion
In this study we evaluated self-consciousness about appearance and its relation with 
QoL in 73 patients in long-term remission of acromegaly, and determined which physical 
aspects have the most influence on the self-consciousness about appearance. 
The main finding of the present study is that, compared to a matched control group, a 
significantly larger proportion of the patients are still self-conscious about their appear-
ance (46.6% vs. 22.8%), even after more than 12 years of remission. This is regardless 
of most clinical and sociodemographic characteristics. The significant correlations 
between the DAS59 scores and the AcroQoL and RAND-36 scores indicate that the 
concerns about appearance are clearly related to an impaired quality of life and general 
well-being. In addition, this is the first study that investigates the association between 
specific “features” and self-consciousness about appearance in patients in long-term 
remission of acromegaly. An impressing 85.3% of the patients who reported self-con-
sciousness of appearance in our cohort indicated that their face is the main source of 
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Table 3) The Derriford Appearance Scale (DAS59) scores and patient group correla- 
 tions to the scores of the RAND-36 and the scores of the AcroQoL.
Mean score (SD) Correlation to 
DAS59-score
Questionnaire Patients treated 
for acromegaly 
(N=73)
Controls 
(N=57)
P-value Spearman’s 
rho
P-value
RAND-36
Physical functioning 72.8 (23.1) 91.2 (13.3) < 0.01*   -0.114 0.335
Social functioning       75.7 (23.1) 93.0 (11.1) < 0.01*     -0.236 < 0.05**
Role limitations due 
to physical problems
53.8 (44.8) 94.7 (14.7) < 0.01* -0.234 < 0.05**
Role limitations due 
to emotional problems
78.1 (38.2) 94.7 (18.7) < 0.01*    -0.262 < 0.05**
Vitality 57.5 (20.2) 77.1 (12.5) < 0.01*     -0.225 0.055
Mental health 74.9 (17.5) 84.4 (10.4) < 0.01*     -0.322 < 0.01*
Bodily Pain   71.5 (21.7) 89.0 (14.9) < 0.01* -0.159 0.179
General Health 
Perception       
54.8 (20.8) 73.9 (16.6) < 0.01*     -0.189 0.109
Change in health          50.0 (17.2) 56.1 (17.2) 0.064 -0.086 0.470
AcroQoL 
Total 64.0 (16.6) -0.570 < 0.01*
Physical performance 61.3 (20.0) -0.365 < 0.01*
Psychological 
well-being
65.5 (17.4) -0.638 < 0.01*
Appearance 57.1 (19.5) -0.597 < 0.01*
Personal relations                     73.9 (18.2)     -0.570 < 0.01*
*P < 0.01, **P <0.05 by Mann-Whitney U test or Spearman’s rho
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discontent. In the general population the distribution of ‘features’ that cause self-con-
sciousness of appearance is much more evenly distributed throughout the body with 
only 25-27% focus on the face 11 . This is in concordance with the results of our control 
group. Moreover, 34 % of the patients scored their facial appearance below 6 on the 0-10 
VAS scale compared to 0% in the control group (Figure 2). Our study therefore clearly 
demonstrates that patients in long-term remission of acromegaly still have significant 
problems with their facial appearance.
The findings in this study are in line with the findings of previous studies that found 
that the most affected dimension of the AcroQoL was appearance 4,5. Matta et al. 6 and 
Paisley et al. 7 showed an improvement in the appearance subdomain of the AcroQoL 
after treatment-induced improvement in IGF-1 levels. However they did not compare 
these “after treatment” outcomes with the normal population, because the AcroQoL 
is a disease-generated questionnaire specifically designed for patients. Furthermore, 
previous studies were not able to point out the specific anatomical features that caused 
the concern and discontent about appearance, while the DAS-59 clearly identifies the 
face as the primary source of self-consciousness. 
Studies about the prevalence of concern about appearance in the general population 
showed that concern about physical appearance is twice as common among women 
as among men. The prevalence of concern about appearance is highest during the late 
teens and early twenties, while it normally decreases with age 8,11 . In our series there was 
no correlation between the DAS59 score and gender or age in the patient group, but a 
statistically significant correlation between the DAS59 scores and age was found in the 
control group (r=-0.327, p=<0.05). This indicates that, in contrast to the general popula-
tion, the individuals in the patient group remained self-conscious about their appear-
ance despite the fact that they aged and men and women are equally affected.
A positive perception of appearance is related to successful psychological functioning 
and well-being 11 . Therefore, the self-consciousness about appearance and impaired QoL 
in patients in long-term remission of acromegaly are even more concerning, as these 
patients are already in remission and these disturbances seem to persist. The concerns 
about appearance in patients in remission of acromegaly are probably caused by 
persisting anatomical alterations such as craniofacial disproportions remain present, 
even after long-term remission 2. A delay in initial diagnosis, often by several years, 
probably is the major cause of the irreparable changes and damage 6,21 . In our study 
persisting comorbidities may have also contributed to decreased QoL as previously 
reported 22, as hypertension was present in 39.7% of our patients, diabetes mellitus 
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in 19.2% and joint related complaints in 16.4% of our patients. However no correlations 
were found between comorbidities and DAS59 scores. 
When the results of the DAS59 mean subscale score on facial self-consciousness 
of appearance (FSC) of our patient group are compared to the results of previously 
described clinical subgroups, it is notable that the score of our patients (2.8) is compa-
rable or worse than the scores in males considered suitable for rhinoplasty (2.6), and 
other cosmetic surgery (2.5) and females considered suitable for a facelift (2.5) and other 
cosmetic surgery (2.5) 9. Surprisingly plastic/craniofacial surgery is not widely performed 
in (former) acromegaly patients, especially not in Europe. Only a limited number of case 
reports about corrections of the acromegalic face have been published in literature. 
However individualized procedures, for example reduction of the vertical dimension of 
the body of the mandible, rhinoplasty, posterior displacement of the prominent frontal 
bone, recession and remodeling of cheeks (zygoma) or correction of mandibular prog-
nathism can greatly improve appearance and potentially reduce self-consciousness 
and associated distress about appearance 23-26. Another method to support patients 
that still have concerns about their appearance after remission of acromegaly could be 
psychological support or psychotherapeutical interventions to prevent evolution of a 
maladjusted coping style 27-29. 
An additional finding in this study is that patients in remission are more likely to be 
unemployed. This could be a result of the previous illness, but it is interesting to consider 
the possibility that their appearance could play a role in their unemployment. Literature 
shows that faces are key to our perception of others and people widely believe that 
the character of a person can be recognized from his or her face. This phenomenon 
is commonly labeled the halo effect 30. In addition the slightly higher education level 
in the control group could also in part explain the differences we observed. Further-
more, an interesting correlation was found between hypothyroidism and the DAS59 full 
scale score. Especially the GSC subscale of the DAS59 turned out to be correlated with 
hypothyroidism, which could be explained by the fact that hypothyroidism, even when 
adequately treated, is known to be associated with depressive symptoms 31 . 
Some limitations of this study should be acknowledged. A cross-sectional design was 
used, which did not account for variability of QoL and perception of appearance over 
time. However good test-retest reliability for both the AcroQoL and DAS59 has previously 
been demonstrated 4,9. The refusal of 5 patients to participate because they did not 
have any problems with their appearance might have introduced some bias. However 
even when these patients would have participated the proportion of patients that 
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reported to be self-conscious about a ‘feature’ would still be 43.6%. The difference in 
BMI between both groups was at the limit of significance (p=0.05). However, no correla-
tion was found between BMI and full scale DAS59 score. Therefore, we believe that this 
cannot explain the difference in DAS59 scores found between patients and controls.
In conclusion, even after long-term remission of acromegaly, a large number of patients are 
self-conscious about their appearance, leading to psychological distress and disruptions 
to everyday life and a decreased QoL. The facial features were the most important source 
of self-consciousness. The findings in this study highlight the importance of the fact that 
physicians should not ignore self-consciousness about appearance in patients treated 
for acromegaly, but have to address these concerns during follow-up. Patients should be 
encouraged to discuss their concerns about their appearance and should be offered indi-
vidualized advice about corrective interventions to improve not only their appearance but 
also functionality. There is a lot of potential for improvement in the support of people 
with acromegaly regarding their difficulties concerning their appearance and therefore 
their QoL as shown by a recent study that detected a significant effect of exercise on 
body self-perception in patients with acromegaly 32. To optimize management, not only 
biochemical and radiological parameters but also dimensions like appearance that reflect 
QoL should be evaluated. In practice the DAS59 is easy to use by physicians and can be an 
excellent instrument during follow-up. For patients, the DAS59 provides the opportunity 
to more easily address problems with their appearance and to discuss possible treatment 
options like psychological support or plastic/craniofacial surgery.
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Impaired quality of life in 
patients in long-term
remission of Cushing’s 
syndrome of both adrenal
and pituitary origin: 
a remaining effect of 
longstanding hypercortisolism? 
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Abstract
Objective: The determinants that cause impaired quality of life (QoL) in patients in long-
term remission of Cushing’s syndrome (CS) are unknown. The aim of this study was to 
get more insight in the patient and disease characteristics related to impaired QoL in 
these patients.
Design: Cross-sectional study. 
Methods: The QoL of 123 patients in remission of CS (age 52.2 ± 12.0 years, 106 women, 
duration of remission 13.3 ± 10.4 years, 80% pituitary CS), assessed with seven validated 
questionnaires, was compared to the QoL of an age- and sex-matched control group 
(n=105). To investigate the influence of the aetiology of CS on QOL, patients in remis-
sion of pituitary and adrenal CS were compared. Furthermore, the influence of hormonal 
deficiencies, treatment strategy, duration of remission, gender and age on QoL was 
investigated.
Results: QoL in the total patient group and each patient subgroup was significantly 
worse on practically all dimensions of questionnaires compared to the control group 
(p < 0.05), except for patients in remission of pituitary CS without hormonal deficiencies 
who had an impaired QoL on 50% of the QoL dimensions. Subgroup analysis revealed no 
difference in QoL between different patient groups, especially no difference between 
patients in remission of adrenal and pituitary CS. Female gender and a shorter duration 
of remission had a negative influence on QoL in the patient group.
Conclusions: QoL remains impaired in patients in long-term remission of CS regard-
less of aetiology, presence of hormonal deficiencies and treatment strategies. More 
research is needed to establish the causes.
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Introduction
Endogenous Cushing’s syndrome (CS) is associated with significant morbidity and 
mortality 1 . Although the Cushingoid phenotype improves after curative treatment, 
there is accumulating evidence that not all changes in body composition, cardiovas-
cular risk profile and cognitive function are reversible 2, 3, 4. Furthermore, a number of 
studies have reported that quality of life (QoL) remains impaired in patients in long-
term remission of CS 5-15. However, most of these studies have major limitations (e.g., 
assessment of QoL was not the main purpose of the study, small numbers of patients, 
no control group, unvalidated questionnaires, missing data on clinical characteristics 
and biochemical follow-up). Furthermore, most studies have only investigated QoL in 
patients in remission of pituitary CS 8, 9, 11, 12, 14, while studies that did include patients in 
remission of adrenal CS, did not compare QoL between different patients groups 5, 13, 15. 
This has made it difficult to establish patient or disease characteristics related to 
impaired QoL in patients in long-term remission of CS. In this respect hypopituitarism, 
glucocorticoid deficiency or a persisting effect of the previous period of hypercorti-
solism have been suggested as possible determinants. 
The aim of this study was to investigate QoL in a large group of patients in long-term 
remission of CS using 7 validated questionnaires concerning different dimensions of 
QoL and to compare the QoL of the patients to a sex- and age-matched healthy control 
group. Furthermore, to investigate the influence of the aetiology of CS on QOL, we 
compared the QoL of patients in remission of pituitary CS to that of patients in remis-
sion of adrenal CS. We also investigated the influence of treatment strategy and coex-
isting hormonal deficiencies on QoL in patients in remission of pituitary CS.
Subjects and methods
Protocol
After approval of the study by the Medical Research Ethics Committee region Arnhem- 
Nijmegen, all patients treated for CS from 1967 until 2007 in our hospital were identi-
fied. Medical records of all patients were retrospectively reviewed to assess data on 
demographics, diagnosis of CS, the aetiology of CS, the type and number of treatments 
that patients received and follow-up data on remission, relapses, hormonal deficien-
cies, and mortality. Patients that were assumed to be in remission for at least two years, 
according to the medical records, were eligible for inclusion. Patients with ectopic CS, 
active malignancy or systemic treatment for malignancy in the past were excluded. 
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Furthermore, all patients that were unable to answer the questionnaires (because they 
could not comprehend the questionnaires or the Dutch language) were excluded. All 
other eligible patients were asked to participate in this study. They were sent two sets 
of questionnaires by mail. Non-responders received a reminder letter after four weeks. 
If they still did not respond we attempted to contact them by telephone. 
To obtain a sex- and age-matched control group, patients were asked to find their own 
control subject with the same age and gender among their family or friends. Written 
informed consent was obtained from all patients and controls before their question-
naires were enrolled in the study.
All patients underwent a 1 mg dexamethasone suppression test after they completed 
the questionnaires to confirm that they were still in remission. In patients who had been 
treated with radiation therapy of the pituitary gland a 24-hour urinary free cortisol was 
measured. 
The results of the questionnaires of the patient group were compared to the results of 
the control group. Furthermore we compared the results of different patient subgroups. 
To investigate if the aetiology of CS influences QoL we compared patients in remission 
of adrenal CS to patients in remission of pituitary CS. To investigate if the presence of 
hormonal deficiencies influences QoL we compared patients in remission of pituitary 
CS with hormonal deficiencies to patients in remission of pituitary CS without hormonal 
deficiencies. We hypothesized that the hormonal deficiency that would impact QoL the 
most would be glucocorticoid deficiency. Therefore we compared patients in remission 
of pituitary CS with hormonal deficiencies including glucocorticoid deficiency to those 
with hormonal deficiencies without glucocorticoid deficiency. To investigate if treat-
ment strategy influences QoL we compared patients in remission of pituitary CS treated 
with bilateral ADX to those treated without bilateral ADX. Furthermore, the results of 
each patient subgroup were compared to the results of the control group. 
Study population
Two hundred and thirty-six patients met the inclusion criteria. However, 38 patients 
were known to be deceased and 9 patients were lost to follow-up. The remaining 189 
patients were invited to participate in this study. One hundred and forty-nine patients 
(79%) responded, of whom 127 (85% of the patients that responded, 67% of the patients 
that were invited) were willing to participate. Four patients had recurrent CS and had to 
be excluded, leaving 123 patients (age 52.2 ± 12.0 years, 106 women) that were included. 
The duration of remission at the time of answering the questionnaires was 13.3 ± 10.4 
years (range 2-39). 
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There was no significant difference in response rate and willingness to participate 
between patients that were in remission of pituitary CS or adrenal CS: 114 of 146 patients 
(78%) in remission of pituitary CS responded, of whom 99 (68%) were willing to partici-
pate, compared to 31 of 43 patients (72%) in remission of adrenal CS, of whom 24 (56%) 
were willing to participate.
One hundred and five controls (age 51.3 ± 12.8 years, 71 women) completed the question-
naires. Sex and age did not differ significantly between the patient and control group 
(Table 1). 
Table 1) Socio-economic characteristics and comorbidity of patients and controls.
patients (n=123) controls (n=105) P - value
age (years) 52.2 (± 12.0) 51. 3 (± 12.8) 0.56
gender (female) 78% 71% 0.25
self-reported comorbidity 79% 57% <0.01*
hypertension 28% 20% 0.18
chronic back complaints 18% 12% 0.25
osteoporosis / arthrosis 13% 10% 0.40
psychological problems 11% 5% 0.07
pulmonary disease 11% 12% 0.67
recurrent sinusitis 10% 6% 0.26
diabetes mellitus (type 1 or 2) 9% 4% 0.12
cardiovascular disease 6% 7% 0.76
number of self-reported diseases 1.8 (±1.6) 1.1 (±1.3) <0.01*
active smoker 20% 12% 0.15
smoked in the past 33% 40% 0.29
paid work 51% 70% <0.01*
self-reported inability to work 25% 0% <0.01*
education level 1.8 (±0.8) 2.1 (±0.8) 0.02*
relationship 75% 89% 0.01*
number of children 1.5 (± 1.5) 1.6 (± 1.3) 0.53
Education level:  1=low, 2=middle, 3=high. *: significant difference between patients and control subjects.
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Definitions
Remission was defined as suppression of plasma cortisol to ≤ 50 nmol/L after overnight 
1 mg dexamethasone, and absence of clinical signs and symptoms of active hypercor-
tisolism (16) or, if a patient had received pituitary radiotherapy, a 24-hour urinary free 
cortisol value of <240 nmol/24h for men or <150 nmol/24h for women (reference range at 
our institution) and absence of clinical signs and symptoms of active hypercortisolism. 
Hormonal deficiency was defined as deficiency of one or more hormones. Hypothy-
roidism was defined as the use of thyroid hormone substitution therapy. Hypogonadism 
was defined as use of testosterone substitution in men and use of estrogen in women 
(no difference was made between suppletion or contraceptive therapy). GH deficiency 
was defined as a maximal GH response < 15.3 mU/L during an insulin tolerance test (ITT), 
or as a maximal GH response of < 12.3 mU/L during an Arginine/GHRH test (17). Glucocorti-
coid deficiency was defined as the use of glucocorticoids. In virtually all cases glucocor-
ticoid deficiency was confirmed by a plasma morning cortisol <100 nmol/L, or a maximal 
cortisol response < 550 nmol/L during an ITT (18). Hypopituitarism was defined as defi-
ciency of one or more of the hormones that are secreted by the pituitary gland. 
Quality of life questionnaires
The following set of QoL questionnaires was used in this study:
RAND-36. The Dutch translation of the RAND-36 was used, which is very similar to the 
Short Form-36 questionnaire 19. It comprises 36 items regarding general wellbeing during 
the past 30 days. The items are formulated as statements or questions to assess 9 
health concepts: 1) physical functioning; 2) social functioning; 3) role limitations 
because of physical health problems; 4) role limitations because of emotional prob-
lems; 5) mental health; 6) vitality; 7) bodily pain, 8) general health perceptions, 9) health 
change in the last year. Scores are calculated for each health aspect on a 0-100 scale, in 
which higher scores represent a better QoL 20.
Hospital Anxiety and Depression Scale (HADS). The HADS consists of 14 items 
concerning anxiety and depression, measured on a four-point scale 21, 22. Scores range 
from 0-21 for the anxiety and depression subscales and from 0-42 for the total score. 
Higher scores indicate more anxiety or more depressive symptoms, 
Checklist Individual Strength Questionnaire (CIS). The CIS is designed to measure 
several aspects of fatigue 23. It consists of four dimensions: 1) the subjective expe-
rience of fatigue; 2) reduction in motivation; 3) reduction in activity and 4) reduction 
in concentration. The questionnaire consists of 20 statements, scored on a 7-point 
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Likert scale. The statements refer to aspects of fatigue experienced during the last 
two weeks. Scores range from 20 to 140 points. Higher scores indicate a higher degree 
of fatigue. 
Cognitive Failures Questionnaire (CFQ). The CFQ detects everyday mistakes and prob-
lems regarding perception, memory, motor function and orientation 24. The first part of 
the questionnaire consists of 25 items and the second part indicates the influence of 
these items on daily life. Scores range from 0 to 100, in which a higher score indicates 
more severe problems. 
Appearance Self-Esteem (ASE). The ASE is a section of the Self-report State Self-Es-
teem Scale and comprises satisfaction with ones appearance 25. Separate use of the 
ASE has been reported before 26. The questionnaire consists of six statements, scored 
on a 5-point Likert scale. Scores range from 6 to 30. A higher score indicates more 
self-esteem concerning a person’s own appearance. 
Cushing’s Quality of Life (CushingQoL). This unidimensional questionnaire, with a time 
frame referring to the preceding four weeks, covers several Cushing-related problems. 
It has been designed to analyse QoL in patients with active CS 27. We used the ques-
tionnaire to analyse if patients in long-term remission of CS still have more CS-related 
symptoms than healthy controls. The answers are scored on a five-point Likert scale. 
The total score is converted to a 0-100 scale in which 0 indicates the worst and 100 the 
best possible QoL.
Nottingham Health Profile (NHP): The NHP contains 38 yes/no items that focus on 
general wellbeing and current health perception 28, 29. The items are subdivided into six 
subscales that assess different health aspects: 1) energy; 2) pain; 3) emotional reaction; 
4) sleep; 5) physical ability and 6) social isolation. Subscale scores are calculated as a 
weighted mean of the associated items and are expressed as a value between 0 and 
100. A higher score is associated with a worse QoL. 
Employment status and self-reported comorbidity. All participants received a ques-
tionnaire regarding their employment status. The most important aspects of this ques-
tionnaire were current employment, number of working hours per week, current sick 
leave and inability to work. Furthermore, participants received a checklist mentioning 
16 common diseases (e.g. diabetes mellitus, cardiovascular disease, hypertension, and 
psychiatric problems). They were asked if they currently had any of these problems. 
They could also describe other health problems they experienced at the moment.
128
Statistics
Data were analysed using SPSS for Windows version 16.0 (SPSS Inc., Chicago, Ill). Data 
were expressed as mean ± SD, unless otherwise mentioned. To compare biometric and 
socio-economic characteristics of patients and controls we used unpaired t tests and χ2 
tests. To compare the results of the questionnaires of patients and controls, and those of 
the different patient subgroups, we chose to use the Kruskal-Wallis equality-of-popula-
tions rank test because the data of several questionnaires were not normally distributed. 
Furthermore, using multiple regression analysis, the influence of duration of remission 
(between 2 and 5 years, 5 and 10 years and more than 10 years), age and sex on the results 
of the questionnaires was investigated. Statistical significance was defined as P < 0.05. 
Results
Patient characteristics
Eighty percent of the patients (n=99) were in remission of pituitary CS. Transsphenoidal 
surgery (TS) was the primary therapy for 85% (n=84) of these patients (Figure 1). Twelve 
percent (n=12) underwent a bilateral ADX and 3% (n=3) underwent radiotherapy of the 
pituitary gland as primary treatment. Forty patients received one or more additional 
treatments because of persistent or recurrent hypercortisolism (n=28), and/or because 
they developed Nelson’s syndrome after bilateral ADX (n=12). 
Twenty percent of all patients (n=24) were in remission of adrenal CS and were previ-
ously treated by unilateral ADX. 
Partial or total hypopituitarism was present in 51% of all patients (n= 63) and all of these 
patients had been treated for pituitary CS. Hormonal deficiencies due to any cause, 
including primary adrenal insufficiency after bilateral ADX and primary hypothyroidism, 
were present in 65% of all patients (n=81) of whom 4 had been treated for adrenal CS. 
In contrast to all other hormonal deficiencies, presence of GH deficiency had only been 
investigated in 74% (n=73) of the patients that were in remission of pituitary CS (insulin 
tolerance test or GHRH-arginine test). GH deficiency was present in 58% (n=42) of these 
patients. However, 21 of these 42 patients were not receiving treatment with GH at the 
time of the study, despite the proven GH deficiency, for various reasons (the initiation 
of treatment was pending at the time of the study, the treatment was discontinued 
or refused by the patients, there was a (relative) contraindication for GH substitution 
therapy, or the deficiency was not severe enough for treatment to be covered by the 
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health insurance companies). Four of these patients did not have other hormonal defi-
ciencies. Furthermore, 11 of the 26 patients in whom GH deficiency had not been inves-
tigated, did not have other hormonal deficiencies. For our analyses we classified these 
patients as patients without hormonal deficiencies. 
Figure 1) Overview of the treatments that the 123 patients in remission of Cushing’s 
 syndrome had received.
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At the time they participated in the study, 63% of all patients (n=77) received replace-
ment therapy with at least one hormone (replacement of cortisol in 55 patients (45%), 
thyroid hormone in 49 patients (40%, of whom 9 patients had primary hypothyroidism), 
growth hormone in 21 patients (17%), testosterone in 11 of the 17 males (68% of all males), 
estrogen in 5 females (5% of all females), desmopressin in 6 patients (6%), and flud-
rocortisone in the 33 patients that had been treated by bilateral ADX). Substitution 
therapy was individually titrated to achieve at least the lower limit of our institutional 
reference values if a hormonal deficiency was present (except for GH therapy in the 21 
patients with GH deficiency described earlier).
Comparison of QoL between the total patient group and the healthy 
control group
Each questionnaire showed that QoL in the total patient group was significantly reduced 
compared to the healthy control group. The only items that were not significantly 
different between the patient and control group were ‘health change’ and ‘emotional 
role limitation’ of the RAND-36. Furthermore, compared to the control subjects, signifi-
cantly fewer patients had a relationship, their education level was lower, they had less 
paid work and more patients were unable to work (Table 1). Compared to the control 
subjects significantly more patients reported comorbidity and the average number of 
comorbidities was significantly higher (Table 1). However, the prevalence of different 
diseases (e.g. hypertension, cardiovascular disease, diabetes) in the patient and control 
group did not significantly differ, nor did smoking habits (Figure 2).
Comparison of QoL between different patient subgroups:
Adrenal CS (n=24) versus pituitary CS (n=99) (Figure 2): QoL did not significantly differ 
between these groups on any item of any questionnaire. Both patients with adrenal CS 
and pituitary CS scored significantly worse on all items compared to the control group 
with the exception of the items ‘health change’ and ‘emotional role limitation’ of the 
RAND-36.
Pituitary CS with hormonal deficiencies (n=77) versus pituitary CS without hormonal 
deficiencies (n=22): Patients treated for pituitary CS without permanent hormonal defi-
ciencies scored significantly better than patients with hormonal deficiencies on the 
items fatigue and motivation of the CIS questionnaire, the CushingQOL questionnaire, 
and the item energy of the NHP questionnaire. Furthermore, although the patients in 
remission of pituitary CS without hormonal deficiencies do have a significantly impaired 
QoL compared to the control group on approximately 50% of the items of QoL ques-
tionnaires (physical functioning, role limitations because of physical health prob-
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lems, vitality, and general health perceptions of the RAND-36, depression of the HADS, 
experience of fatigue and concentration of the CIS, the CushingQOL questionnaire and 
emotional reaction and physical ability of the NHP), differences were not significant on 
the other items.
Pituitary CS treated with bilateral ADX (n=33) versus no bilateral ADX (n=66) and Pitu-
itary CS with hormonal deficiencies with glucocorticoid substitution (n=58) versus 
without glucocorticoid substitution (n=19): QoL did not differ between these groups on 
all items of all questionnaires.
Figure 2) The difference in mean score on each dimension of the quality of life ques- 
 tionnaires between patients in remission of pituitary and adrenal Cushing’s 
 syndrome compared to the control group, with the standard error of the 
 mean. The maximum score has been recalculated to be 100 for all question- 
 naires.
Difference to the control group (%)
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Influence of duration of remission, age and gender on QoL
Multiple regression analysis showed that in the patient group duration of remission 
(analysed as remission for 2-5 years, 5-10 years or 10 years and longer) significantly 
affected QOL, with a lower QoL if duration of remission was shorter, on the dimension 
‘depression’ of the HADS, the dimension ‘concentration’ of the CIS, on the CFQ and on 
the CushingQOL questionnaire. Furthermore, as could be expected, duration of remis-
sion significantly affected the dimension ‘health change’ of the RAND-36, with more 
improvement in health in the past year, if duration of remission was shorter. Older age 
negatively influenced QoL only on the dimension ‘depression’ of the HADS question-
naire. Female gender negatively influenced QoL on the dimensions ‘physical func-
tioning’, ‘mental health’, ‘vitality’, ‘pain’, and ‘general health perception’ of the RAND-36, 
the dimension ‘fatigue’ of the CIS questionnaire, the CFQ, ASE and Cushing QoL question-
naire, and the dimension ‘energy’, ‘pain’, ‘sleep’ and ‘social isolation’ of the NHP. 
In the control group, older age had a much stronger negative influence on the reported 
QoL, significantly affecting QoL on most items. On the other hand, female gender only 
significantly affected QoL in the CushingQOL questionnaire and the dimension ‘mental 
health’ of the RAND-36.
Discussion
 
In this study we evaluated QoL in 123 patients in long-term remission of CS, to get more 
insight in the determinants related to impaired QoL. The results of this study show that, 
compared to a gender- and age-matched control group, QoL remains impaired in all 
subgroups of patients in long-term remission of CS, regardless of the aetiology of CS, 
presence of hormonal deficiencies and the treatment received. Importantly, QoL was 
impaired to the same extent in patients treated for adrenal CS and in patients treated 
for pituitary CS. Furthermore, duration of remission only affected QoL on a number of 
dimensions, with a better QoL if duration of remission was longer. Women in remission of 
CS scored worse than men on approximately 60% of items of QoL questionnaires, while 
gender was of no significant influence on QoL in the control group. Age, however, did not 
have a strong influence on QoL in the patient group while it did have a strong influence 
in the control group. 
Although a few previous studies on QoL in patients in remission of CS have included 
patients that were in remission of adrenal CS, until now there were no studies that had 
specifically made a comparison between QoL in patients in long-term remission of pitu-
itary CS and in long-term remission of adrenal CS 5, 7, 13, 15, 27. Lindholm et al. 7 made a short 
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comment that QoL seemed quite satisfactory in the patients treated for an adrenal 
adenoma. However QoL was not the main outcome of their study and data about the 
clinical characteristics of their patients are sparse. Furthermore, they defined relative 
health impairment as a score below the 25th percentile of the Danish norm. No direct 
comparison was made with an age- and sex-matched control group. Webb et al (27) 
compared 18 patients with adrenal and 107 patients with pituitary CS and did not find 
a difference in QoL between the two groups, assessed by two questionnaires (SF-36 
and CushingQOL). However a substantial part of their patients (31%) were hypercorti-
solemic at the moment of investigation or had only recently been treated. Interestingly, 
we found that after long-term remission, QoL is at least as impaired in patients in remis-
sion of adrenal CS as in patients in remission, of pituitary CS. To our knowledge, this is 
the first study to show this, which is surprising as we hypothesized that patients in 
remission of adrenal CS would have a better QoL than patients in remission of pituitary 
CS because they are expected not to have any hormonal deficiencies and normal endo-
crine physiology is restored.
The presence of hormonal deficiencies in patients treated for CS has previously been 
associated with impaired QoL. Van Aken et al. previously found that hypopituitarism was 
the main independent predictor of impaired QoL in patients in remission of pituitary CS 9. 
We confirmed this finding in our study, and found that not only hypopituitarism, but 
also hormonal deficiencies caused by bilateral ADX were associated with worse QoL. Our 
patients in remission of pituitary CS without hormonal deficiencies did have a signifi-
cantly better QoL than patients with hormonal deficiencies on a number of QoL items, 
and they were the only patient group that did not have significantly worse QoL than the 
control group on approximately 50% of QoL dimensions, but QoL remained impaired in 
the other 50% of dimensions. 
Current glucocorticoid replacement regimens are not physiological and there is a risk of 
overreplacement. QoL has been found to be impaired in patients receiving glucocorti-
coid substitution (30). Therefore we hypothesized that glucocorticoid substitution might 
be an important cause of impaired QoL in patients with hormonal deficiencies. To inves-
tigate this hypothesis we first compared the QoL of patients receiving glucocorticoid 
substitution with the QoL of patients with hormonal deficiencies but without glucocor-
ticoid substitution, and second the QoL of patients that had been treated with bilateral 
ADX to the QoL of patients with hormonal deficiencies that had not been treated with 
bilateral ADX. Because there was no difference in QoL between these patient groups it 
is unlikely that the impaired QoL in patients in long-term remission of CS with hormonal 
deficiencies is strongly influenced by the glucocorticoid replacement regime. 
134
Because QoL is impaired in all patient groups in long-term remission of CS, the cause 
of impaired QoL could be the previous period of longstanding exposure to high cortisol 
levels. There is accumulating evidence that longstanding hypercortisolism has irrevers-
ible effects on cardiovascular risk and that patients in remission of CS have persistent 
centripetal obesity which may lead to a state of low-grade inflammation 2, 3, 31, 32. Further-
more, CS is associated with morphological changes of the brain (including brain atrophy, 
reduction in total and cortical grey matter, and reduced hippocampal volume), which 
at least partially persist after long-term remission 33, 34. This may explain the chronic 
cognitive impairments described in patients in long-term remission of CS 4, 35 which may 
negatively influence QoL. Other explanations for the impaired QoL could be the previous 
experience of suffering a severe illness, ineffective coping strategies or ineffective 
illness perceptions 35, 36. Future research will have to determine the exact causes of 
impaired QoL in patients in long-term remission of CS.
Multiple linear regression analysis showed that, in our patient group, female gender 
negatively influenced QoL. This effect was not present in the control group. Although 
previous studies have also described that female gender negatively influences QoL 
in patients in remission of CS, it is still unclear what causes this phenomenon 9, 27. A 
possible explanation of the negative influence of female gender on QoL could be differ-
ences in the long term effects of the previous period of hypercortisolism in men and 
women. This could be caused by a different clinical presentation, which has previously 
been described in pituitary CS 37. Another explanation could be differences in coping 
strategies and illness perceptions between men and women. Although gender differ-
ences in coping strategies and illness perceptions have been reported in numerous 
other diseases 38, 39, this has not yet been investigated in patients with CS. 
Although shorter duration of remission did have a negative impact on QoL on a number 
of dimensions, most dimensions of QoL was not affected by duration of remission on 
most dimensions of QOL, suggesting that the majority of effects of CS on QoL have 
reached a stable situation after 2 years of remission. Van Aken et al. even found that 
duration of remission did not affect QoL at all 9. However, in contrast to van Aken, who 
analysed duration of remission as a continuum, we analysed duration of remission in 
different categories (from 2-5 years, 5-10 years and >10 years), because we hypothe-
sized that the largest effect of remission on QoL would take place in the first decade 
after treatment. Interestingly, in our study, the (dimensions of the) QoL questionnaires 
that were affected by duration of remission with a lower QoL if duration of remission 
was shorter, were the dimension ‘depression’ of the HADS, ‘concentration’ of the CIS, the 
CFQ and on the CushingQOL questionnaire. The combination of these QoL dimensions 
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suggests problems in coping with the recent experience of CS, which improves as time 
goes by. Another possible explanation could be that the effect of hypercortisolism on 
the brain, causing psychological problems and cognitive impairments, takes longer to 
reach a stable situation after remission than other effects of hypercortisolism. 
Strengths of this study are the relatively large number of patients included and the long 
average duration of remission (13.3 ± 10.4 years). A limitation of this study is the fact 
that GH deficiency was not ruled out in 26 patients in remission of pituitary CS. Because 
11 of these patients had no other hormonal deficiencies and normal IGF-1 values, we 
analysed these patients as having no hormonal deficiencies. If some of these patients 
do have GH deficiency this may have negatively influenced QoL in the patient group 
without hormonal deficiencies. Furthermore 21 patients with proven GH deficiency were 
not receiving treatment for a number of different reasons. This could have negatively 
influenced the QoL of the total patient group and the patient group with hormonal defi-
ciencies. However, in patients with adult-onset GH deficiency, GH therapy has only been 
found to have a positive effect on QoL if disease-specific questionnaires are used. 
In studies that use generic QoL questionnaires, as we used in this study, the positive 
effect of GH therapy on QoL in GH deficient patients is much more controversial and 
most studies that did find a positive effect of QoL only found this in a few dimensions 
of the generic QoL questionnaires 40. Therefore the presence of untreated GH deficiency 
can certainly not account for the obvious impairment of QoL of the total patient group. 
Another possible limitation of this study is that not all patients found a control subject 
and not all control subjects were gender matched. However, we controlled for gender in 
our analysis by using a multiple regression analysis. Furthermore, not all control subjects 
were healthy, reporting comorbidity in 57% (Table 1). However, if this influenced QoL in 
the control group it would have been a negative influence on QOL, reducing the differ-
ence in QoL between the patient and control group. 
In conclusion, QoL remains impaired in patients in long-term remission of CS, regardless 
of aetiology, presence of hormonal deficiencies and treatment strategies. The cause of 
impaired QoL remains unclear and is probably multifactorial. More research is needed to 
establish the causes of impaired QOL, and hopefully this will provide targets for inter-
ventions that can improve QoL in patients in long-term remission of CS in the future.
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Abstract
Purpose: The exact quantification of craniofacial characteristics in patients with acro-
megaly is important because it provides insight in the pathophysiology of the disease 
and offers a tool to evaluate the effects of treatment on tissue-specific endpoints. 
However, until recently this was not feasible due to limitations of available cephalo-
metric methods. The new technique of three-dimensional (3D) cephalometry enables 
the accurate quantification of facial anatomical characteristics of both soft tissue and 
bone. This is the first study that uses 3D cephalometry to analyze craniofacial dispro-
portions in patients in long-term remission of acromegaly.
Methods: Sixteen patients in remission of acromegaly for over 24 months (50% male, 
mean age 56.0 ± 10.7 years, mean BMI 29.3 ± 5.5 kg/m2) were compared to 16 matched 
control subjects. A 3D cone beam computed tomography scan and 3D stereophoto-
graph of each individual were acquired and analyzed using 3D cephalometry.
Results: In addition to an accurate quantification of the classical craniofacial charac-
teristics, 3D cephalometry, shows that many typical soft tissue deformities persist, 
even after long-term remission. Furthermore, we found that, compared to controls, the 
patients in remission of acromegaly have a wider face at the level of the zygoma and a 
longer maxilla (p<0.05). 
Conclusions: 3D cephalometry is an attractive novel imaging modality to accurately 
investigate craniofacial disproportions of both soft tissue and bony parts of the face 
in patients with acromegaly, which makes it a promising technique for future research 
purposes and clinical practice.
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Introduction
Acromegaly is a rare clinical syndrome caused by prolonged exposure to excessive 
amounts of growth hormone (GH) 1 . The GH excess causes proliferation of many tissues, 
including connective tissue, cartilage, bone and skin 2. Because the signs and symp-
toms of acromegaly develop insidiously, there is often a delay in diagnosis for up to ten 
years. Therefore, most patients have a pathognomonic phenotype with marked cranio-
facial disproportions when acromegaly is finally diagnosed 1 . 
Since acromegaly was first described in 1886 the craniofacial disproportions have been 
investigated. In the early days, a multitude of case reports already described the char-
acteristic frontal bossing, prominence of the supraorbital ridges and mandibular prog-
nathism in combination with hypertrophy of the tongue, lower lip and nose, which can 
be seen in virtually all patients with active acromegaly 3-6. 
The changes in appearance in active acromegaly are associated with a significantly 
impaired quality of life 7, both due to cosmetic aspects as to maxillofacial complaints 
8. However, nowadays acromegaly can almost always be cured or controlled. After 
successful treatment some features of acromegaly, such as sleep apnea and cartilage 
thickening in joints, show at least partial reversibility 9,10. The exact quantification of 
craniofacial characteristics in patients with acromegaly is important because it offers 
a tool to evaluate the effects of treatment on tissue-specific endpoints and provides 
insight in the pathophysiology of the disease. However, at present it is unknown if the 
craniofacial disproportions are reversible after successful treatment, as the current 
clinical assessment of craniofacial changes does not enable exact quantification. 
As a consequence, it is unclear how patients should be informed about cosmetic 
changes after successful treatment, and if and how maxillofacial pathologies should 
be followed-up or treated. 
Since the 1960’s standardized radiographic cephalometry by using two-dimen-
sional (2D) cephalograms has been widely adopted for the evaluation of craniofacial 
morphology and growth 11 . A number of studies have analyzed the extent of craniofa-
cial disproportions in acromegaly using this technique 8, 12-16. However, 2D cephalom-
etry has many limitations. The data collected from 2D cephalograms can only describe 
the hard tissue and soft tissue profile with regard to the midfacial plane, omitting the 
morphologic features in all other facial regions. Thus, the use of 2D imaging to describe 
complex three-dimensional (3D) craniofacial structures will inevitably lead to loss of 
data. Furthermore the measurements obtained are subject to magnification and land-
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mark identification errors. This limits the value of all previous cephalometric studies 
on craniofacial characteristics in patients with acromegaly. Furthermore, all previous 
studies have other limitations, such as mixed study populations of active and cured 
acromegaly and unspecified duration of follow-up in cured patients.
In the past decade cephalometry using 3D imaging technology has rapidly evolved 17. 
Cone beam computed tomography (CBCT) has become a well-established alternative 
to 2D cephalograms, providing 3D image data of bony tissue structures in the facial 
region. In order to capture the 3D soft tissue facial profile, 3D stereophotogrammetry 
was developed 18-19. By image fusion, the hard tissue data of CBCT and soft tissue data 
of 3D stereophotogrammetry can be combined into a 3D virtual head model, making 
it possible to quantify all dimensions of the face (bone and soft tissues) 20. Because 
3D cephalometry is much more accurate than 2D cephalometry, and relatively easy to 
perform with the use of computers, it has already been implemented in the daily prac-
tice in oral and maxillofacial surgery, but it has never been used to quantify the cranio-
facial disproportions in patients with acromegaly. 
The aim of the present study was to evaluate the differences in craniofacial dimensions 
of soft and bony tissues between patients in long-term remission of acromegaly and 
control subjects matched for gender, age, body mass index (BMI) and ethnicity, using 3D 
cephalometry and 3D image fusion head models, which were used for the first time for 
this purpose.
 
Subjects and Methods
Subjects 
All adult patients of the Department of Medicine, Division of Endocrinology, of the 
Radboud University Nijmegen Medical Center, who were in remission of acromegaly for 
at least 2 years after successful transsphenoidal pituitary surgery, were eligible for this 
cross sectional case-control study. The initial diagnosis of acromegaly was based on 
clinical grounds and biochemical tests, including assessment of serum GH levels (basal 
and during an oral glucose tolerance test (OGTT)) and serum insulin-like growth factor 
type-1 (IGF-1) levels. Remission was defined as disappearance of clinical symptoms of 
active GH hypersecretion with normal serum IGF-1 levels (≤ mean + 2 standard deviations 
for age) and suppression of serum GH levels to < 2 mU/L during OGTT 21 . All patients who 
had undergone maxillofacial surgery in the past were excluded from this study. Further-
more, all patients that received GH substitution therapy because of GH deficiency after 
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remission of acromegaly were excluded. A total of 5 patients used another form of 
hormonal replacement therapy: 4 patients used levothyroxine suppletion and 1 patient 
used testosterone suppletion. They had received this suppletion for at least 2 years. All 
patients had been screened for hormonal deficiencies several times after transsphe-
noidal pituitary surgery. 
Sixteen patients met all inclusion and no exclusion criteria, and agreed to participate. 
Fifty percent of the patients were male, age at time of study was 56.0 ± 10.7 years 
(mean ± SD) and BMI was 29.3 ± 5.5 kg/m2. The patients had been in remission of acro-
megaly for an average of 8.5 ± 8.6 years (range 2-36). Each patient was matched to 
a healthy gender-, age-, BMI- and ethnicity-matched healthy control subject. The 16 
control subjects were recruited via an advertisement in a local newspaper. They had no 
history of maxillofacial surgery or trauma. In the control group 50% of the subjects were 
male, age was 56.6 ± 11.1 years and BMI was 29.5 ± 4.7 kg/m2, which is not statistically 
different from the patient group. As all control subjects were healthy, they did not use 
any hormonal replacement therapy. 
The study was approved by the Ethics Committee of the Radboud University Nijmegen 
Medical Center and conformed to the declaration of Helsinki. All participants gave 
written informed consent prior to their participation in the study.
Study protocol and image acquisition 
On the day of the study, serum IGF-1 was determined in all patients to exclude recur-
rent acromegaly. A CBCT scan and 3D stereophotograph were acquired from all patients 
and control subjects. The CBCT scan was acquired using the i-CAT™ 3D Imaging System 
(Imaging Sciences International, Hatfield, PA, USA). CBCT scanning was performed in 
“Extended Field” mode (field of view: 16 cm diameter/22 cm height; scan time: 2 x 20 
seconds; voxel size: 0,4 mm) at 120 kV and 3-8 mAs pulse mode resulting in a radia-
tion dose of 136 µSv for a single scan. All subjects were scanned vertically in a natural, 
seated position with the occlusal plane parallel to the horizontal positioning line of the 
scanner. They were asked to bite in maximum intercuspidation, relax their lips and keep 
their eyes open.
Three-dimensional stereophotographs were acquired using a stereophotogrammet-
rical camera set-up (3dMDCranial™ System, 3dMD LLC, Atlanta, USA), which generates 
a 3D stereophotograph from six 2D photographs taken simultaneously (four grey-scale 
photographs and two full color photographs). All subjects were photographed seated, 
with their head in a natural position, habitual occlusion, opened eyes and relaxed facial 
musculature. 
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3D cephalometric analysis
Data from the CBCT scan and 3D stereophotography were registered using a surface 
based registration algorithm [20] and rendered to a 3D virtual head model using Maxilim® 
software (Medicim NV, Mechelen, Belgium). In order to align all virtual head models in 
the same orientation, a 3D cephalometric reference frame was set up according to the 
procedure described by Swennen et al. 22. Thirty-three soft tissue and 21 hard tissue 
landmarks were identified (Table 1). A modified Swennen hard tissue and soft tissue 
cephalometric analysis was carried out 17. This resulted in a total of 39 hard tissue and 111 
soft tissue measurements, consisting of distances, angles and proportions. 
Distance color mapping
Four average faces were computed according to the method described by Zhurov et al 
23 (an average male acromegalic face, an average female acromegalic face, an average 
male control face and an average female control face). Comparing these average faces, 
a color histogram was rendered, illustrating the differences between the acromegaly 
group and control group, for both males and females. 
Statistical analyses
Data were analyzed using SAS 9.2. (SAS Institute, Cary, NC). Data are presented as 
median unless otherwise stated. The outcomes of the soft tissue and hard tissue ceph-
alometric measurements of the patient and control groups were compared using the 
Wilcoxon signed rank test. Confidence intervals for the median difference were calcu-
lated according to the method of Conover. Statistical significance was defined as P < 
0.05.
In order to investigate whether the increase in total mandibular length (Co-Pog) is 
correlated to the observed increase in horizontal (Go-Pog) and/or vertical (Co-Go) dimen-
sion of the mandible, differences in Co-Go, Go-Pog and Co-Pog between the patients 
and controls were calculated, resulting in ΔCo-Go, ΔGo-Pog and ΔCo-Pog. ΔCo-Pog was 
analyzed using a mixed linear model, with factors side (left or right), covariates ΔCo-Go, 
ΔGo-Pog and ΔCo-Go*ΔGo-Pog (the interaction between ΔCo-Go and ΔGo-Pog) and a 
random effect of the factor side to deal with the correlation between the left and right 
side outcomes. The model was simplified by stepwise removing of the non-significant 
factor side and the interaction term (ΔCo-Go*ΔGo-Pog ), resulting in a final model with 
only the covariates ΔCo-Go and ΔGo-Pog: ΔCoPog=4.4633+0.4203xΔCoGo+0.6928xΔ-
GoPog.
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Table 1) Hard and soft tissue landmarks and their definitions. (page 147-149)
Hard tissue landmarks Definition
A-point (A) The point of maximum concavity in the midline of the alveolar 
process of the maxilla
Anterior nasal spine (ANS) The most anterior midpoint of the anterior nasal spine of the maxilla
B-point (B) The point of maximum concavity in the midline of the alveolar 
process of the mandible
C-point (C) The most caudal point of the margin of the sigmoid notch
Condylion (Co)* The most postero-superior point of the mandibular condyle
Frontozygomatic
suture (Fz)*
The most medial and anterior point of the left frontozygomatic 
suture at the level of the lateral orbital rim
Gonion (Go)* The most caudal and most posterior point of the mandibular angle
Lower incisor (LI)* The most mesial point of the tip of the crown of the lower central 
incisor
Lower molar (LM)* The most superior point of the mesial cusp of the crown of the left 
first lower molar in the sagittal plane
Pogonion (Pog) The most anterior midpoint of the chin
Menton (Men) The most inferior midpoint of the chin on the outline of the 
mandibular symphysis
Nasion (N) The midpoint of the frontonasal suture
Orbitale (Or)* The most inferior point of the inferior orbital rim
Pogonion (Pog) The most anterior midpoint of the chin on the outline of the 
mandibular symphysis
Porion (Po)* The most superior point of the meatus acusticus externus
Posterior maxillary
point (PMP)
The point of maximum concavity of the posterior border of the 
palatine bone in the horizontal plane
Posterior nasal spine
(PNS)
The most posterior midpoint of the posterior nasal spine of the 
palatine bone
Sella (S) The center of the hypophyseal fossa (sella turcica)
Upper incisor (UI)* The most mesial point of the tip of the crown of the upper central 
incisor
Upper molar (UM)* The most inferior point of the mesial cusp of the crown of the first 
upper molar in the sagittal plane
Zygion (Zy)* The most lateral point on the outline of the right zygomatic arch
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Soft tissue landmarks Definition
Alar curvature point (ac)* The point located at the facial insertion of the alar base
Alare (al)* The most lateral point on the left alar contour
Columella constructed
point (c`)
The midpoint of the columella crest at the level of the nostril top 
points
Cheilion (ch)* The point located at the labial commissure
Christa philitri (cph)* The point at the crossing of the vermilion line and the elevated 
margin of the philtrum
Endocanthion (en)* The soft tissue point located at the inner commissure of the eye 
fissure
Exocanthion (ex)* The soft tissue point located at the outer commissure of the eye 
fissure
Glabella (g) The most anterior midpoint on the fronto-orbital soft tissue contour
Glabella`(g`) The point localized on the midline tangent of the frontal contour 
cranial to glabella
Gonion (go)* The most lateral point on the soft tissue contour of the left 
mandibular angle, located at the same level as the 3D hard tissue 
cephalometric Gonion landmark
Gnathion (gn) The most inferior midpoint of the soft tissue contour of the chin, 
located at the level of the 3D cephalometric hard tissue Menton 
landmark
Gnathion` (gn`) The point localized on the midline tangent of the chin contour 
posterior to gnathion
Labiale inferius (li) The midpoint of the vermilion line of the lower lip
Labiale superius (ls) The midpoint of the vermilion line of the upper lip
Maxillofrontale (mf)* The soft tissue point located at the lateral margin of the nose base 
at the level of endocanthion
Nasion (n) The midpoint on the soft tissue contour of the base of the nasal 
root at the level of the frontonasal suture
Nostril base point (nb)* The lowest point of the nostril or the inferior terminal point of 
the nostril axis
Proximal nasal root 
tangent (nrt1)
The proximal point on the midline of the nasal root
Distal nasal root tangent (nrt2) The distal point on the midline of the nasal root
Nostril top point (nt) The highest point of the nostril or the superior terminal point 
of the nostril axis
149
7)  Facial analysis in cured acromegaly
7
Soft tissue landmarks Definition
Orbitale inferius (oi)* The soft tissue point located at the most inferior level of the 
left infraorbital rim, located at the level of the 3D hard tissue 
cephalometric Orbitale landmark
Orbitale superius (os)* The soft tissue point located at the most superior level of the 
supraorbital rim
Pogonion (pg) The most anterior midpoint of the chin
Porion (po)* The soft tissue point located at the level of the 3D hard tissue 
cephalometric Porion landmark
Pronasale (prn) The most anterior midpoint of the nasal tip
Sellion (se) The most posterior point of the frontonasal soft tissue contour 
in the midline of the base of the nasal root
Sublabiale (sl) The most posterior midpoint on the labiomental soft tissue 
contour that defines the border between the lower lip and the chin
Subnasale (sn) The midpoint on the nasolabial soft tissue contour between the 
columella crest and the upper lip
Subnasale` (sn`)* The point at the margin of the midportion of the columella crest
Subspinale (ss) The most posterior midpoint of the philtrum
Stomion inferius (sti) The midpoint of the upper border of the lower lip
Stomion superius (stu) The midpoint of the lower border of the upper lip
Zygion (zy)* The most lateral point on the soft tissue contour of the zygomatic 
arch, located at the level of the 3D hard tissue cephalomteric 
Zygion landmark
*=Bilateral landmarks
Results
3D Hard tissue cephalometry
The outcomes of the hard tissue cephalometric measurements are presented in Supple-
mental Table 1 (at http://link.springer.com/article/10.1007%2Fs11102-014-0565-x). Nine of 
the 39 hard tissue measurements are significantly different between the patients in 
long-term remission of acromegaly and the matched healthy control subjects (Figure 1). 
Compared to the control subjects, the patients have both a longer and wider facial skel-
eton expressed by a larger total anterior facial height and lower anterior facial height 
(median + 12.0 and + 10.8 mm, both p<0.01) and an increase in the bizygomatic width (+ 
2.95 mm, p<0.01). 
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Furthermore, both the maxilla and the mandible are larger in patients: the maxillary 
length is increased (+ 3.8 mm, p < 0.01) as well as the vertical mandibular height (right 
side + 5.7 and left side + 6.2 mm, p=0.02 and p=0.01, respectively) and total mandibular 
length (right side + 7.6 mm and left side + 8.9 mm, both p <0.01). As can be seen in Table 2, 
an increase in both the vertical mandibular ramus height and the horizontal mandibular 
ramus length significantly contribute to increase in the total mandibular length.
Additionally, the angle of the frontal inclination of the occlusal plane to the horizontal 
plane is greater in the patient group (+ 1°, p<0.01), indicating the tendency of transversal 
asymmetry in the lower third of the face in the acromegalic patients.
Figure 1)  3D cone beam CT scan of the scull of one of the patients in remission of 
 acromegaly. The projected lines depict the hard tissue measurements that 
 differ between patients and controls. 
FigurA) 1) Bizygomatic width (Zy r - Zy l) 2) Anterior total facial height (N - Men), 3) Anterior lower facial 
 height (ANS - Men). The lines are. 
FigurB) 1) Maxillary length (ANS – PNS), 2) Mandibular vertical ramus length ColGol/CorGor), 
 3) Mandibular total length (ColPog/CorPog), 4) Anterior lower facial height (ANS - Men) 
 5) Anterior total facial height (N - Men).
1
1
5
42
2
3 3
A B
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3D soft tissue cephalometry
The distance color maps (Figure 2) show how the average soft tissue profile of the 
patients in long-term remission of acromegaly differs from the average soft tissue 
profile of the healthy control subjects for both men and women. The outcomes of the 
soft tissue cephalometric measurements are presented in Supplemental Table 2 (at 
http://link.springer.com/article/10.1007%2Fs11102-014-0565-x). Thirty of the 111 soft tissue 
measurements are significantly different between the patients in long-term remis-
sion of acromegaly and the matched healthy control group, all indicating growth in the 
patient group. 
Compared to the healthy control group, the patients in long-term remission of acro-
megaly have a longer face: the morphological height of the face (+ 9.4 mm, p<0.01), 
the height of the upper face (+ 5.1 mm, p=0.01), the height of the lower face (+ 7.5 mm, 
p=0.01), the height of the lower profile (+ 5.5 mm, p=0.02), the lower right and left half of 
the craniofacial height (+ 10.5 mm, p< 0.01) and the right and left orbitogonial distances 
(+ 7.7 and 5.3 mm, p=0.02) are significantly larger. The face is also proportionally longer in 
the patient group, expressed in a greater facial index (+ 8 in the ratio total facial length 
and facial width, p=0.01) and the patients have a proportionally narrower lower third of 
the face (-11.5 in the ratio lower face width / morphological height of the face, p<0.01). 
Furthermore the patients have a larger nose, characterized by a longer nasal bridge 
(+ 4.9 mm, p=0.02), a wider nasal root (+ 2.3 mm, p<0.01), a greater nasal tip (+ 2.8 mm, 
p=0.01) and nasal root protrusion (right side + 0.3 and left side + 1.8 mm, p=0.18 and 
p=0.04), a larger columella base-facial insertion depth (right side + 2.3 and left side 
+ 2.1 mm, p<0.01) and a larger 3D alar length (right side + 3.6 and left side + 4.6 mm, 
p <0.01). In the patient group nasolabial angle is decreased (-9.0 °, p=0.01). 
Table 2) Summary of mixed model analysis to study if the increase in length of 
 the total mandibula can be explained by an increase in the vertical and/or 
 horizontal dimension.
Estimate SE P-value
Intercept 4.4633 1.6550 0.0173
Δ CoGo 0.4203 0.0959 0.0007
Δ GoPog 0.6928 0.1955 0.0027
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With regard to the orbital region, the right and left endocanthion-facial midline distance 
is larger in the patient group (right side + 2.0 and left side + 2.8 mm, p= 0.07 and p=0.01), 
resulting in a large intercanthal width. The intercanthal index is larger in the patient 
group which indicates a tendency to develop telecanthus (+2.9, p=0.02. The angle of 
inclination of the right and left orbital rim line from the vertical plane is also greater, 
which suggests frontal bossing (right side + 4.6° and left side + 2.15°, p=0.03 and p=0.15). 
Furthermore the mandible is larger in the patient group with an increased height (+ 4.2 
mm, p=0.02) and depth of the mandible (+ right side 1.7 mm, and + left side 3.2 mm, 
p=0.24 and p=0.03). In comparison to the control group, the patient group has a signifi-
cantly wider mouth (+ 2mm, p=0.04). The lower lip of the patients is longer (+ 3.2 mm 
in height of lower lip, p=0.02) and tends to incline more anteriorly, making the lower lip 
even more pronounced in the facial profile (+ 13.5°, p=0.04). The mentocervical angle is 
smaller ( - 8.3°, p=0.01), which indicates a more prominent chin.
Figure 2) Comparison between the average A) female and B) male faces of the acro- 
 megaly patient group and control group. 
 Blue areas represent areas in which the average acromegalic face is more prominent than 
 the average control face and orange areas represent areas were the average control face is 
 more prominent than the average acromegalic face. 
A
B
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Discussion
This is the first study that uses 3D cephalometry to analyze craniofacial dispropor-
tions in (former) acromegaly patients. Because of the advantages of 3D cephalometry 
compared to 2D cephalometry, our study is the first study that accurately describes 
which craniofacial disproportions of both bony structures and soft tissues persist in 
patients in long-term remission of acromegaly and accurately quantifies the magnitude 
of the disproportions. 
We investigated the differences in craniofacial dimensions between 16 patients in 
long-term remission of acromegaly and a control group matched for gender, age, BMI 
and ethnicity. Because all previous studies on craniofacial changes in patients with 
acromegaly performed a 2D cephalometric analysis using standardized lateral ceph-
alograms, their focus was on changes in the length of the viscerocranium, neglecting 
dimensional changes in the transverse plane 8, 12, 14. In line with the findings of Dostálová 
et al. who analyzed a group of patients with active and treated acromegaly 14, we found 
that the total facial height and the height of the lower face are enlarged in patients 
in long-term remission of acromegaly. However, our study also shows that patients in 
long-term remission of acromegaly have an increased skeletal width at the level of the 
zygoma. This indicates that the facial growth takes place both in vertical and in trans-
verse directions, although, proportionally, the vertical growth is the largest. Interest-
ingly, with the soft tissue cephalometric analysis no differences in the bizygomatic and 
bigonial width are found between the patient and the control group, suggesting that 
patients in long-term remission of acromegaly have less soft tissue in the region of the 
zygoma and mandibular angles than control subjects. It is known that active GH hyper-
secretion is associated with a reduced fat mass due to increased lipolysis 24. As the soft 
tissue in the region of zygonion and gonion is mainly composed of malar and subcu-
taneous adipose tissue, the reduced amount of soft tissue indicates that the facial 
adipose tissue volume remains reduced among patients, even after long-term remis-
sion of acromegaly.
In line with all previous studies on craniofacial changes in acromegaly, we found a marked 
increase in the size of the mandible (total mandibular length) among patients in long-
term remission of acromegaly. We demonstrated that this increase can be explained by 
growth of the mandible both in the vertical and horizontal directions, although the hori-
zontal growth of the horizontal ramus was not statistically significant. In contrast with 
the previous studies we found that the maxillary length was also increased in former 
acromegaly patients compared to control subjects. Kunzler and Herrmann found an 
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increased sella-nasion-B point (SNB) angle and an unchanged sella-nasion-A point (SNA) 
angle in patients with controlled and active acromegaly, which suggested absence of 
maxillary growth 8,12. Dostálová even found retroposition of the maxilla (a diminished SNA 
angle) in women 14. In the current study the SNA and SNB angles did not differ between 
the patient and control groups. A possible explanation for this discrepancy is the differ-
ence in imaging and cephalometry techniques. Three-dimensional cephalometry is less 
susceptible to magnification and landmark identification errors than 2D cephalometry. 
Furthermore the previous studies did not use an adequately matched control group, so 
their results could be influenced by differences in age, ethnicity and BMI.
With the 2D imaging technique it is much more difficult to quantify soft tissue changes 
than with the 3D image fusion technique. Therefore this is the first study to quantify 
facial soft tissue changes in acromegaly. Our results show that many typical soft tissue 
deformities persist even after long-term remission of acromegaly. The nose is larger in 
all dimensions and the lower lip is also larger. This shows that the period of GH hyperse-
cretion has remaining effects on soft tissues, probably on both cartilage and connec-
tive tissue, in addition to the remaining effects on the bony structures. 
The differences in measurements between the patients in long-term remission of acro-
megaly and the healthy control group may seem small, but the human eye is able to 
detect very small changes 25. Furthermore, a majority of studies on facial esthetics 
suggests that facial measurements closest to the mean are considered to be the most 
attractive 26. Therefore, patients in long-term remission of acromegaly are more at risk 
to be considered unattractive than healthy control subjects, although other aspects, 
such as complexion, posture, sex and age are also important for the judgment of attrac-
tiveness 27. Indeed, there are indications that patients in long-term remission of acro-
megaly are insecure about their general appearance, which may have a large psycho-
logical impact and can affect quality of life 28. Moreover, the craniofacial disproportions 
may cause functional problems such as jaw pain, mastication problems or mouth 
breathing. Both appearance and functional problems may be a reason for intervention, 
for example consultation of a specialized nurse, psychologist or a specialist in recon-
structive surgery. We therefore believe that all patients in remission of acromegaly 
should be asked about any issues regarding their appearance and functional problems 
that may require interventions, and all intervention possibilities should be discussed.
A limitation of this study is the relatively small sample size, which is caused by the rare-
ness of acromegaly and our strict in- and exclusion criteria. The major strengths of this 
study, besides the one-on-one matching of patients and control subjects, are the use 
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of the 3D imaging technique and the 3D cephalometric analysis of both soft and hard 
tissues. The reliability of 3D measurements is dependent on inaccuracies that are mainly 
related to the manual identification of 3D cephalometric landmarks. The 3D cephalo-
metric analysis according to Swennen has a low intra- and interobserver measurement 
error, which does not exceed 1 mm 19,29. In this study all measurements were performed 
by one experienced observer in order to reduce the magnitude of the measurement 
error even more. The use of a color-encoded distance map to visualize and quantify the 
facial morphology between patients and controls is especially advantageous as it is not 
influenced by landmark identification errors and provides a better representation of the 
clinical situation, since all image data of the facial regions are used. Beside 3D cepha-
lometry, the employment of a distance map should therefore be an integral part of the 
3D facial analysis. 
Because of the advantages of 3D facial analysis it is a very promising technique for the 
evaluation of the effects of acromegaly on the viscerocranium in both clinical prac-
tice and research settings. For example, we know that, like soft tissue, bone is an active 
organ that undergoes continuous remodeling throughout life 30. During normal growth the 
craniofacial bones respond to alterations in the functional matrix 31. Therefore, although 
this study demonstrates that changes in craniofacial dimensions persist after long-
term remission of acromegaly, it is possible that the viscerocranium keeps remodeling 
for many years after the patients have been cured. To investigate how the viscerocra-
nium changes over time and whether a stable state is reached, a longitudinal prospec-
tive study is necessary . Furthermore, at present, besides determination of IGF-1 levels, 
there are no methods to compare the effectiveness of different treatment modalities 
(e.g. pituitary surgery or different kinds of medication) for acromegaly on tissue-specific 
endpoints. Three-D cephalometry is a promising method for the evaluation of the effect 
of different treatment modalities for acromegaly on soft and bony tissue.
Finally, because acromegaly only causes subtle changes in appearance in the first years 
of the disease which are difficult to recognize by the human eye, there is often a delay 
in diagnosis for up to 10 years. It has recently been demonstrated that, if 2D photo-
graphs are analyzed with a computer model, the computer could sort photographs of 
patients with acromegaly from photographs of normal subjects much more accurately 
than medical experts could 32, 33. So potentially, relatively simple imaging techniques 
could be applied to risk populations for acromegaly in order to shorten the delay in diag-
nosis, which will presumably result in less disfiguration. It is very well possible that the 
use of a 3D stereophotograph, instead of a regular 2D photograph, will be even more 
accurate. This should be investigated in the future. 
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In conclusion, the application of 3D cephalometry on 3D fusion head models is a good 
method to investigate craniofacial disproportions in patients with acromegaly, and is a 
promising technique for both clinical practice and research settings. Significant cranio-
facial changes persist even after long-term remission of acromegaly. Longitudinal 
prospective studies are required to evaluate to what extent the craniofacial changes 
are reversible after remission, how different treatment modalities for acromegaly affect 
craniofacial characteristics, and to what extent (ex-)patients suffer from psychosocial 
inconveniences caused by the persisting craniofacial disproportions.
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Abstract
Objective: Centripetal obesity is associated with systemic low-grade inflammation 
and an increased cardiovascular risk. Patients in long-term remission of Cushing’s 
syndrome (CS) report persisting abdominal fat accumulation. However, this has never 
been adequately objectified. Therefore we investigated the adipose tissue distribution 
and adipocytokine profiles of patients in long-term remission of CS. 
Design: Cross sectional case-control study in a tertiary referral centre. 
Patients: Fifty-eight patients, in remission of CS for at least 5 years, were compared to 
58 age-, gender- and BMI-matched healthy control subjects.
Measurements: measures of body composition (assessed with clinical evaluation and 
Dual Energy X-ray Absorptiometry (DEXA) scanning) and serum adipocytokine profiles. 
Results: Compared to the matched control subjects, patients in long-term remission of 
CS had a greater waist circumference (p<0.01), a smaller thigh circumference (p<0.01), a 
higher waist-to-hip ratio (p<0.01) and a higher hip-to-thigh-ratio (p<0.01). As measured 
with DEXA scanning, patients had a higher percentage of truncal fat mass (p=0.01) 
and the truncal fat mass to leg fat mass ratio was greater (p<0.01). Patients had lower 
adiponectin levels (p<0.01), higher leptin levels (p<0.01) and higher resistin levels (p=0.04) 
than control subjects. 
Conclusion: Even after long-term remission, patients who suffered from CS in the past 
continue to have a centripetal adipose tissue distribution and an adverse adipokine 
profile. This is independent of etiology of CS, treatment strategies, hormonal deficien-
cies and comorbidity, and probably contributes to the persistently increased cardiovas-
cular risk.
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Introduction
Endogenous Cushing’s syndrome (CS) is associated with significant morbidity and 
mortality 1. Although the Cushingoid phenotype dramatically improves after curative 
treatment, quality of life remains impaired, even after long-term remission. This is 
regardless of etiology, presence of hormonal deficiencies and treatment strategies 2. 
The cause of the remaining impaired quality of life is most likely multifactorial, but there 
is probably an important physical component 3. 
Research in patients with obesity has shown that excess visceral adipose tissue (VAT) 
causes a state of systemic low-grade inflammation4-6. This process is triggered when 
macrophages infiltrate the VAT in response to microhypoxia and rupturing of adipo-
cytes 4, 5. As a result, the secretion of adipocytokines by the VAT changes, leading to an 
adverse adipocytokine profile, which causes insulin resistance, endothelial dysfunction 
and eventually macrovascular cardiovascular disease 4-6.
When CS is diagnosed, centripetal obesity is present in the majority of patients and it 
usually developed in a relatively short period of time. Even though the volume of centrip-
etal obesity diminishes after remission, patients report persisting abdominal fat accu-
mulation despite overall weight loss 7. Besides the psychological burden of the changed 
appearance, the metabolic consequences of centripetal obesity may be a major cause 
of persisting impaired quality of life and increased morbidity and mortality in patients 
in remission of CS 8, 9. Previously, a number of studies have investigated if centripetal 
obesity and systemic low-grade inflammation persist after remission of CS 10-13. However, 
these studies have some methodological limitations and the results are conflicting. 
The aim of this study was therefore to investigate the adipose tissue distribution, adipo-
cytokine profiles and metabolic risk profiles of patients in long-term remission of CS. 
 
Materials and methods
Subjects
All adult patients of the Department of Medicine, Division of Endocrinology, of the 
Radboud University Medical Centre Nijmegen, who had successfully been treated for CS 
(caused by either an ACTH-producing pituitary adenoma or a benign adrenal adenoma) 
and had been in remission for at least five years, were eligible for inclusion in this cross 
sectional case-control study. Remission was defined as absence of clinical signs and 
164
symptoms of hypercortisolism and suppression of plasma cortisol to ≤ 50 nmol/l after 
1 mg dexamethasone overnight 14 or, if a patient had received radiotherapy of the pitu-
itary gland, a 24-hour urinary free cortisol value of <240 nmol/24h for men or <150 
nmol/24h for women. The medical records of all patients were retrospectively reviewed 
to assess clinical data regarding the etiology of CS, the type and number of treatments 
that patients received, duration of remission, hormonal deficiencies and comorbidities.
Patients with untreated hormonal deficiencies or hormonal deficiencies that had not 
been treated adequately in the last 5 years according to international standards, except 
for estrogen deficiency, were excluded. Hypothyroidism was defined as free thyroxin 
(fT4) plasma concentrations < 8 pmol/l (institutional reference range 8-22 pmol/l). 
Testosterone deficiency in men was defined as testosterone levels < 11 nmol/l (refer-
ence range 11-45 nmol/l). In women, estrogen deficiency was defined as untreated 
secondary hypogonadotropic hypogonadism or a postmenopausal state without the 
use of estrogen substitution therapy. Growth hormone (GH) deficiency was investi-
gated in all patients and defined as a maximal GH response of < 5.1 µg/l during an insulin 
tolerance test (ITT), or as a maximal GH response of < 4.1 µg/l during an arginine/GHRH 
test 15. Glucocorticoid deficiency was defined as a maximal cortisol response < 550 
nmol/l during an ITT 16.
Patients with active malignancy or systemic therapy for malignancy in the past, auto-in-
flammatory diseases and psychiatric pathology were also excluded. All patients under-
went a new 1 mg dexamethasone suppression test (or a 24-hour urinary free cortisol 
measurement in case of pituitary RT) before entering the study to confirm remission. 
Each patient was matched to a control subject with the same gender, age (± 2 years) 
and BMI (± 2 kg/m2). Control subjects were recruited via advertisements. They were not 
allowed to have a known disease (with the exception of obesity) or use of medication. 
This study was performed according to the Declaration of Helsinki and was approved 
by the institutional Medical Ethics Committee. Written informed consent was obtained 
from all participants.
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Clinical assessment
All participants visited our outpatient clinic for data collection. Before their visit, all 
subjects completed a questionnaire about medical history, current complaints and life-
style. In order to detect unknown comorbidities extensive physical examination was 
performed. Furthermore, the following anthropometric measurements were performed 
in a standardised way: 1) weight 2) height, 3) systolic and diastolic blood pressure 
(average of 10 measurements, every 3 minutes with an oscillometric sphygmomanom-
eter (Criticon model 1846; Criticon Inc., Tampa, FL)), 4) heart rate, 5) skinfold thickness 
(using a Harpenden skinfold calliper) at the biceps, triceps, subscapular, and suprailiac 
level 17 and 6) the circumference of the waist, hip and left thigh. Body mass index (BMI), 
waist to hip- and hip to thigh-ratios were calculated with these measurements. 
Biochemical evaluation
Fasting blood samples were drawn for biochemical evaluation of the following measure-
ments: plasma glucose, glycated hemoglobin (HbA1c), insulin, total cholesterol, 
triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and creati-
nine, and serum fT4 and insulin-like growth factor type 1 (IGF-1). Insulin sensitivity was 
assessed by homeostasis model assessment (HOMA-IR). Furthermore, serum adipo-
cytokine profiles were measured: interleukin 6 (IL-6), interleukin 8 (IL-8), macrophage 
chemotactic protein-1 (MCP-1), Tumour necrosis factor alpha (TNF-α), adiponectin, leptin 
and resistin. 
DEXA evaluation
Total body dual-energy X-ray absorptiometry scanning (DEXA) was performed using a 
Hologic QDR 4500 densitometer (Hologic, Bedford, Zaventem, Belgium) to determine the 
percentage of total body fat mass and total lean body mass. Furthermore, in order to 
assess the presence of a centripetal adipose tissue distribution, the fat percentage of 
different body compartments was measured. This enabled us to calculate the trunk/leg 
fat ratio and the trunk/extremities fat ratio.
Assays
Serum concentrations of IL-6, IL-8, MCP-1, leptin and resistin were measured by Multiplex 
Fluorescent Bead Immunoassays (xMAP technology, Millipore, Billerica, MA, USA) and a 
Bio-plex microbead analyzer (Luminex, Austin, TX, USA) according to the manufacturers 
protocol. Serum concentrations of adiponectin and TNF-α were determined by enzyme-
linked immunosorbent assays (RandD Systems, Minneapolis, MN, USA). Fasting plasma 
glucose, HbA1c, insulin, total cholesterol, triglycerides, LDL, HDL and creatinine, and 
serum fT4 and IGF-1 were measured by standard automated procedures of our hospital.
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Statistical methods
Data were analyzed using SPSS 20.0 statistical package for Windows (SPSS Inc, Chicago, 
IL). Data are expressed as mean ± SD, unless otherwise mentioned. Data distribution 
was analyzed by means of the Kolmogorov-Smirnov test. Before statistical analyses 
a logarithmic transformation was performed on non-normally distributed data. Differ-
ences between patients and controls were tested by means of paired t-tests. Differ-
ences in categorical variables were analyzed using χ2 tests. Subgroup analyses were 
performed to assess the effect of glucocorticoid replacement therapy and estrogen 
status. Stepwise backward multiple linear regression analysis was performed in 
the patient group in order to detect the influence of clinical patient characteristics 
(etiology of CS, treatment strategies, presence of hormonal deficiencies, use of alcohol, 
smoking and comorbidity) as predictors for the outcomes of centripetal fat distribution 
and adipokine profiles. Tests were two-tailed and p<0.05 was considered statistically 
significant. 
Results
Subject characteristics
Table 1 shows the clinical characteristics of the patients and controls. Fifty-eight 
patients met all inclusion criteria and were willing to participate. Seventy-nine percent of 
patients were female. The age of the total group was 50.8 ± 12.3 years and BMI was 26.5 
± 4.2 kg/m2. Data did not differ between the patient and control group, thus confirming 
adequate matching. Sixty-nine percent of patients had had CS caused by a pituitary 
adenoma and 31% CS caused by an adrenal adenoma. Patients had been in remission of 
CS for an average of 13.6 ± 8.0 years. At the time of investigation, 7% of all patients were 
treated for diabetes mellitus, 31% for hypertension and 21% for hyperlipidemia. Fifty-
nine percent of all patients had one or more hormonal deficiencies which had been 
treated accurately for at least 5 years (except for the women with estrogen deficiency 
who were all over 50 years of age). At the time of the study 13 of the 21 patients with 
GC deficiency used hydrocortisone, 7 patients used cortisone acetate and one patient 
used dexamethasone. The mean dose, in equivalents of hydrocortisone, for these 21 
patients was 19.7 ± 9.7 mg daily. 
Patients only differed from controls with respect to smoking habits, with 14 smoking 
patients versus 5 controls (p<0.024). 
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Table 1)  Group A: Clinical characteristics of patients in long-term remission of
 Cushing’s syndrome and healthy controls. 
Patients (n=58) Controls (n=58) P-value
Gender (n): male/female 12/46 12/46
Age: mean (± SD) (years) 50.8 (12.3) 51.2 (12.4) 0.863
BMI: mean (± SD) (kg/m2) 26.5 (4.2) 26.3 (4.1) 0.793
Duration of remission: 
median (± range) (years)
13.6 ± 8.0
Smoking (yes/no)
 Pack-years (± SD)
14/44
11.5 (15.6)
5/53
6.9 (13.9)
0.024*
Alcohol consumption: yes/no 10/48 13/45 0.485
Treatment modalities: n (%)
Unilateral adrenalectomy
Bilateral adrenalectomy
Pituitary surgery
Pituitary radiotherapy
19 (32.8)
12 (20.7)
38 (65.5)
13 (22.4)
-
-
-
-
-
-
-
-
 Hormonal deficiencies: n (%)
Glucocorticoid deficiency
Growth hormone deficiency
Thyroid hormone deficiency
Mineralocorticoid deficiency   
Testosterone deficiency
Estrogen deficiency 1
21 (36.2)
15 (25.9)
25 (43.1)
11 (19.0)
6/12 (50.0)
25/46 (54.3)
-
-
-
-
-
29/46 (63.0)
-
-
-
-
-
-
Comorbidities: n (%)
Hypertension
Diabetes mellitus
Hypercholesterolemia
18 (31.0)
4 (6.9)
12 (20.7)
0 (0)
0 (0)
0 (0)
-
-
-
Cushing type: n (%)
Pituitary
Adrenal
40 (69.0)
18 (31.0)
-
-
-
-
BMI: body mass index; CS: Cushing’s syndrome.; * P<0.05; 
Note 1: Secondary hypogonadotropic hypogonadism or a postmenopausal state without the use of 
chronic estrogen replacement.
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Comparisons between patients in remission of CS and 
healthy controls
Table 2 shows the comparisons between patients and controls with regard to the 
different outcome measures. Figure 1 shows the main findings of this study. 
Figure 1) Scatter plots of the main differences in adipokine profiles and adipose 
 tissue distribution and adipokine profiles between patients in remission of 
 Cushing’s syndrome (N=58) and healthy controls (N=58). Depicted are the 
 absolute values or ratios of each individual and the result of the of the 
 paired t-test. P<0.05 was considered statistically significant. The bars 
 represent the mean values.
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Table 2) Outcomes in patients and controls. (page 169-170)
Variable Controls (n=58)
(mean)
SD Patients(n=58)
(mean)
SD P-value
Biochemical evaluation
Total serum cholesterol (mmol/l) 5.38 0.198 5.16 0.165 0.188
HDL-cholesterol (mmol/l) 1.44 0.242 1.33 0.216 0.061
LDL-cholesterol (mmol/l) 3.38 0.255 3.05 0.236 0.055
Triglycerides (mmol/l) 1.01 0.445 1.43 0.531 <.001***
Creatinin (μmol/l) 68.10 0.144 70.81 0.188 0.194
Insulin (mE/l) 6.51 0.552 6.51 0.722 0.933
Hba1c (mmol/mol) 37.49 0.088 39.10 0.151 0.355
Fasting glucose (mmol/l) 4.98 0.107 4.99 0.172 0.973
HOMA_IR 1.71 0.99 2.36 5.08 0.371
fT4 (pmol/l) 12.28 0.136 15.20 0.202 <.001***
IGF-1 (nmol/l) 16.02 0.353 13.25 0.434 0.011*
Adipocytokines
Adiponectin (pg/ml) 1478.82 0.972 915.07 1.074 <.001***
Leptin (pg/ml) 1358.31 1.114 3739.33 1.182 <.001***
Resistin (pg/ml) 2435.73 0.958 3001.90 0.855 0.036*
IL-6 (pg/ml) 0.58 1.118 0.61 0.994 0.602
IL-8 (pg/ml) 0.33 2.130 0.48 1.845 0.328
TNF-α (pg/ml) 2.00 1.345 2.01 1.455 0.988
MCP-1 (pg/ml) 64.46 0.536 67.36 0.581 0.614
Clinical assessment
Systolic blood pressure (mmHg) 132.37 19.06 126.04 14.55 0.095
Diastolic blood pressure (mmHg) 77.24 9.27 73.85 9.02 0.134
Heart rate (bpm) 64.03 8.42 66.81 9.48 0.151
Thigh circumference (cm) 53.68 6.17 50.57 4.14 <.001***
Hip circumference (cm) 104.17 9.29 103.84 8.55 0.854
Waist circumference (cm) 90.13 13.10 94.79 12.89 <.001***
Skinfold thickness (mm) 74.74 0.452 80.48 0.276 0.255
Waist: hip 0.86 0.08 0.91 0.08 <.001***
Hip: thigh 1.95 0.19 2.06 0.18 0.002**
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Body composition and anthropometry
Anthropometric measurements demonstrated that, compared to healthy control 
subjects, patients had a significantly larger waist circumference (p<0.001), a smaller 
thigh circumference (p<0.001) and thus a greater waist to hip ratio (p< 0.001) and hip to 
thigh ratio (p=0.02). The hip circumference and skinfold thickness did not differ between 
patients and control subjects. Results of the DEXA scans showed that patients had a 
significantly larger percentage of trunk fat than control subjects (p=0.01) and that the 
trunk to leg fat percentage ratio was higher (p<0.001). Total lean body mass percentage, 
total body fat percentage, leg fat percentage, systolic- and diastolic blood pressure and 
heart rate were not significantly different between patients and controls. 
Adipocytokine profiles
Compared to control subjects, patients had a significantly lower serum total adiponectin 
level (p<0.001), a higher leptin level (p< 0.001) and a higher resistin level (p=0.036). The 
levels of IL-6, Il-8, TNFα and MCP-1 in serum did not differ between patients and controls.
Laboratory outcomes
Compared to control subjects, patients had a significantly higher level of plasma 
triglycerides, but total cholesterol, HDL-cholesterol and LDL-cholesterol levels did not 
Variable Controls (n=58)
(mean)
SD Patients(n=58)
(mean)
SD P-value
DEXA evaluation
Total fat mass (%) 40.28 51.88 33.93 6.69 0.371
Total lean body mass (%) 47.10 8.40 46.81 8.79 0.830
Trunk fat (%) 32.44 8.77 34.42 7.39 0.010*
Extremity fat (%) 36.87 9.52 36.68 8.32 0.939
Leg fat (%) 35.90 8.94 34.15 7.97 0.107
Trunk: leg 0.92 0.18 1.04 0.24 <.001***
Trunk: extremities 0.89 0.16 0.96 0.18 <.001***
Differences were tested by means of paired t-tests. For logarithmically transformed data the geometric 
means were calculated using back transformation to enable clinical interpretation of the outcomes. HDL, 
high density lipoprotein; LDL, low density lipoprotein; Hba1c, glycated hemoglobin; HOMA-IR, homeostatic 
model assessment of insulin resistance; IGF-1, insulin like growth factor type 1; IL-6, interleukin 6; IL-8, inter-
leukin 8; TNF-α, tumor necrosis factor alpha; MCP-1, monocyte chemotactic protein 1. 
* p<0.05; ** p<0.01; *** p<0.001
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Table 3A) Outcomes in patients and controls without glucocorticoid deficiency.
Variable Controls (n=37) 
(mean)
SD Patients (n-=37) 
(mean)
SD P-value
Adipocytokines
Adiponectin (pg/ml) 1274.11 0.98 962.95 1.10 0.030*
Leptin (pg/ml) 1436.55 1.20 4146.42 1.23 0.001**
Resistin (pg/ml) 2489.91 0.94 2892.86 0.89 0.215
Clinical assessment
Systolic blood pressure (mmHg) 133.44 19.17 125.73 12.78 0.041*
Thigh circumference (cm) 53.94 6.70 50.69 4.28 0.004**
Waist circumference (cm) 90.31 14.01 94.78 13.45 0.010*
Waist:hip 0.86 0.08 0.90 0.08 0.006**
Hip:thigh 1.95 0.18 2.07 0.18 0.004**
DEXA evaluation
Trunk fat (%) 32.55 8.88 34.85 7.98 0.030*
Trunk:leg 0.91 0.18 1.00 0.20 0.004**
Trunk:extremities 0.88 0.16 0.93 0.15 0.010*
Table 3B) Outcomes in estrogen sufficient women. 
Variable Controls (n=14)
(mean)
SD Patients (n=14) (mean) SD P-value
Adipocytokines
Adiponectin (pg/ml) 2121.76 0.88 1299.84 1.29 0.058
Leptin (pg/ml) 1141.39 1.25 3677.54 0.64 0.009**
Resistin (pg/ml) 2835.57 1.01 2779.43 0.87 0.911
Clinical assessment
Thigh circumference (cm) 52.62 5.91 51.15 3.93 0.394
Waist circumference (cm) 80.00 10.04 85.08 7.57 0.093
Waist:hip 0.80 0.08 0.84 0.05 0.179
Hip:thigh 1.90 0.17 1.98 0.09 0.108
DEXA evaluation
Trunk fat (%) 29.25 8.62 31.85 6.00 0.196
Trunk:leg 0.80 0.18 0.86 0.15 0.228
Trunk:extremities 0.79 0.14 0.81 0.10 0.454
Differences were tested by means of paired t-tests. For logarithmically transformed data the geometric 
means were calculated using back transformation to enable clinical interpretation of the outcomes 
* p<0.05, ** p<0.01, *** p<0.001
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differ. Furthermore, fasting plasma glucose and insulin levels were not significantly 
different, nor were the level of HbA1c and the calculated HOMA-IR. IGF-1 levels were 
significantly lower in patients compared to control subjects (p=0.011), and fT4 levels 
were higher (p<0.001).
Effect of glucocorticoid replacement therapy
When data were reanalyzed excluding the 21 patients that used glucocorticoid replace-
ment therapy (including their matched controls, Table 3a), the differences found were 
largely the same as in the total group. However, HDL-cholesterol levels and systolic 
blood pressure were now significantly lower in patients compared to controls (p=0.041). 
Furthermore, the difference in resistin levels was no longer significant (p=0.215).
Effect of estrogen status
If the 14 couples of women in whom the patient and control subject were both estrogen 
sufficient are compared, most differences were no longer significantly different (Table 
3b), although there was a trend towards a more centripetal adipose tissue distribu-
tion with adverse adipokine profile in the patient group compared to the control group. 
Furthermore, leptin levels remained significantly higher in the patients (p=0.009). 
Stepwise backward multiple linear regression
Stepwise backward multiple linear regression analysis in the patient group identi-
fied smoking behaviour (yes/no) as being significantly related to waist circumference 
(β 3.35; p=0.02). Mineralocorticoid substitution therapy (yes/no) was significantly 
related to trunk fat percentage (β 3.10; p=0.02). Exclusion of all couples containing a 
smoker in the patient or control group did not change the statistically significant differ-
ence in waist circumference between the groups (p=0.02). Furthermore, after exclusion 
of the patients using mineralocorticoid substitution therapy, the difference in trunk fat 
percentage between patients and controls remained statistically significant (p=0.03). 
No relationship was found between other patient-related factors (e.g. deficiency of 
GH, GC, testosterone or estrogen) and the outcomes of centripetal fat distribution and 
adipokine profiles.
Discussion
In the present study we investigated the adipose tissue distribution and adipocyto-
kine profiles of patients in long-term remission of CS and compared the results with 
a healthy gender-, age- and BMI-matched control group. Previously, a small number of 
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studies have investigated if centripetal obesity and systemic low-grade inflammation 
persist after remission of CS 10-13. However, these studies have some methodological 
limitations (e.g. small numbers of patients, patients with untreated hormonal deficien-
cies included, patients included shortly after remission), and the results are conflicting: 
two studies 10-11 describe persisting centripetal obesity and an adverse adipokine profile 
in patients in long-term remission of CS, while two other studies 12-13 concluded that 
adipose tissue distribution and adipokine profiles become more favourable after remis-
sion of CS and suggest that in time it might even normalise. The strengths of this study 
are the large group of patients (n=58) who had been in remission of CS for at least 5 
years, so changes in body composition most likely had reached a steady state. In all 
patients presence of hormonal deficiencies had been investigated and, if present, 
treated for at least 5 years to make sure that untreated hormonal deficiencies would 
not influence our findings. Furthermore, we performed one-to-one matching of each 
patient to a healthy age-, gender- and BMI-matched control subject. Because of the solid 
methodology and adequate selection of subjects, we believe that this study provides 
convincing data concerning the adipose tissue distribution and adipocytokine profiles 
of patients in long-term remission of CS. Furthermore, this is the first study that investi-
gates resistin and leptin values in patients in long-term remission of CS. 
In line to what Barahona et al. and Colao et al. previously reported 10, 11 , this study confirms 
that patients in long-term remission of CS continue to have a centripetal adipose tissue 
distribution, even though total fat percentage and BMI did not differ from controls. 
Furthermore, patients had an adverse adipokine profile with decreased adiponectin and 
increased resistin and leptin levels. The concentrations of the cytokines IL-6, IL-8, TNF-α 
and MCP-1 did not differ between patients and controls. 
We measured adipose tissue distribution by performing manual measurements of 
circumferences of different body parts and DEXA scanning. Unfortunately, DEXA scan-
ning cannot distinguish between different adipose tissue depots 18. However, because 
skinfold thickness, which can be seen as a measure for subcutaneous fat accumulation, 
did not differ between patients and control subjects, it is very likely that the abnormal 
centripetal adipose tissue distribution in the patients is caused by an increase in VAT. 
The significantly increased triglyceride values and the abnormal adipokine profiles in 
patients support this conclusion 18, 19.
Adiponectin is an adipokine mainly produced by VAT and circulates in different forms 
of varying molecular weight4, 20. Levels are markedly decreased in visceral obesity. 
Adiponectin levels correlate inversely with insulin resistance. A number of studies have 
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investigated adiponectin levels in active CS, or (mostly shortly) after remission, but 
results have been conflicting 10, 12, 21-23. In line with what Barahona et al. previously found 
in women, this study confirms that adiponectin levels are decreased after long-term 
remission of CS, in both women and men, compared to healthy matched controls. 
Resistin is produced by macrophages and adipocytes predominantly in VAT 4. Levels 
are elevated in obese patients. Resistin is positively associated with insulin resistance 
and is a contributor to atherogenesis and cardiovascular disease 4, 20. Until now, only one 
study investigated resistin levels in 10 female patients with CS 24. Resistin levels were 
elevated during active disease, and declined 9 months after remission. However, the 
difference was not statistically significant. Our study is the first that shows that resistin 
levels are elevated after long-term remission of CS compared to healthy matched 
controls. 
Leptin is an anorexigenic hormone secreted by adipocytes in proportion to (predomi-
nantly subcutaneous) adipose tissue content 4, 20. Leptin levels are typically elevated 
in obesity, which is considered a leptin-resistant state. Hyperleptinemia in obese indi-
viduals has been widely recognised as an independent cardiovascular risk factor asso-
ciated with insulin resistance. It also has a pathogenetic role in atherothrombosis and 
endothelial dysfunction. Most previous studies show elevated levels of leptin in active 
CS, which seem to decline after remission 13, 21, 25, 26. It has been speculated that hyper-
leptinemia in active CS may be a mechanism to antagonise glucocorticoid excess or to 
reduce the stimulatory effect of cortisol on food intake 20. Our study is the first study 
that shows that leptin levels are elevated even after long-term remission of CS. There-
fore, in patients in remission of CS, hyperleptinemia is more likely a result of a leptin-re-
sistant state, like in obesity. 
Another interesting finding in this study is that thigh circumference was significantly 
smaller (±3 cm) in patients in long-term remission of CS than in control subjects. It is well 
known that hypercortisolism causes sarcopenia 27. Possibly this is not entirely revers-
ible after remission. Indeed, patients in remission of CS still complain about muscle 
weakness and inability to exercise 2, 28. Total lean body mass was not different between 
patients and control subjects. 
At the time of investigation, 31% of patients were treated for hypertension and 21% for 
hyperlipidemia, which seems to be adequate, as no differences in blood pressure and 
(LDL) cholesterol levels between patients and controls were found. Seven percent of 
all patients were treated for diabetes mellitus. Measures of insulin resistance did not 
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differ, but this is influenced by the treatment for diabetes mellitus in the patient group. 
Free T4 values were slightly higher and IGF-1 values were slightly lower in the patients. 
This is related to relative overtreatment for secondary hypothyroidism and relative 
undertreatment of growth hormone deficiency in a number of patients (even though 
individual levels of fT4 and IGF-1 were always within the normal reference ranges), as the 
differences disappear if the patients who receive substitution are excluded. However, 
this did not affect the results in the total group, as subgroup analysis excluding the 
couples of whom the patients had either GH deficiency or hypothyroidism revealed 
essentially the same results as in the total group (data not shown).
Because a large percentage of our patients used substitution with glucocorticoids, 
which could potentially have contributed to the differences we observed in adipose 
tissue distribution and adipokine profiles between patients and controls in the total 
group, we performed a subgroup analysis comparing only the couples in whom the 
patients did not use glucocorticoids. Except for resistin, which was no longer signifi-
cantly different between patients and control subjects, all other differences remained 
statistically significant. Furthermore, we performed a stepwise backward multiple linear 
regression analysis to investigate if other clinical parameters of the patients (etiology 
of CS, treatment strategies, presence of hormonal deficiencies, use of alcohol, smoking 
and comorbidity) could explain the differences we found. Only smoking behaviour had 
a statistically significant relation with waist circumference. Furthermore, use of miner-
alocorticoid substitution therapy turned out to have a statistically significant relation 
with trunk fat percentage. However, separate subgroup analyses excluding smokers 
and mineralocorticoid users did not change total group differences. No other associa-
tions were found between clinical patient characteristics and outcome parameters. We 
therefore strongly believe that the previous period of exposure to high levels of cortisol 
is the main cause of the centripetal adipose tissue distribution and adverse adipokine 
profile in patients in long-term remission of CS. 
Barahona et al. found that the differences in adipose tissue distribution and adipo-
kine profile between patients and controls were no longer significantly different if the 
estrogen sufficient women were analysed separately. They therefore suggested that 
the findings in the total group might be caused by estrogen deficiency. We performed 
a subgroup analysis in our estrogen sufficient group, even though in only 14 couples 
both patient and control were estrogen sufficient. In our study, the measurements for 
adipose tissue distribution also lose significance in this small group, although patients 
still had, on average, an almost 5 cm larger waist circumference and a 2.5% larger 
truncal fat percentage. Furthermore, leptin remained significantly higher in the patients. 
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A major issue in both studies is that the sample size is severely reduced in the subgroup 
analysis and that, hence, statistical significance is easily lost. Indeed, in the study of 
Barahona et al. the estrogen sufficient patients still have a centripetal adipose tissue 
distribution and adverse adipokine profile compared to control subjects but, like in our 
study, the difference is no longer statistically significant. Therefore, further research 
in larger groups is needed to investigate the influence of estrogen status on adipose 
tissue distribution and adipokine profiles after long-term remission of CS.
Further research is also needed to investigate the cause of the persisting centripetal 
adipose tissue distribution in patients in long-term remission of CS. We hypothesise that 
during the rapid expansion of visceral adipose tissue during active CS, macrophages 
infiltrate the adipose tissue in response to microhypoxia, and that these macrophages 
continue to cause a vicious circle of inflammation and centripetal adipose tissue accu-
mulation after remission, as is observed in obesity. Furthermore, future research should 
investigate the consequences of the persistent centripetal obesity and adverse adipo-
kine profile in patients in remission of CS. 
In conclusion, even after long-term remission, patients that suffered from CS in the 
past continue to have a centripetal adipose tissue distribution and an adverse adipo-
kine profile. This is independent of etiology of CS, treatment strategies, presence of 
hormonal deficiencies and comorbidity, and probably contributes to the remaining 
decreased quality of life and persistent increased cardiovascular risk in these patients. 
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Vascular health in patients 
in long-term remission of 
Cushing’s syndrome and 
no or adequately treated 
comorbidity is comparable 
to BMI-matched subjects 
182
Abstract
Context: In active Cushing’s syndrome (CS), patients suffer from endothelial dysfunc-
tion and premature atherosclerosis. However, it is uncertain to what extent vascular 
health recovers after long-term remission. This is highly relevant as this topic relates to 
future development of cardiovascular disease.
Objective: To investigate whether micro- and macrovascular health is impaired after 
long-term remission of CS, in patients with no or adequately treated comorbidities. 
Design and setting: Cross-sectional case-control study in two tertiary referral centers.
Patients and main outcome measures: 63 patients (remission of CS for ≥ 4 years) and 63 
healthy, well-matched controls were compared. In group A (58 patients and 58 controls) 
serum biomarkers associated with endothelial dysfunction, intima-media thickness, 
pulse wave velocity and pulse wave analysis were studied. In group B (14 patients and 
14 controls) endothelium-dependent and -independent vasodilatation was studied in 
conduit arteries (flow-mediated dilation of the brachial artery) and forearm skeletal 
muscle resistance arteries (vasodilator response to intra-arterial acetylcholine, sodi-
um-nitroprusside and NG-monomethyl-L-arginine using venous occlusion plethysmog-
raphy). 
Results: There were no significant differences between the outcome measures of 
vascular health in patients and controls, neither in group A nor in group B. 
Conclusion: Vascular health of patients in long-term remission of Cushing’s syndrome 
seems to be comparable to that of healthy gender-, age- and BMI-matched controls, 
provided that the patients have no, or adequately controlled comorbidities. Therefore, 
the effects of hypercortisolism per se on the vasculature may be reversible. This accen-
tuates the need for stringent treatment of metabolic comorbidities in these patients.
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Introduction
Patients with chronic hypercortisolism due to endogenous Cushing’s syndrome (CS) 
have a very high mortality rate, with an estimated 5-year survival of 50% in untreated 
patients 1 . Cardiovascular disease is the main cause of mortality 1 . Multiple studies have 
shown that endothelial function is impaired in these patients 2-5, with an increased inci-
dence of atherosclerosis 6,7. It has been suggested that this is mainly caused by the 
fact that most patients with CS have centripetal obesity, impaired glucose tolerance, 
systemic hypertension, hypercoagulability and dyslipidemia8. All these factors are 
associated with impaired endothelial function and premature atherosclerosis, espe-
cially if they occur simultaneously 9. In addition, one should realize that the hypercorti-
solism itself has a direct effect on the vasculature (via both the glucocorticoid and the 
mineralocorticoid receptor) 10,11 . 
Successful surgical treatment of CS, resulting in normalization of cortisol secretion, 
significantly decreases cardiovascular risk and reduces mortality rate 1,12. However, it 
is unclear to what extent vascular health recovers in patients in long-term remission of 
CS. Full recovery is not self-evident, since centripetal obesity and an adverse adipokine 
profile (which is known to be associated with endothelial dysfunction and eventually 
macrovascular disease 13,14) persists even after long-term remission of CS 15,16. Further-
more, it is questionable if the direct effects of hypercortisolism on the vasculature are 
fully reversible. 
A number of studies have previously investigated vascular health in small groups of 
patients in remission of CS 17-23. These studies reported inconsistent results, which 
may partly be explained by the small group size and/or selection of single markers of 
vascular health that, therefore, cannot provide a broad insight. 
The aim of this study was to investigate micro- and macrovascular health in a large group 
of patients in long-term remission of CS with adequately treated comorbidity if present, 
in comparison with a matched healthy control group. We measured serum biomarkers 
associated with endothelial dysfunction, performed gold standard measurements of 
endothelial function and investigated the presence of overt atherosclerosis. 
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Subjects and methods
Subjects
All adult patients of Radboud University Medical Centre Nijmegen and Leiden University 
Medical Centre, who had been successfully treated for CS (caused by either an ACTH-pro-
ducing pituitary adenoma or a benign adrenal adenoma) and were in remission for at 
least four years, were eligible for inclusion in this multi-center cross-sectional matched 
case-control study. Remission was defined as absence of clinical signs and symptoms 
of hypercortisolism and suppression of plasma cortisol to ≤50 nmol/l after 1 mg dexa-
methasone overnight or, if a patient had received radiotherapy of the pituitary gland, a 
24-h urinary free cortisol value of <240 nmol/24 h for men or <150 nmol/24 h for women. 
The medical records of all patients were retrospectively reviewed to assess clinical data 
regarding the etiology of CS, the type of treatments that patients had received, duration 
of remission, presence of hormonal deficiencies and comorbidities.
In our study we investigated 2 different patient groups: The first group (group A, n=58) 
was the same group of patients that we previously described in our study on body 
composition 16. The following exclusion criteria were applied: untreated (or inadequately 
treated) hormonal deficiencies, active malignancy or systemic therapy for malignancy 
in the past, severe inflammatory diseases and psychiatric pathology. Each patient was 
matched to a control subject with the same gender, age (±2 years), and body mass index 
(BMI, ±2 kg/m2). Control subjects, recruited via advertisements in a local newspaper, had 
to be healthy and without current use of medication. 
For the second group of patients (group B, n=14), even stricter exclusion criteria were 
used: all subjects with hormonal deficiencies, except for adequately treated hypothy-
roidism (free T4 range 8.0-22.0 pmol/l), were excluded. Furthermore, besides the previ-
ously mentioned comorbidities, all patients with comorbidities that are known to affect 
vascular function or who used medication that may interfere with the cardiovascular 
system were excluded. In addition to gender, age and BMI, the healthy control subjects 
were also matched for smoking, ethnicity, and physical activity levels (estimated via 
metabolic equivalent of task scores and measured for one week with a SenseWear Pro 
ArambandTM (Body Media, Pittsburg, USA)). Female controls were matched for estrogen 
status and oral contraceptive use. Nine patients were included in both groups A and 
group B.
The Medical Ethics Committees of our institutions approved this study and all partici-
pants provided written informed consent prior to participation.
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Methods
All subjects refrained from smoking, alcohol, caffeine, chocolate and vitamin C for 
at least 18 hours, and vigorous physical exercise for at least 24 hours before testing. 
Subjects fasted at least 6 hours before testing. 
Biochemical markers associated with endothelial dysfunction (group A)
Serum concentrations of plasminogen activator inhibitor-1 (PAI-1), intracellular adhesion 
molecule-1 (ICAM-1) and soluble E-selectin were measured by Multiplex Fluorescent Bead 
Immunoassays (xMAP technology, Millipore, Billerica, MA, USA) and a Bio-plex microbead 
analyzer (Luminex, Austin, TX, USA) according to the manufacturer’s protocol. Serum 
concentrations of vascular cell adhesion molecule-1 (VCAM-1) were determined by an 
enzyme-linked immunosorbent assay (RandD Systems, Minneapolis, MN, USA). 
Non-invasive measurements of atherosclerosis and arterial stiffness (group A)
Measurements of carotid intima-media thickness (cIMT), pulse wave velocity (PWV) and 
pulse wave analysis (PWA) were performed according to a highly standardized protocol 
and performed by the same experienced technician (SH) in all patients 24. Mean cIMT was 
calculated from the mean of four measured segments of the vessel: far wall left, far wall 
right, near wall left and near wall right. Subsequently the presence of plaques and size was 
evaluated at the level of the common, internal and external carotid arteries. Plaque was 
defined as any focal protrusion above the surrounding intima of at least 1.5 x mean cIMT.
PWV and PWA were measured with applanation tonometry, using SphygmoCor system 
version 7.1 (Atcor Medical, Sydney. Australia). Central arterial pressure (CAP) and central 
systolic pressure (CSP) were derived and central augmentation index (AIx) was calcu-
lated. As AIx is influenced by heart rate, an index normalized for a heart rate of 75 beats/
min was used. To determine pulse wave velocity, pulse wave forms were recorded at the 
right carotid artery and left femoral artery sequentially. Wave-transit time was calcu-
lated using the R-wave of a simultaneously recorded ECG as a reference frame. The 
coefficient of variation (CV) for measuring PWV is 5-10%25.
Endothelial function (group B)
Brachial artery flow mediated dilation (FMD) is widely accepted to reflect endothe-
lium-dependent and largely nitric oxide-mediated function of conduit arteries 26. 
Measurements were performed by two experienced vascular sonographers (DT and TS). 
A 10 MHz multifrequency linear array probe attached to a high-resolution ultrasound 
machine (T3000; Terason, Burlington, Massachusetts, USA) was used for imaging of the 
brachial artery in the distal third of the upper arm. Subjects rested in a supine posi-
tion for at least 15 minutes to enable baseline assessment of arterial diameter and 
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blood flow. The arm was extended and positioned at an 80o angle from the torso. A rapid 
inflation pneumatic cuff (Hokanson, Bellevue, Washington, USA) was positioned on the 
forearm immediately distal to the olecranon to provide the forearm ischemic stimulus. 
After obtaining an optimal image, the probe was manually stabilized and the ultrasound 
parameters were set to optimize longitudinal B-mode imaging of the lumen-arterial wall 
interface. Continuous Doppler velocity was measured using the lowest possible inson-
ation angle (< 60o). The forearm cuff was inflated to 220 mmHg for 5 minutes. Diameter 
and flow recordings resumed 30 seconds prior to cuff deflation and continued for 5 
minutes thereafter. Following a 15-minute resting period, a 1-minute baseline recording 
of the brachial artery diameter and flow was taken. Subsequently, brachial artery endo-
thelium-independent vasodilatation was examined after administration of a single 
spray of sublingual glyceryl trinitrate (GTN), which serves as a direct nitric oxide (NO) 
donor, to detect endothelium-independent vasodilator capacity. This was followed by 5 
minutes of continuous recording of brachial artery diameter and blood flow. Post-test 
analysis of brachial artery diameter was performed using customized edge detection 
and wall tracking software 27. Baseline diameter, flow and shear rate were calculated as 
the mean of data acquired across the 1-minute preceding the cuff inflation period. Peak 
diameter following cuff deflation was automatically detected as previously described 
28. FMD was calculated as the percentage rise of the peak diameter from the preceding 
baseline diameter. The time to peak diameter (seconds) was calculated from the point 
of cuff deflation to the maximum post-deflation diameter. According to a recent study, 
inadequate scaling for FMD would be present if the upper confidence limit of the regres-
sion of the relation between logarithmically transformed base diameter and peak diam-
eter is <1.0 29. In such an event, FMD% is not an appropriate measure for the estimation 
of endothelial function. Data were checked for this phenomenon and subsequently allo-
metric modeling was applied 29. Furthermore, FMD% was corrected for shear rate stim-
ulus by adding this factor as a covariate in our analysis 30. The CV for measuring FMD with 
our protocol is 6.7% 30.
Forearm blood flow measurements using venous occlusion plethysmography (FBF)
measures changes in blood flow (mainly determined by arteriolar resistance arteries 
in the muscle bed) in response to the infusion of intra-arterial vasoactive medica-
tions 25,31. It therefore mainly assesses microvascular function. FBF was measured at 
the forearm using ECG-triggered bilateral strain-gauge venous occlusion plethysmog-
raphy 31. Measurements were performed at 09:00 AM in a quiet, temperature controlled 
room (22°C). Mercury in silastic strain gauges placed around the widest portion of 
the upper third of both forearms were electrically coupled to a plethysmograph cali-
brated to measure normalized changes in volume. For each measurement, venous flow 
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was occluded just proximal to the elbow by rapidly inflating a blood pressure cuff to 
60 mmHg. A wrist cuff was inflated to suprasystolic (220 mmHg) pressures to exclude the 
hand circulation from the blood flow during the measurement, starting 30 seconds prior 
to each measurement. After local anesthesia (lidocaine 2%), a brachial artery catheter 
(angiocath 20G 1.88in, BD Angiocath) was inserted in the non-dominant arm (after local 
anesthesia (lidocaine 2%)), which was elevated slightly above the right atrium. Systolic 
blood pressure (BP), diastolic BP, mean arterial BP and heart rate were monitored contin-
uously. The other arm was used as a control for systemic changes in vasomotor tone. 
To establish resting FBF, we administered 0.9% saline for 30 minutes. Vasoactive agent 
infusions were then started. Between each series of drug infusions, FBF was allowed to 
return to basal value during a 20-minute resting period, during which solvent (0.9% saline 
for acetylcholine (Ach) and 5% glucose for sodium-nitroprusside (SNP)) was infused 
to maintain a constant infusion rate. Ach (Miochol-E intraocular solution, 20 mg, Baus-
chandLomb; 1-2-4 µg/dL forearm volume/minute) was used to explore endothelium-de-
pendent vasodilatation. SNP (25mg/ml, 2ml, Sigma-Aldrich; 0.2-0.4-0.8 µg/dL forearm 
volume/minute) was used to explore non-endothelium dependent vasodilatation. Finally, 
the nitric oxide synthase inhibitor NG-monomethyl-L-arginine (L-NMMA acetate 250 mg, 
Clinalfa® Basic, Bachem 0.2-0.4-0.8 µmol/dL forearm volume/minute) was infused to 
investigate the contribution of nitric oxide to basal vascular tone. Each substance dose 
was infused for 5 minutes. FBF values are reported in ml/min/ 100 ml of forearm volume. 
The baseline value is a mean of all measurements during the baseline measurement 
period. The values during drug infusion are a mean value of the last 6 measurements per 
drug dose during a measurement period. Besides changes in blood flow, the blood flow 
ratio between the infusion and control arm was also calculated to correct for possible 
systemic effects32. The CV of FBF has been reported to be 8-10% during stimulation 31,33.
Statistical methods
Data were analyzed using SPSS 20.0 statistical package for Windows (SPSS Inc, 
Chicago, IL). Data were expressed as mean ± SD, unless mentioned otherwise. Data 
distributions were analyzed and logarithmic transformation was performed before 
statistical testing when appropriate. Differences between patients and controls were 
tested with paired t-tests. Differences in categorical variables were analyzed using 
the χ2 test. In group A, stepwise backward multiple linear regression analysis was 
performed in the patients in order to test whether clinical characteristics (etiology of 
CS, treatment strategies, presence of hormonal deficiencies, use of alcohol, smoking 
and comorbidity) were predictors of vascular function. A stepwise backward multiple 
linear regression analysis could not reliably be performed in group B because of the 
small sample size. P < 0.05 was considered statistically significant.
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Table 1)  Group A: Clinical characteristics of patients in long-term remission of
 Cushing’s syndrome and healthy controls. 
Patients (n=58) Controls (n=58) P-value
Gender (n): male/female 12/46 12/46
Age: mean (± SD) (years) 50.8 (12.3) 51.2 (12.4) 0.863
BMI: mean (± SD) (kg/m2) 26.5 (4.2) 26.3 (4.1) 0.793
Duration of remission: 
median (± range) (years)
13.6 ± 8.0
Smoking (yes/no)
 Pack-years (± SD)
14/44
11.5 (15.6)
5/53
6.9 (13.9)
0.024*
Alcohol consumption: yes/no 10/48 13/45 0.485
Treatment modalities: n (%)
Unilateral adrenalectomy
Bilateral adrenalectomy
Pituitary surgery
Pituitary radiotherapy
19 (32.8)
12 (20.7)
38 (65.5)
13 (22.4)
-
-
-
-
-
-
-
-
 Hormonal deficiencies: n (%)
Glucocorticoid deficiency
Growth hormone deficiency
Thyroid hormone deficiency
Mineralocorticoid deficiency   
Testosterone deficiency
Estrogen deficiency 1
21 (36.2)
15 (25.9)
25 (43.1)
11 (19.0)
6/12 (50.0)
25/46 (54.3)
-
-
-
-
-
29/46 (63.0)
-
-
-
-
-
-
Comorbidities: n (%)
Hypertension
Diabetes mellitus
Hypercholesterolemia
18 (31.0)
4 (6.9)
12 (20.7)
0 (0)
0 (0)
0 (0)
-
-
-
Cushing type: n (%)
Pituitary
Adrenal
40 (69.0)
18 (31.0)
-
-
-
-
BMI: body mass index; CS: Cushing’s syndrome.; * P<0.05; 
Note 1: Secondary hypogonadotropic hypogonadism or a postmenopausal state without the use of 
chronic estrogen replacement.
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Results
Subject characteristics
Table 1 shows the clinical characteristics of the patients and control subjects for group 
A, and Table 2a for group B. Intra-arterial cannulation was not successful in 3 patients 
and therefore the vasomotor response to intra-arterial drug infusions was investigated 
in 11 patients and controls (Table 2b). Adequate matching was reflected by the fact that 
no differences between patients and controls were present in both groups in gender, 
age and BMI. In group A patients only differed from controls with respect to smoking 
habits (more smokers in the patient group, P<0.05).
Biochemical markers associated with endothelial dysfunction (Group A)
No statistically significant differences in sVCAM-1, sICAM-1, E-selectin and PAI-1 were 
detected between patients and controls (Table 3). 
Table 2A) Group B (Flow Mediated dilation): Clinical characteristics of patients in long 
 term remission of Cushing’s syndrome and healthy controls.
Patients (n=14) Controls (n=14) P-value
Gender (n): male/ female 2/12 2/12 1.00
Age at time of test: mean (SD) (years) 46.8 (11.8) 45.7 (10.9) 0.79
Duration of remission: median 
(range) (years)
12.9 (4.8-29.4) - -
BMI: mean (SD) (kg/m2) 25.6 (2.3) 25.6 (2.5) 0.98
Cushing’s syndrome type: n (%) 
Pituitary
Adrenal
7 (50.0)
7 (50.0)
- -
Treated hypothyroidism: n (%) 4 (28.6) - -
Estrogen status in females (n):
Sufficient
Insufficient
7 (58.3)
5 (41.7)
7 (58.3)
5 (41.7)
1.00
BMI: body mass index
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Table 2B) Group B (venous occlusion plethysmography): Clinical characteristics in 
 long-term remission of Cushing’s syndrome and healthy controls.
Patients (n=11) Controls (n=11) P-value
Gender (n): male/ female 2/9 2/9 1.00
Age at time of test: mean (SD) 
(years)
45.6 (13.2) 45.8 (12.1) 0.98
Duration of remission: median 
(range) (years)
 12.8 (4.8-28.8) - -
BMI: mean (SD) (kg/m2) 25.7 (1.7) 25.3 (2.7) 0.62
Cushing’s syndrome type: n (%) 
Pituitary
Adrenal
5 (45.5)
6 (54.5)
- -
Treated hypothyroidism: n (%) 3 (27.3) - -
Estrogen status in females (n):
Sufficient
Insufficient
5 (55.6)
4 (44.4)
5 (55.6)
4 (44.4)
1.00
BMI: body mass index
Non-invasive measurements of atherosclerosis and arterial stiffness (Group A)
cIMT, PWV and CAP were not different between patients and controls (Table 3). A trend 
towards a statistically significant difference between the two groups was found for 
the AIx (P=0.056). Atherosclerotic plaques were detected in 10 patients and 10 controls. 
Plaque thickness was not significantly different between patients and controls.
Endothelial function (Group B)
No statistically significant differences were found between patients and controls in 
all FMD measurements (Table 3). Furthermore, no statistically significant differences 
were found between patients and controls regarding FBF or blood flow ratio responses 
at baseline or in response to the incremental doses of Ach, SNP and L-NMMA (all p >0.09) 
(Figure 1). 
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Table 3) Micro- and macrovascular health parameters in patients in long-term  remis- 
 sion of Cushing’s syndrome and matched controls. 
Variable Patients N Controls  N P-value
Mean 95%-CI Mean 95%-CI
GROUP A
Serum biomarkers 
*ICAM-1 (pg/ml) 280.4 226.7-346.7 57 314.9 234.7-422.4 57 0.545
*PAI (pg/ml) 1810.8 1505.8-2163.1 57 1940.5 1653.9-2276.7 57 0.497
*VCAM-1 (pg/ml) 670.0 615.1-729.9 57 682.4 637.3-730.6 57 0.721
*E-Selectin (pg/ml) 40.0 35.7-44.6 57 38.5 34.6-43.0 57 0.661
Non-invasive measurements of arterial stiffness and atherosclerosis
CAP (mmHg) (HR75) 10.1 8.8-11.5 52 9.4 7.6-11.3 52 0.457
Aortic AIx (HR75) 26.0 23.2-28.8 53 23.1 19.6-26.6 53 0.056
PWV (m/s) 8.4 8.0-8.9 58 8.3 7.8-8.8 58 0.648
Mean cIMT (mm) 0.75 0.72-0.78 58 0.75 0.72-0.77 58 0.617
Plaque thickness (mm) 2.66 1.94-3.38 10 1.95 1.71-2.18 10 0.092
GROUP B
Measurements of flow mediated dilation
Baseline diameter (mm) 3.60 3.33-3.86 14 3.56 3.30-3.82 14 0.839
FMD (%) 5.13 4.10-6.15 14 6.22 4.72-7.72 14 0.125
GTN (%) 18.6 15.5-22.0 14 19.4 15.0-22.9 14 0.691
Time to peak diameter (s) 40.3 33.4-47.3 14 54.3 42.1-66.6 14 0.059
SRAUC (s, 10
3) 30323 25530-35115 14 32164 26471-37857 14 0.597
Note 1 *: For ln-transformed data the geometric means and back-transformed 95%-CI were calculated 
to enable clinical interpretation of the outcomes.
Note 2: For plaque thickness the comparison between the groups was performed using an unpaired t-test
ICAM-1, intracellular adhesion molecule 1; PAI-1, plasminogen activator inhibitor 1; VCAM-1, vascular cell 
adhesion molecule 1; CAP, central augmented pressure; AIx, augmentation index; cIMT, carotid inti-
ma-media thickness; PWV, pulse wave velocity; HR75, corrected for a heart rate of 75 beats per minute. 
FMD, flow mediated dilation; GTN, glyceryltrinitrate; SRAUC, shear rate area under the curve; CI, confidence 
interval 
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Figure 1) Change in forearm blood flow from baseline in response to infusion of 
 different vasoactive agents in increasing dosages.
 Note: On group level, no acute vasomotor responses were observed in the control arm after 
 drug infusions. Error bars: 95% CI.
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Stepwise backward multiple linear regression analysis (Group A)
Having DM predicted both a higher PWV (p=0.01) and higher sVCAM-1 levels (p<0.01). 
Subgroup analysis was performed for these two outcomes after exclusion of all matched 
patient-control couples containing a patient with DM. This did not lead to significant 
differences between patients and controls (PWV p=0.796; sVCAM-1 p=0.865). Being a 
smoker was a predictor for a higher AIx (p<0.01). Subgroup analysis, after exclusion of all 
patient-control couples with a smoker, did not lead to a significant difference between 
patients and controls (AIx; p=0.078). Mineralocorticoid replacement was a predictor for 
higher E-selectin levels (p<0.01). Subgroup analysis, after exclusion of all couples with 
mineralocorticoid users, did not lead to a significant difference between patients and 
controls (E-selectin; p=0.913). Thyroid hormone replacement was a predictor for higher 
sVCAM-1 levels (p<0.01). Subgroup analysis after exclusion of couples with thyroid 
hormone users did not lead to a significant difference between patients and controls 
(sVCAM-1; p=0.504).
Discussion
In this study we investigated micro- and macrovascular health in patients in long-
term remission of CS who had no, or adequately treated comorbidities using a combi-
nation of state-of-the-art methods that has not been used in any previous study. We 
compared the patient group to a strictly one-to-one matched healthy control group. 
The main finding of our study is that the vascular health of patients in remission of CS is 
not significantly different from that seen in healthy control subjects matched for age, 
gender and BMI. This suggests that the direct effect of the period of hypercortisolism 
per se on the vasculature during the active disease is potentially reversible. 
Our findings that endothelial function recovers after remission of CS are in line with the 
study of Akaza et al. who investigated arterial endothelial function, with FMD, in a group 
of 12 patients shortly after remission (>3 months) of CS 22. They found that the impaired 
FMD in active CS was reversible after remission. Previous studies have shown that in 
vitro (cell culture) and in vivo (mouse) exposure of endothelial cells to glucocorticoids 
reduced the mRNA and/or protein content of endothelial NO synthase 34,35 and reduced 
acetylcholine induced vasodilation of mouse resistance arteries 34 and rat aortas 36. 
Therefore Akaza et al. 22 proposed that endothelial dysfunction in active CS is largely 
accounted for by the direct effect of hypercortisolism on vascular endothelium and that 
this is reversible after treatment. 
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On the other hand, five other studies observed persistent impaired vascular health 
after remission of CS 17,18,20,21,23. However, in three of these studies there was either a 
short period of remission 17 or a pediatric study population 20,21 , so these studies are not 
comparable to our study. The studies reported by Colao et al. 18 and Barahona et al. 23 are 
more comparable. They both found a higher prevalence of atherosclerosis (measured 
by cIMT and presence of coronary artery disease detected by computed tomography, 
respectively) compared to gender-, age- and BMI-matched controls 18,23. However, the 
patients in these studies had significantly more uncontrolled metabolic comorbidities 
than their matched controls. In our study population the comorbidities in Group A were 
adequately treated 16, and the patients in Group B had no known co-morbidities (except 
for treated hypothyroidism in 4 patients). 
A more recent publication of Colao et al. 19 also supports our findings. This study 
measured differences in cIMT and arterial stiffness between active disease and one 
year after remission of CS in 25 patients. There was a significant decrease in both vari-
ables between active disease and remission. After 1 year of remission both variables did 
not differ from a gender-, age- and BMI-matched control group as used in our study, but 
they were still higher than in controls with a lower BMI, matched only for gender and age. 
Moreover, diastolic blood pressure, LDL and HDL cholesterol levels were not different 
between the patients and the BMI-matched control group, but were significantly more 
adverse in the patients compared to the controls with a lower BMI. This emphasizes 
the importance of strict matching of each patient to a healthy individual of at least the 
same gender, age and BMI if one wants to investigate the effect of the previous period 
of hypercortisolism per se. 
Taken both our results and the previous findings into account, we conclude that patients 
in remission of CS, who are equally well-controlled for comorbidities as age-, gender- and 
BMI-matched healthy subjects, have comparable vascular health. This accentuates the 
need for stringent treatment of metabolic comorbidities in these patients. Interestingly, 
the normalized vascular health seems to be irrespective of the fact that these patients 
have, as we have previously shown, a more centripetal adipose tissue distribution and 
adverse adipokine profile than their age-, gender- and BMI-matched controls 16. 
As could be expected in group A, DM was associated with a higher PWV and higher 
sVCAM-levels and smoking predicted a higher AIx, but this did not affect the results 
of the total group. Moreover the trend towards a higher AIx in the patient group disap-
peared after correcting for smoking. Interestingly, except for an association between 
mineralocorticoid replacement and E-selectin levels and the use of thyroid hormone 
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replacement and VCAM-1 levels, no other patient characteristic (e.g. etiology of CS, treat-
ment strategies, hormonal deficiencies) negatively affected vascular health parame-
ters. This is in contrast to previous studies, where for example the use of glucocorticoid 
replacement therapy was associated with an increased cardiovascular risk 10.
The major strength of our study is the broad spectrum of methodologies we used to 
investigate vascular health. All techniques are well-validated and reproducible 25,30,31. 
Furthermore this is the first study that investigates endothelial function in patients in 
long-term remission of CS both in conduit arteries (FMD) and forearm resistance arteries 
(FBF, which is considered the gold standard procedure to measure endothelial dysfunc-
tion)25. Thus we have investigated both the macrovasculature and the microvasculature. 
A possible limitation of this study is the relatively small sample size for group B. For 
FBF and FMD a number of about 10 patients was found to be adequate to detect a rele-
vant difference 31,37, however the subjects within our patient group (and thus also the 
control group) were more heterogeneous than in most previous studies, leading to a 
greater SD. Therefore it is possible that we missed subtle but relevant differences. For 
example, there seems to be a non-significant trend towards a lower baseline FBF in the 
patients, which could indicate a reduction in muscle microvascular density. The latter 
might explain the exercise intolerance experienced by the patients 38. As blood flow 
in the skin and subcutaneous adipose tissue also contribute to FBF 31 , future research 
measuring microvascular density in muscle biopsies will have to confirm whether skel-
etal muscle microvascular density is indeed lower in patients in remission of CS.
A multitude of epidemiological studies reported an increased cardiovascular risk and 
standardized mortality rate (SMR) in patients in long-term remission of CS compared 
to an age- and gender- but not BMI-matched reference population 1 . As patients in 
remission of CS tend to have an overall higher BMI and waist circumference than the 
general population, this may negatively affect cardiovascular risk and SMR. Furthermore 
these studies did not analyze potential differences between patients with and without 
comorbidities. However it may be possible that cardiovascular risk is still elevated in the 
healthiest patients in remission of CS because of a persistent effect of the prior hyper-
cortisolism on other organs than the vasculature, e.g. the myocardium 10,11 . However, this 
was not supported by a small study 39. Therefore further research is necessary to inves-
tigate these issues. 
In conclusion, vascular health of patients in long-term remission of Cushing’s syndrome 
seems to be comparable to that of healthy gender-, age- and BMI-matched controls, 
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provided that the patients have no, or adequately controlled comorbidities. Therefore, 
the effects of the previous hypercortisolism per se on the vasculature may be revers-
ible. This accentuates the need for stringent treatment of metabolic comorbidities in 
these patients.
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This thesis focuses on the treatment and long-term effects of two diseases in which the 
pituitary gland plays a key role: acromegaly, which is caused by overproduction of growth 
hormone (GH), and Cushing’s syndrome (CS), caused by overproduction of cortisol. 
PART 1
Treatment of acromegaly and Cushing’s disease by 
transsphenoidal surgery
The endoscopic technique of transsphenoidal pituitary surgery (TS) was introduced in 
the 1990s as an alternative to the traditional microscopic technique of TS, which was 
considered the “gold standard”. Compared to the microscopic technique, the endo-
scopic technique of TS theoretically has both advantages and disadvantages. Advan-
tages include the panoramic view with increased illumination of the operating field and 
the possibility to use different operating angles, making it possible to reach suprasellar 
and parasellar regions. Disadvantages include the two-dimensional view and the easy 
clouding of the lens in case of bleeding 1,2. For these reasons, there has been contro-
versy among neurosurgeons about the position of endoscopic TS for the treatment of 
pituitary adenomas 1,2. However, despite the fact that the endoscopic technique was 
received with skepticism soon after its introduction, a recent report by Rolston et al. 
that analyzed nationwide data from the USA shows that in more recent years its popu-
larity has steadily increased among neurosurgeons. This is illustrated by a clear increase 
in the use of the endoscopic technique of TS at the expense of the microscopic tech-
nique 3. But, as the report states, the underlying causes of these trends are not yet clear.
Because our centre was the first in the Netherlands to introduce the endoscopic tech-
nique of TS and has accumulated ample experience over the years with this technique, 
the first aim of this thesis was to gain more insight in the role of endoscopic TS for the 
treatment of both acromegaly and CD by systematically analyzing the results of endo-
scopic TS in our hospital.
In chapter 2 we analyzed the outcome of endoscopic TS in 40 patients with a growth 
hormone (GH)-secreting macroadenoma (thus causing acromegaly) treated in our 
hospital between 1998 and 2007. In 36 patients, the intent of TS was cure, whereas in 
four patients TS was aimed at debulking of the tumor. We found that of the 36 patients, 
remission was achieved in 20 patients (56%). The overall remission rate was 50%. 
However, remission was achieved in 6 out of 18 patients (33%) in the first 5 years after 
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Figure 1) Trends in pituitary surgery in the United States. 
            A) National data from the Centers for Medicare and Medicaid Services. 
            B) State-level data, shown as the average number of cases per year during the 
 periods 2005–2007 and 2009–2011 3. 
 Reproduced from Rolston et al, 2015, with permission of Springer.
A
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introduction of the endoscopic technique compared to 14 out of 22 patients (63%, or 
77% if the patients who underwent debulking are excluded) in the following 5 years 
(p=0.06 and p=0.01, respectively). Thirteen patients had a mild transient perioperative 
complication. Before TS 37.5% of the patients received hormonal substitution therapy 
compared to 33% after TS. 
In chapter 3 we analyzed the outcome of endoscopic TS in 86 patients with Cush-
ing’s disease (CD), treated in our hospital between 1998 and 2011. The remission rate in 
different adenoma subclasses varied significantly: 60% in magnetic resonance imaging 
(MRI)-negative CD, 83% in microadenomas, 94% in noninvasive macroadenomas, and 
40% in macroadenomas that invaded the cavernous sinus. The recurrence rate was 
16% after 71 ± 39 (mean ± SD) months of follow-up. All perioperative complications were 
relatively mild and did not cause any permanent damage. Before TS 15% of the patients 
received hormonal substitution therapy compared to 35% after TS. 
The main conclusion of both chapters 2 and 3 was that the remission rates that were 
achieved by endoscopic TS in noninvasive and invasive macroadenomas were compa-
rable with or even better than previously reported remission rates after conventional 
microscopic TS. Furthermore, complication rates, types of complications and recur-
rence rates seemed comparable between the two techniques. In order to support these 
conclusions an extensive literature search was performed in both studies to gain more 
insight in the previously published remission rates. However, the multitude of defini-
tions of remission and recurrence that were used in studies reporting on both CD and 
acromegaly made it very difficult to compare the various studies. Standardization of the 
definitions for remission and recurrence and of the methods required to analyze results 
of TS is essential in order to improve clinical practice and maximize patient outcomes. In 
acromegaly this is already done: most recent series have used the consensus criteria of 
remission of either 2000 4(as we did) or 2010 5. In CD consensus on the criteria for remis-
sion still has to be reached 6. 
Nevertheless, recent large reviews covering the literature on TS in pituitary adenomas 
concluded that in macroadenomas, especially when invasive, the endoscopic technique 
of TS seems to result in better remission rates than microscopic TS, whereas in microad-
enomas the remission rates and complication rates are comparable between both tech-
niques 7,8. The better results achieved by the endoscopic technique in macroadenomas 
may be explained by the fact that different operating angles can be used with an endo-
scope, which makes it possible to effectively reach suprasellar and parasellar portions 
of the lesion, including the cavernous sinus 9. 
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Theoretically the endoscopic technique of TS may also have advantages compared to 
the microscopic technique in case of repeated TS. The wider view of the endoscopic 
technique may provide an advantage during repeated TS, particularly in cases in which 
the anatomy is altered due to the previous operation 10. Repeated TS is theoretically of 
particular value in CD, as all other treatment options (bilateral adrenalectomy, radio-
therapy and medication) have substantial disadvantages. 
To gain more insight in the value of repeated endoscopic TS for CD, we analyzed the 
remission rates and complications of repeated endoscopic TS in 14 patients with 
persistent (n=6) or recurrent (n=8) CD  who underwent surgery in our hospital between 
1999 and 2007 (Chapter 4). A remission rate of 71% was achieved, which compared favor-
ably with the remission rates previously reported after repeated TS via the conventional 
microscopic technique. Cerebrospinal fluid leakage was the most frequent complication 
(6 patients). Eleven patients required hormonal substitution after the second surgery, of 
whom 3 already received hormonal substitution therapy after the first TS. We concluded 
that repeated TS via the endoscopic technique is a good treatment option for selected 
patients with recurrent or persistent CD following primary pituitary surgery.
In chapter 2 we also analyzed the results of repeated endoscopic TS for persistent and 
recurrent CD. We confirmed that repeated endoscopic TS seems to be a good thera-
peutic option for patients with recurrent CD with remission achieved in four of five (80%) 
patients. However, repeated endoscopic TS seemed to be of less value for patients with 
persistent CD as remission was only achieved in three of 11 patients (27%). A possible 
explanation why repeated endoscopic TS was less successful in patients with persistent 
CD than with recurrent TS in our series is the fact that the same neurosurgeon who did 
the first operation also performed the second operation in case of persistent hypercor-
tisolism. This makes it understandable that if the adenoma could not be removed the 
first time by the same well-trained neurosurgeon using the same operating technique, 
the chance that it can be removed the second time is small. However we believe that 
repeated TS in persistent CD should nevertheless be considered, as long as no better 
alternative therapy (such as effective medication) exists. Until now no other series of 
repeated endoscopic TS in CD have been published, so we cannot compare our results 
with the literature.
To accurately assess the superiority of one technique over the other, a robust large 
comparative study should be performed. Indeed some groups have attempted to 
perform such a trial 11-14, but these are all single center trials where one surgeon used one 
technique and another surgeon used the other. Therefore, the differences described 
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(if present) could possibly be explained by differences in the technique-specific skills 
of the surgeons. Ideally a trial should be multicenter, randomized, with standardized 
surgical protocols and a large number of patients included. Besides remission rates it 
should assess recurrence rates, complications, cost-effectiveness and patient-related 
outcome measures. However, it will be very difficult to perform such a trial because of 
several reasons: 1) Acromegaly and CD are very rare diseases, so inclusion will take a very 
long time and inclusion of a sufficient number of patients would require participation by 
a large number of centers. 2) Many neurosurgeons have their own personal preference, 
which makes it difficult to start a randomized trial 3) It will be difficult to obtain financial 
support for such a study. Therefore the second best option to gain knowledge on the 
results of these techniques is to encourage publication of outcomes of TS, particularly 
in large series of different tumor types from different centers applying the technique in 
a standardized way. Another possibility would be to initiate mandatory registries for all 
patients undergoing TS.
In chapter 2 we showed that remission rates achieved for GH-secreting macroade-
nomas was significantly lower in the first 5 years after the introduction of the endo-
scopic technique compared to the second 5 years (33% versus 63%). Because the char-
acteristics and number of the patients operated on in the first and second 5 years were 
comparable, we concluded that the learning curve of the surgeons probably explains 
the difference in remission rates. Indeed other series have described a learning curve 
as well after the endoscopic technique was introduced 15-18. But also for microscopic TS 
there is strong evidence that remission rates depend on the skills of the surgeon 19,20. 
Although a second attempt to perform TS can be done, as we described in chapter 4, 
remission rates are considerably lower than after the first TS. Keeping these consider-
ations in mind we believe that TS, particularly for rare hormone-producing tumors such 
as in CD and acromegaly, should only be performed in highly specialized centers. Apart 
from specific surgical expertise these centers should have extensive experience with 
the complex problems these patients are facing both in the perioperative phase and 
during long-term follow-up. In the Netherlands 14 hospitals currently perform TS for pitu-
itary adenomas. Only 2 hospitals perform more than 50 operations per year while in 6 
hospitals less than 7 operations per year are performed (www.qrns.nl). Centralization of 
TS could represent a valuable step towards optimization of the care of patients with 
pituitary adenomas in the Netherlands. 
In conclusion, based on all published series, endoscopic TS is a safe and effective 
treatment for all patients with acromegaly and CD. In case of noninvasive and invasive 
macroadenomas the endoscopic technique of TS should be the treatment of choice, as 
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Figure 2) Factors which have been found to significantly influence QoL in pituitary 
 adenomas. 
 Normal letters: consistent between studies. Italic letters: inconsistent between studies. 
 ACRO acromegaly, NFA non-functioning pituitary adenoma, CD Cushing’s disease, PRL 
 prolactinoma. Reproduced from Andela et al, 2015, with permission of Springer 21. 
remission rates seem to be higher than those reported for microscopic TS. Furthermore 
repeated endoscopic TS seems to be a good therapeutic option for patients with recur-
rent CD. Ideally the endoscopic and microscopic techniques of TS would be compared 
via a comparative study but this is virtually impossible to perform. Therefore different 
centers should continue to publish their TS results, using consensus criteria for cure. 
Furthermore, because there is a clear learning curve for both techniques of TS, TS should 
be centralized in order to optimize treatment outcomes. 
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PART 2
Long-term Quality of Life after treatment of acromegaly 
and Cushing’s syndrome
A growing number of studies show that QoL is impaired in patients with pituitary 
adenomas, and that successful treatment improves, but does not normalize QoL 21. 
Furthermore, patients in long-term remission of CS and acromegaly generally have a 
more impaired QoL than patients treated for other pituitary adenomas 21. In order to 
understand why QoL remains impaired in patients in long-term remission of CS and acro-
megaly, it is essential to determine which patient- or disease-specific characteristics 
negatively influence QoL. A large number of studies have described multiple factors 
that might influence QoL in patients with pituitary adenomas (Figure 2) 21
In acromegaly (which causes marked changes in appearance that partially persist after 
remission) the influence of self-consciousness about appearance on QoL, which is well 
known to affect QoL in the general population 22,23, had never been adequately investi-
gated. Furthermore in CS most previous studies had methodological limitations or only 
included patients with CD, which made it difficult to establish patient or disease charac-
teristics related to impaired QoL in patients in long-term remission of CS. 
Therefore the second aim of this thesis was to get more insight in patient- or 
disease-specific characteristics that negatively influence QoL in patients in long-
term remission of acromegaly and CS.
In chapter 5 we investigated the psychological distress and dysfunction related to 
self-consciousness about appearance and its effect on QoL in 73 patients in long-term 
remission of acromegaly. To do so, participants were asked to complete the Derriford 
appearance scale 59 (DAS59) questionnaire, which assesses psychological distress 
and disruptions to everyday life associated with self-consciousness of appearance. To 
measure QoL they were asked to complete the research and development 36 (RAND-36) 
and acromegaly quality of life questionnaire (AcroQoL) and a sociodemographic ques-
tionnaire. The results of the patients were compared to the results of a gender-, age- 
and BMI-matched control group (n=57). We found that significantly more patients than 
control subjects reported self-consciousness about their appearance (46.6% versus 
22.8%). Eighty-five percent of the patients that were self-conscious about appear-
ance indicated that their face was the most prominent source of self-consciousness 
compared to 23 % of the controls. In the patient group, significant correlations were 
found between the scores of the DAS59 and the AcroQoL and RAND-36. Furthermore 
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there was no correlation between the DAS59 score and gender or age in the patient 
group. We concluded that even after long-term remission of acromegaly, a large number 
of patients are self-conscious about their appearance, especially about their facial 
appearance, and that this leads to psychological distress, disruptions of everyday life 
and decreased QoL. 
Our results are in line with the recent findings of Tiemensma et al, who asked patients in 
remission of acromegaly to complete a drawing test (two retrospective drawings of their 
body perception before acromegaly and during the active phase of acromegaly, and 
one drawing on the current condition after long-term remission) 24. Patients who drew 
larger (in cm) drawings to depict their current condition had a worse QoL. Moreover, in our 
study, the scores of our patients on the DAS-59 are comparable to scores of groups that 
are considered suitable for cosmetic surgery 25. This underlines the major impact that 
the changes in appearance caused by acromegaly have on the patients. In retrospect, 
it may not be so surprising that in the present society, where the normal population is 
increasingly pressured to maintain beauty (as is reflected by the rapid increase in the 
use of botox and fillers 26) patients in remission of acromegaly may remain concerned 
and self consious about their appearance. Therefore this aspect should be addressed 
during follow-up in order to improve QoL in these patients. 
In chapter 6 we assessed the QoL of 123 patients in long-term remission of CS and 
compared it with the QoL of an age- and sex-matched control group (n= 105). To do 
so, participants completed seven validated questionnaires (both general health and 
disease-specific) concerning different dimensions of QoL. To investigate the influ-
ence of the etiology of CS on QoL, patients in remission of pituitary and adrenal CS were 
compared. Furthermore, the influence of hormonal deficiencies, treatment strategy, 
duration of remission, gender and age on QoL was investigated. We found that QoL in the 
total patient group and each patient subgroup was significantly worse on practically all 
dimensions of the questionnaires compared with the control group, except for patients 
in remission of pituitary CS without hormonal deficiencies, who had an impaired QoL 
on only 50% of the QoL dimensions. Subgroup analysis revealed no difference in QoL 
between different patient groups, especially no difference between patients in remis-
sion of adrenal and pituitary CS. Female gender and a shorter duration of remission had 
a negative influence on QoL in the patient group. 
We concluded that QoL remains impaired in patients in long-term remission of CS, regard-
less of etiology, presence of hormonal deficiencies and treatment strategies. The cause 
of impaired QoL is probably multifactorial. However the fact that QoL is impaired in all 
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patient groups in long-term remission of CS is suggestive for the fact that the previous 
period of long-standing exposure to high cortisol levels per se might be an important 
cause of the impaired QoL. 
Other factors that may influence QoL of patients in remission of CS and acromegaly
Coping strategies and illness perceptions
Coping is defined as the way a person responds (behaviorally, cognitively, and emotion-
ally) to situations that require adjustments in dealing with an adverse event and/or its 
consequences, for example an illness and its treatment. It has been found that patients 
in remission of CD and acromegaly have less active coping strategies (and have more 
avoiding coping strategies, and seek less social support than a healthy sample from the 
Dutch population 27. However compared with patients with chronic pain and psycholog-
ical problems, patients treated for pituitary adenomas have somewhat better coping 
strategies 27. Nevertheless, coaching patients in remission of CD and acromegaly toward 
more effective coping strategies may improve QoL. 
Illness perceptions concern the pattern of beliefs that patients develop about their 
illness. These views are determinants of behavior directed at the illness. Tiemensma et 
al. found that patients in remission of CS have more negative illness perceptions than 
patients with other acute or chronic conditions (vestibular schwannoma, acute or chronic 
pain, and to a lesser extent chronic obstructive pulmonary disease) 28. They attributed 
more symptoms to their disease, had stronger beliefs regarding the chronic nature of 
the disease, reported more negative consequences and experienced less personal 
controlability. Another study showed that patients in remission of acromegaly reported 
more negative illness perceptions than patients with acute illness, but more positive 
illness perceptions than patients with chronic diseases or CS 29. In both studies illness 
perceptions were strongly correlated with QoL. However, it is very well possible that the 
perception that the disease is chronic is adequate, as many patients in remission of CS 
and acromegaly remain chronic patients because they require hormonal substitution 
or still need medication to control the disease. Indeed in CS the patients that required 
hormonal substitution had more negative illness perceptions than patients who did not 
30 and two recent studies have shown that patients who need medication to control 
acromegaly reported stronger beliefs about the chronicity of the disease than patients 
who do not use medication, particularly when they realized the medication had to be 
taken lifelong, which had a strong impact on QoL 31,32. This may explain why our group 
and others found that acromegaly patients who are well controlled with somatostatin 
analogues have a worse QoL than patients that are in remission of acromegaly after TS 
33,34. Another explanation for the fact that patients in remission of CS and acromegaly 
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have such negative illness perceptions, is that there is accumulating evidence that both 
diseases have chronic physical effects, for which there is accumulating evidence (as 
discussed below). However, even if the illness perceptions are adequate, it is important 
to be aware that patients have them. Furthermore it should be investigated if these 
illness perceptions can be modulated in order to improve QoL. 
Effects of the previous disease on personality, behavior and the brain
There is increasing evidence that both CS and (to a lesser extent) acromegaly have 
marked effects on the central nervous system, which affects personality and behavior, 
and that these effects are (at least partially) irreversible 35,36. This can be explained by 
the fact that the brain (predominantly limbic structures like the hippocampus and the 
prefrontal cortex) highly expresses glucocorticoid receptors, is are also rich in GH and 
IGF-1 receptors 37,38. Cognitive function, reflecting memory and executive functions, has 
been found to be impaired in patients in long-term remission of both CD and acromegaly 
35,39,40. Furthermore, both patients in remission of CD and acromegaly have more psycho-
pathology and maladaptive personality traits than healthy control subjects 41-43. More-
over it has been found that patients in long-term remission of CS have structural alter-
ations of the brain, compared to matched controls, with smaller grey matter volumes 
in the anterior cingulated cortex, larger grey matter volumes in the cerebellum 44, wide-
spread reductions in white matter integrity 45, and alterations in specific neuronal 
metabolites in the hippocampus 36,46,47. It is not yet proven that the structural brain alter-
ations are the cause of behavioral phenotype of patients in remission of CS, but this 
seems possible. Structura  l changes in the brain may also be present in patients in 
remission of acromegaly as two studies described larger grey and white matter volumes 
and larger hippocampal volumes in patients compared to matched controls. 48,49. 
Patients own perception of QoL
When discussing QoL of patients with pituitary adenomas it is important to realize that 
all of the available questionnaires, including the disease-specific questionnaires, have 
been developed by physicians. For development of the disease-specific questionnaires, 
patients were interviewed, but the interviews were semi-structured about preselected 
topics. A recent study from Leiden used patient focus groups to identify factors that 
influence QoL in patients in remission of pituitary adenomas as perceived and discussed 
by the patients themselves 50. It identified new QoL aspects from the patients’ perspec-
tive, which are not included in the currently available disease-specific questionnaires 
(Figure 3). The most important lesson that can be drawn from this study is that patients 
themselves have to be inquired about their concerns and consulted when we develop 
strategies aimed to improve their QoL.
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In conclusion, the cause of impaired QoL of patients in remission of CS and acromegaly 
is multifactorial. When designing interventions to improve QoL in these patients, patient- 
related determinations of QoL should be taken into account in addition to disease- 
specific factors that are identified by physicians. Furthermore, coping strategies and 
illness perceptions of individual patients should be taken into account. We believe that, 
to optimally improve QoL, each patient should be offered a personalized rehabilitation 
program in which each individual patient is counseled by a team consisting of at least 
Figure 3) QoL in patients with pituitary diseases, as perceived by patients. 
 Bold letters: additional aspects which are not included in available disease-specific 
 questionnaires 50. Reproduced from Andela et al, 2015, with permission of Springer.
QoL
Biological
Psychological
Social
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an endocrinologist, a psychologist and a physiotherapist. Future research should inves-
tigate the effectiveness of such an intervention. 
PART 3
Long-term physical sequelae after treatment of acromegaly 
and Cushing’s syndrome
The third aim of this thesis was to gain more insight in the long term effects of the 
previous period of growth hormone or cortisol hypersecretion on physical health of 
patients in long-term remission of acromegaly and CS. 
Acromegaly
Craniofacial disproportions
The introduction and enormous development of three-dimensional (3D) imaging tech-
niques since the 1970s has created new opportunities for researchers and clinicians 
to accurately assess facial deformities in three dimensions. However, although cranio-
facial disproportions are highly prevalent in patients with acromegaly, no studies had 
been performed to quantify these disproportions with 3D imaging techniques. The 
Department of Oral and Maxillofacial Surgery of the Radboud University Medical Centre 
has a 3D laboratory since 2005, with the aim to implement this technique in the daily 
practice of orthodontics and maxillofacial surgery. They developed methods to fuse 
3D cone-beam computed tomography (CBCT) data (which images the facial skeleton) 
with 3D stereophotogrammetry (which captures the 3D soft tissue facial profile) into a 
3D virtual head model, making it possible to quantify in detail all dimensions of the face 
(bone and soft tissues) 51. With this 3D virtual head model accurate measurements can 
be made with 3D cephalometry 52. Therefore this imaging method is ideal to quantify 
craniofacial disproportions in patients with acromegaly. 
As a pilot study to test this technique in patients with acromegaly, we evaluated the 
differences in craniofacial dimensions with 3D cephalometry between 16 patients in 
long-term remission of acromegaly and 16 control subjects matched one on one for 
gender, age, BMI and ethnicity (chapter 7). We found that the previously described (using 
2D cephalometry) classical bony craniofacial deformities in patients with active acro-
megaly (e.g. a larger mandible and a longer total facial height) persist after long-term 
remission. 3D cephalometry also revealed that patients in remission of acromegaly have 
a wider face at the level of the zygoma and a longer maxilla compared to controls. Further-
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more 3D cephalometry shows that many typical soft tissue deformities persist, even 
after long-term remission. We concluded that significant craniofacial changes persist 
even after long-term remission of acromegaly, and that 3D cephalometry is an attractive 
novel imaging modality to accurately investigate craniofacial disproportions of both soft 
tissue and bony parts of the face in patients with acromegaly. 
We believe that 3D imaging is a very promising technique for patients with acromegaly, 
both in research settings and daily practice. Concerning research, 3D facial analysis has 
been shown to be very reproducible in one individual; even if a considerable amount of 
time has passed between two images 53. This makes it an ideal technique to investigate 
how both the soft tissue and bony parts of the face of patients with acromegaly change 
over time. Indeed our group is already performing a longitudinal prospective study in 
which we regularly capture 3D images of patients in the first 2.5 years after diagnosis. 
Furthermore, recently a standardized method to analyze 3D stereophotographs of the 
hand has been developed in our hospital 54,55. This provides a unique chance to investi-
gate the effects of acromegaly on the soft tissue of the hands. We already found that 
significant soft tissue overgrowth of the hand persists in patients in long-term remis-
sion of acromegaly (article submitted). We are currently also studying changes of the 
hand in a prospective way. 
We expect that 3D imaging will have clinical impact for patients with acromegaly who 
need orthognatic surgery because of jaw problems, as it is already used in daily prac-
tice for the planning of orthognatic surgery 56. Furthermore, with the use of a virtual 
head model, personalized printable osteosynthetic plates or templates to guide posi-
tioning during surgery can be made. Another possible future clinical application of 3D 
imaging in acromegaly may be its use as a diagnostic tool. In the last few years several 
reports have suggested that acromegaly can be detected with facial image analysis 
of normal photographs. With this technique, at present, patients and control subjects 
can be accurately classified in up to 90% of cases 57. It is very well possible that, if a 3D 
stereophotograph is used instead of a regular photograph, the accuracy will be even 
more. Furthermore, because 3D stereophotographs are very reproducible in a patient, 
they can possibly be used to detect a relapse or, if a patient uses medication to control 
his acromegaly, as a disease activity score along with the IGF-1 values. 
Other possible long-term physical sequelae caused by acromegaly and recommen-
dations for future research
To date, besides our pilot study on craniofacial disproportions in acromegaly, no other 
study has investigated the long-term physical consequences of acromegaly in a patient 
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group that is in remission after only TS, compared to a matched control group. Most 
studies have been performed in patients who are biochemically controlled with soma-
tostatin analogues and/or pegvisomant, or in a mixed patient population of patients 
in remission after TS and on medication. The use of medication can have a signifi-
cant effect on long-term outcomes. For example, Claessens et al. found that patients 
with biochemically controlled acromegaly using somatostatin analogues had a 9-fold 
increased risk to develop osteophyte progression compared with patients cured by 
surgery or additional radiotherapy 58. Indeed, it has been postulated that somatostatin 
analogues may normalize serum IGF-1 levels, but that increased GH action in extra-he-
patic tissues can persist 59. Furthermore in previous studies on long-term consequences 
of acromegaly many patients had other hormonal deficiencies that may have affected 
the outcomes. Therefore we conclude that the long-term physical consequences of a 
period of long-standing GH excess per se are still unknown. In order to accurately inves-
tigate the long-term effects of GH excess, studies should be performed in patients 
that are in sustained remission of acromegaly after TS and do not have any (or only 
adequately treated) hormonal deficiencies. Major topics that should be investigated are 
body composition, metabolic outcomes, presence of cardiovascular disease, presence 
of OSAS and eventually mortality rates.
Cushing’s syndrome
Adipose tissue distribution and function
Adipose tissue, and especially visceral adipose tissue (VAT), is an important endocrine 
organ that produces various adipokines which regulate the microenvironment of the 
adipose tissue and communicate with the brain, heart, vasculature, liver, and muscle 60. 
These adipokines can be pro-inflammatory or anti-inflammatory, and their balance 
is crucial in maintaining systemic homeostasis. Common obesity has been shown to 
induce adipose tissue dysfunction (a process that is triggered when macrophages infil-
trate the adipose tissue in response to microhypoxia and rupturing of hypertrophic lipid-
laden adipocytes), which leads to a dysregulated adipokine production 61. This induces 
systemic low-grade, chronic inflammation, which contributes to the development of 
metabolic and cardiovascular diseases 60,61. 
CS almost inevitably leads to a redistribution, of body fat deposition resulting in increased 
abdominal adiposity with increased abdominal VAT and subcutaneous adipose tissue 
(SAT), but reduced peripheral SAT 62. Although the biochemical and molecular mecha-
nisms of the depot-specific actions of glucocorticoids (GCs) on adipose tissue remain 
poorly understood, several mechanisms have been suggested to play a role in the cause 
of centripetal adiposity in CS 62. Firstly, hypercortisolism can affect appetite, resulting 
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in an increased caloric intake, especially of dietary fat 63. Secondly, glucocorticoids 
regulate multiple steps in the process of adipogenesis. They increase the expression 
of numerous genes involved in fat deposition, which are depot specific 64. Thirdly, CS 
causes increased adipocyte lipoprotein lipase activity in abdominal adipocytes with 
decreased lipolytic activity, which results in adipocyte hypertrophy. Furthermore, 
activity of 11β-hydroxysteroid dehydrogenase type 1 activity (11β-HDS-1) which converts 
inactive cortisone to active cortisol in peripheral tissues, may play a crucial role in the 
development of centripetal obesity in CS, as was demonstrated by the case of a young 
girl with CS who did not get the Cushingoid phenotype because of a partial defect in 
11β-HSD-1 activity 65. However, while 11β-HSD mRNA in omental adipose tissue is increased 
in obese individuals compared to lean controls, this was not the case in obese patients 
with active CS 66. Other mechanisms that have been suggested to contribute to centrip-
etal obesity in CS are the inhibition of adipose tissue AMPK activity (AMPK regulates 
carbohydrate and lipid metabolism in adipose tissue) or upregulation of LIM domain only 
3 (LMO-3, a proadipogenetic factor) by glucocorticoids 67. In addition to the centripetal 
adipose tissue distribution in active CS there also seems to be adipose tissue dysfunc-
tion, reflected by the fact that adverse adipocytokine profiles have also been described 
in active CS 67. The role of macrophages in adipose tissue dysfunction in active CS may 
differ from common obesity, as hypercortisolism affects the immune system. 
Patients in long-term remission of CS continue to complain about excess of abdominal 
fat 30. Because a centripetal adipose tissue distribution with adipose tissue dysfunc-
tion is strongly associated with metabolic and cardiovascular diseases, we investi-
gated the adipose tissue distribution, adipocytokine profiles and metabolic risk profiles 
of 58 patients in long-term remission of CS in chapter 8. Each patient underwent an 
extensive clinical evaluation with measurement of weight, height, blood pressure, heart 
rate, skinfold measurements and measurement of circumferences. Serum and plasma 
markers for cardiovascular risk and adipokine and cytokine profiles were determined, 
and a dual-energy X-ray absorptiometry (DEXA) scan was performed to determine body 
fat distribution. We compared the patients with a healthy control group matched one 
on one for age, gender and BMI. We found that patients in long-term remission of CS 
had a greater waist circumference, a smaller thigh circumference, a higher waist-to-hip 
ratio and a higher hip-to-thigh ratio. As measured with DEXA, patients had a higher 
percentage of truncal fat mass, and the truncal fat mass to leg fat mass ratio was also 
higher. Biochemically, patients had lower adiponectin levels, higher leptin levels, and 
higher resistin levels than control subjects, which indicatesan adverse adipokine profile, 
indicative for adipose tissue dysfunction. Furthermore patients had higher triglyceride 
levels. We concluded that even after long-term remission, patients who suffered from 
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CS in the past continue to have a centripetal adipose tissue distribution and an adverse 
adipokine profile. This was independent of the etiology of CS, treatment strategies, 
presence of hormonal deficiencies and comorbidity.
To date only three other, smaller, studies have investigated body composition after 
long-term remission of CS, and they are all case-control studies 68-70. They all concluded 
that patients in long-term remission of CS have a centripetal adipose tissue distribution, 
as we did. Barahona et al. also found an adverse adipokine profile with lower adiponectin 
levels in patients in remission of CS, which supports our finding of an adverse adipokine 
profile of patients in long-term remission of CS 69.
However, no study has yet objectified if the increase in abdominal adipose tissue is 
caused by an increase in visceral adipose tissue (VAT) or subcutaneous adipose tissue 
(SAT). Colao et al. estimated the adipose distribution by solely measuring the waist-to- 
hip ratio and both Barahona et al. and Ragnarsson et al. used conventional DEXA scan-
ning protocols as we did. It is important to differentiate between VAT and SAT because, 
although SAT and VAT are both correlated with metabolic risk factors, VAT is more strongly 
associated with an adverse metabolic risk profile 71. It seems most likely that predomi-
nantly VAT is increased in patients in long-term remission of CS because this is also the 
case in active CS 72, and skinfold thickness (which can be seen as a measure for SAT) was 
not different between patients and controls in our study. However a future study should 
determine if this is really the case. Until quite recently VAT could only be adequately 
measured with computed tomography (CT) or MRI. However these techniques are not 
ideal for assessing VAT in larger number of subjects for different reasons (e.g. lack of 
availability of equipment for research, radiation (for CT), manual measurement of VAT 
which is labor-intensive and requires a lot of experience, costs etc.); therefore, we did 
not use these techniques. Recently a new fully automated method for abdominal VAT 
assessment by DEXA has been developed and proven to be accurate 73. This provides an 
easy technique to investigate the different adipose tissue compartments in patients in 
Cushing’s syndrome and should be used in a future study. 
Furthermore the cause of the persisting centripetal obesity should be investigated. 
We hypothesize that after remission of CS, when the immunosuppressive effect of the 
hypercortisolism is resolved, macrophages will massively infiltrate the hypertrophic 
adipose tissue. Like in obesity, this will trigger a process of local inflammation, which 
will upregulate 11β-HSD1, causing persisting local CS and adipose tissue dysfunction. Our 
group is currently performing a study investigating this issue. 
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Vascular health 
The endothelium is a monolayer of cells that comprises the inner lining of blood vessels. 
Over the past decades multiple studies have revealed the complexity of this semi-per-
meable membrane (which facilitates the passage of substances such as nutrients and 
leukocytes across the vessel wall) and its key role in maintaining vascular homeostasis. 
The endothelium secretes numerous mediators that are necessary for normal vascular 
function by regulating vascular tone, coagulation, modulating immune responses and 
controlling vascular cell growth74.
The most important endothelium-derived vasodilator is nitric oxide (NO), which plays 
multiple roles in preventing atherosclerosis. Other important vasodilatory factors are 
endothelium-derived hyperpolarizing factor (EDHF) and prostacyclin (PGI2). The endo-
thelium is also able to secrete potent vasoconstrictors such as endothelin-1, oxygen 
free radicals, angiotensin-II and thromboxane. Under physiological conditions, the endo-
thelium maintains a fine balance between anti- and prothrombotic states 74. 
The term endothelial dysfunction generally refers to reduced NO bioavailability, through 
decreased endothelial nitric oxide synthase (eNOS) expression. Endothelial dysfunction 
has been documented in most conditions that are associated with atherosclerosis and 
is believed to be an early feature in atherogenesis 75. This point is underscored by the fact 
that endothelial dysfunction can be reversed by interventions that reverse the cause of 
endothelial dysfunction, like lifestyle changes and modulatory drug therapies74,75.
Multiple studies have shown that endothelial dysfunction is present in patients with 
active CS 76-79. It has been suggested that this is mainly caused by the fact that most 
patients with CS have centripetal obesity, impaired glucose tolerance, systemic hyper-
tension, hypercoagulability 80 and dyslipidemia 81. However, glucocorticoids also have 
a direct effect on the vasculature 67. Among other effects, glucocorticoids have been 
shown to downregulate eNOS and eNOS cofactor tetrahydrobiopterin (BH4) and GTP 
cyclohydrolase 1, the rate-limiting enzyme in the production of BH4, thus contributing 
to the reduced endothelium-dependent relaxation 82,83. Furthermore CS induces vascular 
remodeling (patients with CS have an increase in IMT and a higher prevalence of arte-
riosclerotic plaques 84,85), and hypercortisolism probably has a cardiotoxic effect per se 
with an increase in myocardial fibrosis 67. After remission of CS many comorbidities that 
are related to endothelial dysfunction can be reversed (for instance, in active CS 55-88% 
of the patients have hypertension, compared to 24-56% after remission of CS 67). 
However, hypertension remains more prevalent in patients who had CS in the past than 
in the general population. 
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Previously, only two small studies have investigated vascular health in patients in 
long-term remission of Cushing’s syndrome, and both were case-control studies 68,86. 
However they only investigated the presence of atherosclerotic disease,  (Colao et al., by 
assessing intima-media thickness (IMT) and Barahona et al., by investigating the pres-
ence of coronary artery disease detected by multi-slice CT, respectively) which they 
both found to be more prevalent in patients than controls. However, no study has ever 
investigated if endothelial dysfunction is still present in patients in long-term remission 
of CS, although one report suggests that it may be reversible87. 
In chapter 9 we investigated whether micro- and macrovascular health is impaired after 
long-term remission of CS in 63 patients with no or adequately treated comorbidities. We 
measured serum biomarkers associated with endothelial dysfunction, IMT, performed 
pulse wave velocity (PWV) and performed pulse wave analysis. Furthermore endothelium 
dependent and independent vasodilation was studied in both conduit arteries (flow 
mediated dilation (FMD) of brachial artery) and forearm skeletal muscle resistance 
arteries (vasodilator response to intra-arterial acetylcholine, sodium-nitroprusside and 
NG-monomethyl-L-arginine using venous occlusion plethysmography). The results of 
the patients were compared to the results in healthy, one to one, well-matched, control 
subjects. We found no significant differences in outcome measures of vascular health 
between patients and controls. We concluded that after long-term remission, vascular 
health of patients treated for CS, who have no or adequately controlled comorbidities, 
does not differ from healthy gender-, age- and BMI-matched controls. Therefore, the 
effects of hypercortisolism per se on the vasculature seem to be reversible in these 
patients, which strengthens the need for stringent treatment of metabolic comorbidities.
The techniques we used in our study to investigate arterial function are all well vali-
dated88:
PWV represents aortic stiffness, which is determined by structural aspects of the aorta, 
with a minor impact from endothelium-dependent NO. PWV can be assessed with an 
easy to perform, non-invasive procedure, that has been found to be highly reproducible 
with a coefficient of variation of 5-10% 88. As demonstrated by a recent meta-analysis 
of 16 studies with 17,635 subjects, PWV is an independent predictor for cardiovascular 
events, with a reported hazard ratio of 1.2-1.3 for each SD increase in PWV 89. 
FMD in general terms describes any vasodilatation of an artery following an increase in 
luminal blood flow and internal-wall shear stress. However it has conventionally come to 
describe the technique that assesses the peripheral conduit artery diameter following 
a period of distal limb ischemia 90. It therefore investigates macrovascular function. FMD 
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is widely believed to reflect endothelium-dependent and largely nitric oxide-mediated 
arterial function. 
FMD is a well-validated non-invasive technique, but it requires a high degree of operator 
skill 88. The investigators that performed the FMD measurements in our study have been 
highly trained in performing this technique and the coefficient of variation while using 
our protocol was found to be only 6.7% 91, which is lower than most reported coefficients 
of variation for FMD 88. FMD has been found to be an independent predictor of future 
cardiovascular events in some but not all studies 88.
With venous occlusion plethysmography changes in tissue blood flow (mainly in 
muscle resistance arteries) can be measured which is reflected as a change in total 
tissue volume88. This technique therefore mainly assesses microvascular function. We 
assessed the vasodilator response to the infusion of three intra-arterial vasoactive 
medications, which makes it possible to identify the mechanisms that are responsible 
for a possible attenuated response. Acetylcholine investigates endothelium-depen-
dent (mainly NO-dependent) vasodilation. Sodium nitroprusside investigates non-en-
dothelium-dependent vasodilation. The nitric oxide synthase inhibitor NG-monometh-
yl-L-arginine investigates the contribution of nitric oxide to basal vascular tone. The 
main disadvantage of this technique is that the insertion of an intra-brachial arterial line 
is required for the infusion of the vasoactive medications, which makes the technique 
invasive. However, the technique is well validated, and reproducible with reported coef-
ficients of variation of 8-10% during stimulation (however, resting forearm blood flow is 
less reproducible) 92,93. It has been shown to be a strong independent predictor of future 
cardiovascular events 88,94.
Our finding that the vascular health of patients in long-term remission of CS, who have no 
or adequately controlled comorbidities, is not different from healthy gender-, age- and 
BMI-matched controls, is in contradiction with the findings of all previously published 
studies. Both Barahona et al. and Colao et al. found an increased incidence of athero-
sclerosis in patients in long-term remission of CS 68,86, and large epidemiological studies 
suggest that cardiovascular risk remains increased after long-term remission 95-97. In 
contrast to our study, all previous studies included patients with uncontrolled comor-
bidities, so this may explain the differences between their results and ours. However, 
because we also showed that the same patients that participated in our vascular study 
had a centripetal adipose tissue distribution and adverse adipokine profile compared to 
healthy age-, gender- and BMI-matched controls, our finding is also in contrast to what 
we hypothesized. It is possible that we missed subtle differences because of the rela-
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tively small sample size of our study population due to the rareness of the disease and 
the stringent exclusion criteria. For example, there seems to be no significant trend 
towards a lower baseline FBF in the patients, which could be an indication of less muscle 
arterioles or capillaries and this might explain the exercise intolerance that the patients 
complain about. Furthermore, because all techniques used remain surrogate markers 
for the presence of atherosclerosis in vivo, it is possible that there are differences in 
vascular health between patients and controls but that we could not detect them with 
the techniques we used. However, at the moment, there are no more accurate tech-
niques to evaluate vascular health are not available. 
Other possible long-term physical sequelae caused by CS and recommendations for 
future research
Patients in long-term remission of CS continue to complain about fatigue and the 
inability to perform exercise, suggesting a reduced level of physical fitness 98,99. Physical 
fitness level is of particular importance, as previous studies have demonstrated that 
the physical fitness level represents a strong and independent risk factor for all-cause 
mortality as well as cardiovascular disease 100. To objectify if physical fitness levels 
are indeed reduced in patients in long-term remission of CS, our group is performing a 
study that investigates the physical fitness level as measured by peak oxygen uptake 
(VO2 peak) during a maximal exercise stress test in 17 healthy patients (i.e. without comor-
bidities or hormonal deficiencies) in long-term remission of CS and 17 healthy controls 
matched for sex, estrogen status, age, BMI, smoking, ethnicity, and physical activity 
level. Furthermore, in order to hopefully establish the mechanism of decreased physical 
fitness levels, we are taking muscle biopsies to investigate mitochondrial and vascular 
density and eNOS content of the muscles, amongst others. Future research should also 
investigate if CS has long-term effects on cardiac function, as this may also explain 
some of the differences we found. 
The question remains why some patients seem to suffer from more long-term 
effects of CS than others. Both our group, and Ragnarsson et al. found that differ-
ences in polymorphisms of the glucocorticoid receptor might partially explain this 
phenomenon 70, 101. However, because of the relatively small sample sizes for genetic 
studies (58 and 50 patients, respectively) the results of these studies need to be inter-
preted with caution and further research in larger CS populations to replicate these find-
ings is needed before drawing definitive conclusions.
In conclusion, both acromegaly and CS have significant long-term physical effects 
after remission, even in the healthiest of patients. In acromegaly we have shown that 
223
10
10)   Discussion and summary
craniofacial disproportions persist after long-term remission. Patients in remission 
of CS have a persisting centripetal adipose tissue distribution with an adverse adipo-
kine profile. Their vascular health seems to normalize to that of an age-, sex- and 
BMI-matched reference population. However there are still many aspects that have not 
been adequately investigated. Furthermore underlying causes of long-term physical 
effects have to be identified in order to develop targeted interventions (like physical 
rehabilitation programs and medication) that will improve health and thus QoL in these 
patients. Because both acromegaly and CS are very rare diseases it would be advis-
able to perform future research in a multicenter setting, so larger numbers of patients 
can be included in studies with stringent in- and exclusion criteria. Prospective trials 
to investigate the long-term consequences would provide important new information 
about the effects of the diseases in individual patients. This information is not only 
important for patients that have or have had acromegaly or CS, but also for patients that 
use exogenous glucocorticoids or growth hormone.
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Nederlandse samenvatting voor niet-medici
Dit proefschrift gaat over de behandeling en lange termijn gevolgen van twee hormonale 
aandoeningen: 1) acromegalie en 2) het syndroom van Cushing. Zowel acromegalie als 
het syndroom van Cushing zijn zeer zeldzame aandoeningen als ze door het lichaam zelf 
worden veroorzaakt (het syndroom van Cushing kan namelijk ook veroorzaakt worden 
door medicijnen zoals prednison, wat vaak voorkomt) maar ze hebben grote gevolgen. 
Acromegalie wordt veroorzaakt door teveel aan groeihormoon. Groeihormoon zorgt voor 
groei van veel weefsels. In kinderen zorgt dit voor snelle en blijvende lengte groei waar-
door ze “reuzen” kunnen worden. Pijpbeenderen van volwassenen kunnen echter niet 
meer in de lengte groeien. Volwassen patiënten zullen dus niet langer worden, maar 
handen, voeten, de onderkaak, neus, wenkbrauwbogen, lippen, tong en huid groeien wel. 
Het uiterlijk wordt dus veel grover en mannelijk. Juist om dat uiterlijk worden patiënten 
met acromegalie regelmatig gecast in films (onder andere “Jaws” van James bond en 
“Lurch” in de Adams Family). Behalve de veranderingen in uiterlijk worden ook veel andere 
organen door het teveel aan groeihormoon aangetast: veel patiënten krijgen gewricht-
sproblemen met vroegtijdige slijtage, het hart wordt te groot en dit kan hartritme stoor-
nissen en hartfalen veroorzaken en ze hebben een grote kans om suikerziekte en een te 
hoge bloeddruk te ontwikkelen net als obstructief slaapapneu syndroom (snurken met 
grote adempauzes).  Acromegalie zorgt dan ook voor een fors verminderde kwaliteit van 
leven en een 3 x verhoogd risico op overlijden, met name door hart- en vaatziekten, in 
onbehandelde patiënten. 
Het syndroom van Cushing wordt veroorzaakt door een teveel aan het stresshormoon 
cortisol. Het syndroom van Cushing veroorzaakt, net als acromegalie, ook forse uiterlijke 
veranderingen: patiënten worden dikker, waarbij het vet vooral op de buik, in de hals en 
het gezicht gaat zitten. Het syndroom van Cushing kan ook zorgen voor een rood gezicht, 
veel blauwe plekken, een dunne kwetsbare huid, brede rode striae (huidstriemen), meer 
haargroei of juist haaruitval en vocht vasthouden. De spieren worden veel dunner en 
zwakker. Daarbij ontwikkelen veel patiënten suikerziekte, een hoge bloeddruk, een te 
hoog cholesterolgehalte, botontkalking enz. Dit alles zorgt ook voor een fors vermin-
derde kwaliteit van leven en een strek verhoogd risico op overlijden, ook met name door 
hart- en vaatziekten, in onbehandelde patiënten. 
Bij zowel acromegalie als het syndroom van Cushing speelt de hypofyse (in lekentaal ook 
wel het hersenaanhangsel genoemd) een centrale rol. De hypofyse is een klier met de 
grote van een erwt die onderaan de hersenen hangt, vlak achter de aanhechting van de 
neusbrug. De hypofyse geeft veel hormonen af: groeihormoon en ACTH, wat de bijnieren 
aanzet tot het maken van cortisol, maar ook hormonen die de geslachtsorganen, de 
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schildklier en de melkproductie van de borsten aansturen. Daarmee vervult de hypofyse 
een centrale rol in de regulatie van onze hormoonhuishouding. Zowel acromegalie en 
het syndroom van Cushing wordt in de meerderheid van de gevallen veroorzaakt door 
een goedaardig gezwel in de hypofyse (een hypofyse adenoom). Indien dit het geval is, 
is de eerste keus van behandeling bij beide ziektes dan ook het weghalen van dit gezwel 
door een operatie van de hypofyse. Tijdens deze operatie wordt de hypofyse trans-
sphenoidaal benaderd, via de neus en de wiggenbeensholte (de sinus sphenoidalis).
Vroeger gebeurde dit altijd met een microscoop, maar sinds de jaren 90 van de vorige 
eeuw wordt de endoscoop (een slang met een cameraatje aan het uiteinde) steeds 
meer gebruikt. Als het syndroom van Cushing wordt veroorzaakt door een adenoom in 
de hypofyse noemen we het de ziekte van Cushing. 
Hoofdstuk 1, de introductie van dit proefschrift, geeft een uitgebreid overzicht van de 
werking en de anatomie van de hypofyse. De werking en regulatie van groeihormoon 
en cortisol worden verder besproken. Er wordt een overzicht gegeven van mogelijke 
aandoeningen van de hypofyse. De symptomen en gevolgen van de ziektes acromegalie 
en het syndroom van Cushing worden besproken en de verschillende behandeling-
smogelijkheden (transsphenoidale hypofysechirurgie, radiotherapie van de hypofyse, 
medicamenteuze therapie en, voor het syndroom van Cushing, verwijdering van beide 
bijnieren) worden besproken. De doelen van dit proefschrift worden besproken en de 
studies worden geïntroduceerd. 
DEEL 1
Het eerste doel van dit proefschrift was om meer inzicht te krijgen in de rol van de 
endoscopische techniek van trassphenoidale hypofysechirurgie voor de behandeling 
van acromegalie en de ziekte van Cushing. 
Daarom hebben we systematisch de resultaten van endoscopische transsphenoidale 
hypofysechirurgie in het RadboudUMC geanalyseerd. Het RadboudUMC was het eerste 
ziekenhuis in Nederland dat de endoscopische techniek van hypofysechirurgie ging 
gebruiken en we hebben er dus relatief veel ervaring mee. 
In hoofdstuk 2 hebben we de resultaten van endoscopische hypofysechirurgie in 40 
patiënten met acromegalie geanalyseerd. Alle patiënten waren geopereerd tussen 1988 
en 2007 en hadden een hypofyse-adenoom dat 1centimer of groter was (een macro-ad-
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enoom). In 36 patiënten was het doel van de operatie om ze te genezen, en in 20 van 
deze patiënten is dat gelukt (dus 56% van de patiënten was genezen na de operatie). In 
de overige 4 gevallen wisten we voor de operatie al dat het adenoom te groot was (en 
ingegroeid in omliggende structuren) om genezing te bereiken en was het doel van de 
operatie om zoveel mogelijk van de adenoom weg te nemen. We vonden dat de ervaring 
van de neurochirurg van belang was om de kans op genezing te vergroten: In de eerste 5 
jaar nadat de endoscopische techniek geïntroduceerd was in ons ziekenhuis werden er 
18 patiënten geopereerd waarvan er slechts 6 waren genezen na de operatie (dus 33%). 
In de tweede 5 jaar werden er 22 patiënten geopereerd van wie er 14 waren genezen (dus 
63%). In de 2de 5 jaar werden echter ook de patiënten geopereerd van wie we vooraf 
wisten dat genezing niet mogelijk was. Als die patiënten niet worden meegeteld was 
zelfs 77% van de patiënten genezen na de operatie. In 13 mensen was er een complicatie 
(een onvoorziene en ongewenste gebeurtenis) van de operatie maar alle complicaties 
waren mild en van voorbijgaande aard. Voor de operatie was er al sprake van uitval van 
productie van hypofysehormonen in 37,5% van de patiënten (waardoor patiënten deze 
hormonen in medicijnvorm toegediend kregen). Na de operatie was dit het geval 33% 
van de patiënten. 
In hoofdstuk 3 hebben we de resultaten van endoscopische hypofysechirurgie in 86 
patiënten met de ziekte van Cushing geanalyseerd. Deze patiënten werden in ons ziek-
enhuis geopereerd tussen 1998 en 2011. De kans op genezing bleek afhankelijk van de 
grootte van het adenoom op de MRI-scan die voor de operatie werd gemaakt: Zestig 
procent van de patiënten waarbij er op de MRI geen adenoom was gezien was genezen na 
de operatie. Van de patiënten met een adenoom dat kleiner was dan 1 cm (een micro-ad-
enoom) op de MRI was 83% genezen. Van de patiënten met een macroadenoom dat niet 
was ingegroeid in de omliggende weefsels was 94% genezen en van de mensen met een 
macroadenoom dat wel ingroeide was slechts 40% genezen. In 16% van de patiënten 
kwam de ziekte van Cushing terug na mediaan (een soort gemiddelde) 71 maanden. Alle 
complicaties waren mild en van voorbijgaande aard. Voor de operatie had 15 % van de 
patiënten hormonale uitval en na de operatie was dit 35%. 
We hebben de onze resultaten vergeleken met alle resultaten die andere ziekenhuizen 
hadden gepubliceerd over de microscopische methode van hypofysechirurgie. De 
belangrijkste conclusie van hoofdstuk 2 en 3 was dat de kans op genezing bij hypofy-
seoperaties met de endoscopische techniek in patiënten met macroadenomen (vooral 
als ze ingroeien) waarschijnlijk groter is dan bij operaties met de microscopische tech-
niek. Dit is theoretisch gezien ook logisch omdat je met een endoscoop ook om een 
hoek kan kijken en opereren, terwijl dat met de microscopische techniek niet mogelijk 
is. Wij vinden dan ook dat de endoscopische techniek de voorkeur heeft in patiënten 
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met macroadenoom. In patiënten met microadenomen lijken de resultaten tussen de 
endoscopische en microscopische techniek vergelijkbaar. Ook het aantal, de aard en 
ernst van de complicaties lijkt vergelijkbaar tussen beide technieken. 
In theorie heeft de endoscopische techniek van hypofysechirurgie ook voordelen ten 
opzichte van de microscopische techniek als patiënten voor de tweede keer aan de 
hypofyse geopereerd moeten worden, omdat de anatomie dan al veranderd is. Een 
tweede operatie is met name bij de ziekte van Cushing wel eens een goede optie omdat 
er nog geen goede medicamenteuze therapie bestaat. In hoofdstuk 4 hebben daarom de 
resultaten van een tweede hypofyseoperatie in 14 patiënten met de ziekte van Cushing, 
die in ons ziekenhuis waren geopereerd tussen 1999 en 2007, geanalyseerd. Zes van 
deze patiënten was niet genezen na de eerste operatie en in 8 patiënten was de ziekte 
van Cushing teruggekomen nadat ze een tijd genezen waren. Eenenzeventig procent 
van deze patiënten was genezen na de tweede operatie, wat een hoger percentage 
is dan wat gerapporteerd wordt over microscopische hypofysechirurgie. De belangri-
jkste complicatie was lekkage van het hersenvocht in 6 patiënten. Elf patiënten hadden 
hormonale uitval na de tweede operatie, van wie er in 3 patiënten al uitval was voor de 
operatie. We concludeerden dat een tweede hypofyseoperatie via de endoscopische 
techniek een goede behandeling kan zijn voor de ziekte van Cushing.
Als het lukt om acromegalie en het syndroom van Cushing te genezen, dan hebben meer-
dere studies aangetoond dat de kwaliteit van leven fors verbeterd. Maar de kwaliteit van 
leven blijft duidelijk minder dan in mensen die de ziekte niet hebben gehad. Het is nog 
niet duidelijk wat hier de precieze oorzaak van is.
DEEL 2
Daarom was het tweede doel van dit proefschrift om meer inzicht te krijgen in de 
oorzaken van de blijvende verminderde kwaliteit van leven in patiënten die langdurig 
genezen zijn van acromegalie en het syndroom van Cushing.
Omdat het uiterlijk van patiënten met acromegalie fors veranderd tijdens de ziekte, 
hebben we in hoofdstuk 5 onderzocht of onzekerheid over het uiterlijk zorgt voor psychol-
ogische problemen in patiënten die langdurig genezen zijn van acromegalie, en of dit van 
invloed is op hun kwaliteit van leven. Om dit te doen hebben we 73 patiënten gevraagd 
om de Derriford Appearence Scale (de DAS) vragenlijst in te vullen. De DAS vragenlijst 
is ontwikkeld door de plastischechirurgie om te meten wat voor een invloed onzeker-
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heid over iemands uiterlijk heeft op hun psychisch functioneren en dagelijks leven en 
over welk lichaamsdeel mensen dan onzeker zijn. Ook vroegen we de patiënten twee 
bekende vragenlijsten in te vullen die kwaliteit van leven meten: de RAND-36 (een gener-
ieke vragenlijst) en de AcroQol (een ziekte specifieke vragenlijst). De resultaten van de 
patiënten hebben we vergelijken met de resultaten van 57 gezonde controle personen 
die vergelijkbaar waren qua geslacht, leeftijd en BMI (Body Mass Index, een verhouding 
tussen lengte en gewicht die aangeeft of er sprake is van een normaal gewicht of juist 
ondergewicht of overgewicht). We vonden dat significant meer patiënten onzeker waren 
over hun uiterlijk, namelijk 46,6% van de patiënte vergeleken met 22,8% van de gezonde 
controle personen. Vijfentachtig provent van de patiënten die onzeker waren over hun 
uiterlijk waren onzeker over hun gezicht, vergeleken met 23,1 % van de gezonde controle 
personen. In de patiëntengroep was er een duidelijk verband tussen onzekerheid over 
uiterlijk en een slechtere kwaliteit van leven. Er was in de patiëntengroep geen verband 
tussen onzekerheid over uiterlijk en leeftijd of geslacht. We concludeerden daarom dat 
zelfs na langdurige genezing van acromegalie patiënten onzeker blijven over hun uiter-
lijk, met name over hun gezicht, en dat dit zorgt voor psychische problemen en dat het 
een negatieve invloed heeft op hun dagelijks functioneren en kwaliteit van leven. 
In hoofdstuk 6 onderzochten we de kwaliteit van leven in 123 patiënten die langdurig 
genezen waren van het syndroom van Cushing, vergeleken met de kwaliteit van leven 
van 105 gezonde controle personen met een vergelijkbaar geslacht, leeftijd en BMI. Om dit 
te kunnen doen vulden deelnemers aan het onderzoek 7 gevalideerde (zowel generieke 
als ziekte specifieke) vragenlijsten in die kwaliteit van leven meten. Om te onderzoeken 
of de oorzaak van het syndroom van Cushing van invloed was op de kwaliteit van leven 
vergeleken we ook de resultaten van patiënten bij wie het syndroom van Cushing was 
veroorzaakt door een afwijking in de bijnieren met de resultaten van patiënten bij wie 
het syndroom van Cushing was veroorzaakt door een adenoom in de hypofyse. Verder 
onderzochten we of hormonale uitval, de verschillende vormen van behandeling die 
patiënten hadden gehad, de duur van genezing, geslacht en leeftijd van invloed waren 
op de kwaliteit van leven van de patiënten. We vonden dat de kwaliteit van leven van de 
gehele patiëntengroep significant lager was dan de kwaliteit van leven van de gezonde 
controle personen op alle onderdelen van alle vragenlijsten, behalve in patiënten die de 
ziekte van Cushing hadden gehad (dus veroorzaakt door de hypofyse) en geen hormo-
nale uitval hadden: in deze groep hadden de patiënten voor 50% van de onderdelen van 
de vragenlijst een slechtere kwaliteit van leven dan de gezonde controles. Tussen de 
verschillende patiëntengroepen werd geen verschil gevonden, maar vrouwen hadden 
een slechtere kwaliteit van leven dan mannen en ook de duur van genezing was van 
invloed op de kwaliteit van leven. We concludeerden dat kwaliteit van leven verminderd 
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blijft na langdurige genezing van het syndroom van Cushing, en dat dit onafhankelijk is 
van de oorzaak van het syndroom van Cushing, de uitval van hornomen en de soorten 
behandelingen die mensen hebben gehad. De verminderde kwaliteit van leven heeft 
waarschijnlijk diverse oorzaken. Maar omdat de kwaliteit van leven verminderd is in alle 
patiëntengroepen is het waarschijnlijk dat de langdurige blootstelling aan te hoge corti-
solwaardes op zich een belangrijke oorzaak is. 
DEEL 3
Het derde doel van dit proefschrift was om meer inzicht te krijgen in de langdurige 
fysieke gevolgen van acromegalie en het syndroom van Cushing.
Zoals eerder genoemd ondergaan vrijwel alle patiënten met acromegalie behoorlijke 
veranderingen van het gezicht. Na genezing worden deze veranderingen meestal minder 
uitgesproken, maar ze blijven zeker bestaan. Het was vroeger moeilijk om deze veran-
deringen te meten en te kwantificeren. Met nieuwe driedimensionale (3D) technieken, 
die ontwikkeld zijn door de mond-, kaak-, aangezichtschirurgie, is dit wel mogelijk. Deze 
techniek was echter nooit gebruikt in patiënten met acromegalie. In hoofdstuk 7 onder-
zochten we daarom de verschillen tussen het gezicht van 16 patiënten die langdurig 
genezen waren van acromegalie en 16 gezonde controle personen. De patiënten en 
controle personen waren een op een gekoppeld qua geslacht, leeftijd, BMI en etniciteit. 
Van alle deelnemers maakten we 3D foto’s en 3D cone-beam CT-scans. Deze foto’s en 
CT-scans kunnen gecombineerd worden tot een virtueel hoofd, dat zeer gedetailleerd 
informatie geeft over de botten en weke delen en waarop zeer nauwkeurig metingen 
kunnen worden verricht. Met deze techniek bevestigden we dat de klassieke veran-
deringen van het de schedel die ontstaan tijdens acromegalie (zoals de grotere onder-
kaak en een langer gezicht) blijven bestaan na genezing. We vonden echter ook dat 
patiënten een breder gezicht hebben ter hoogte van de jukbeenderen en dat de boven-
kaak langer is. Ook vonden we dat veel veranderingen van de weke delen blijven bestaan 
na langdurige genezing van acromegalie. We concludeerden dat patiënten die lang-
durige genezen zijn van acromegalie nog altijd duidelijke veranderingen hebben van het 
gezicht en dat de nieuwe 3D technieken veel belovend zijn om de veranderingen van 
zowel de weke delen als de botten van het gezicht te onderzoeken in acromegalie, ook 
in een persoon in verloop van tijd. 
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Zoals eerder al aangegeven zorgt het syndroom van Cushing voor gewichtstoename 
waarbij het vet met name op de buik gaat zitten. Studies in mensen met overgewicht 
hebben laten zien dat met name dit buikvet ongezond is. Het geeft ongezonde vetho-
rmonen af (adipokines) en zorgt voor een chronische milde ontsteking in het gehele 
lichaam, waardoor de kans op hart en vaatziekten toeneemt. Na genezing van het 
syndroom van Cushing verliezen veel patiënten veel gewicht, maar het was onduidelijk 
of ze in verhouding meer buikvet houden dan gezonde controle personen. 
In hoofdstuk 8 onderzochten we daarom de vetverdeling, de adipocytokineprofielen 
en metabole risicoprofielen van 58 patiënten die langdurig genezen waren van het 
syndroom van Cushing. Elke patiënt werd uitgebreid onderzocht door een arts waarbij 
lengte, gewicht, bloeddruk, de hartslag, de dikte van de huiplooien en de omtrek van buik, 
heupen, armen en benen werd gemeten. Verder werd er bloed afgenomen om de adipo-
cytokine profielen en andere bloedwaardes die geassocieerd zijn met een verhoogd 
cardiovasculair risico te bepalen. Ook kregen ze een dual-energy X-ray absorbomery 
(DEXA) scan waarmee de hoeveelheid vetmassa, botten en spieren gemeten kan worden 
in verschillende lichaamsdelen. Voor elke patiënt werd een gezonde controle persoon 
gezocht met hetzelfde geslacht, leeftijd en BMI en we vergeleken de resultaten van de 
patiëntengroep met de controlegroep. We vonden dat patenten die langdurig genezen 
waren van het syndroom van Cushing een grotere middelomtrek hadden, een kleinere 
dijomtrek, een grotere middel-heup ratio en een grotere heup-dij ratio. Met de DEXAscan 
stelden we vast dat patiënten een hoger vetpercentage van de romp hadden, en dat de 
verhouding tussen rompvetpercentage en extremiteitvetpercentage(dus arm en been) 
groter was. Veder hadden de patiënten een ongezonder adipokine profiel met lagere 
adiponectinewaardes, hogere leptinewaardes en hogere resistinewaardes (precies 
andersom als gezond is). Ook hadden patiënten een hoger trigliceride gehalte (een 
ongezond vet). We concludeerden dat zelfs na langdurige genezing van het syndroom 
van Cushing de ververdeling veranderd blijft, met in verhouding meer buikvet, en dat dit 
samengaat met een ongezond adipokine profiel. Dit bleek verder onafhankelijk van de 
oorzaak van het syndroom van Cushing (dus hypofyse of bijnier), hormonale uitval, de 
behandelingen die patiënten hadden gehad en of ze nog andere ziektes hadden, zoals 
suikerziekte of een hoge bloeddruk. 
Het syndroom van Cushing zorgt dat de gezondheid van de bloedvaten snel wordt aang-
etast. Dit komt door andere aandoeningen (onder andere suikerziekte en hoge bloed-
druk) die patiënten krijgen maar ook door het hoge cortisol zelf. Patiënten krijgen snel 
aderverkalking. Verder gaat het endotheel disfunctioneren. Het endotheel is een aang-
esloten laag cellen aan de binnenkant van de bloedvaten dat er onder andere voor zorgt, 
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door stofjes zoals stikstofoxide af te geven, dat bloedvaten verwijden en vernauwen als 
dat nodig is (bijvoorbeeld tijdens inspanning en extreme kou). Het was echter nooit goed 
onderzocht of de gezondheid van de bloedvaten zich zou kunnen herstellen na genezing 
van Cushing en of er nog sprake is van endotheeldisfunctie en vroegtijdige aderver-
kalking. In hoofdstuk 9 onderzochten we dus de gezondheid van de bloedvaten van 
63 patiënten die langdurig genezen waren van het syndroom van Cushing maar verder 
gezond waren of alleen goed behandelde andere ziektes hadden. We maten stoffen in 
het bloed die geassocieerd zijn met endotheel disfunctie, maten de dikte van de vaat-
wand in de halsslagader (de intima-media dikte) en de stijfheid van de grote slagad-
ereren met Pulse Wave Velocity en Pulse Wave Analysis. Verder onderzochten we de 
endotheelfunctie door te onderzoeken hoeveel een van de slagaderen in de arm kan 
uitzetten, nadat de doorbloeding van onderarm een voor een kwartier was afgesloten, 
met Flow Mediated Dilation. We onderzochten ook de endotheelfunctie van de kleine 
slagadertjes en haarvaatjes in reactie op verschillende medicijnen (met intra-ar-
teriële infusie van acetylcholine, natrium-nitroprusside en NG-monomethyl-L-arginine) 
met veneuze occlusie plethysmografie. Voor elke patiënt werd een gezonde controle 
persoon gezocht met in ieder geval hetzelfde geslacht, leeftijd en BMI en voor de endo-
theelmetingen nog meer variabelen zoals fitheid en roken. We vergeleken de resultaten 
van de patiëntengroep met de controlegroep. We vonden, in tegenstelling tot wat we 
verwachtten, geen verschillen tussen de patiëntengroep en controlegroep voor alle 
uitkomsten van alle metingen. We concludeerden dat na langdurige genezing van het 
syndroom van Cushing, de gezondheid van de bloedvaten van gezonde patiënten of 
patiënten die goed behandeld zijn voor andere ziekten (zoals suikerziekte, hoge bloed-
druk of uitval van hormonen) vergelijkbaar is met de gezondheid van bloedvaten van 
gezonde controle personen met hetzelfde geslacht, leeftijd en BMI. Het lijkt er daarom 
op dat het effect van cortisol op zich op de bloedvaten teruggedraaid kan worden. Dit 
benadrukt het belang van het goed behandelen van andere ziektes in patiënten die het 
syndroom van Cushing hebben gehad.
Hoofdstuk 10 van dit proefschrift is een samenvatting en een algemene discussie. In 
dit hoofdstuk worden de resultaten van dit proefschrift in perspectief geplaatst. Ook 
worden er aanbevelingen gedaan voor toekomstig onderzoek.
241
11
11)  Appendix - Nederlandse samenvatting
242
List of publications
1  Wagenmakers MA, Netea-Maier RT, van Lindert EJ, Timmers HJ, Grotenhuis JA, Her-
mus AR. Repeated transsphenoidal pituitary surgery (TS. via the endoscopic tech-
nique: a good therapeutic option for recurrent or persistent Cushing’s disease (CD.. 
Clinical Endocrinology 2009; 70: 274-80.
2  Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, van den 
Berg G, Pereira AM, de Herder WW, Wagenmakers MA, Kerstens MN, Zelissen PM, 
Fliers E, Schaper N, Drent ML, Dekkers OM, Gerdes VE. Incidence of venous thrombo-
embolism in patients with Cushing’s syndrome: a multicenter cohort study. Journal 
of Clinical Endocrinology and Metabolism 2011; 96: 3525-32.
3  Wagenmakers MA, Netea-Maier RT, van Lindert EJ, Pieters GF, Grotenhuis AJ, Hermus 
AR. Results of endoscopic transsphenoidal pituitary surgery in 40 patients with a 
growth hormone-secreting macroadenoma. Acta neurochirurgica 2011; 153:1391-9.
4  Postma MR, Netea-Maier RT, van den BG, Homan J, Sluiter WJ, Wagenmakers MA, van 
den Bergh AC, Wolffenbuttel BH, Hermus AR, van Beek AP. Quality of life is impaired 
in association with the need for prolonged postoperative therapy by somatostatin 
analogs in patients with acromegaly. European Journal of Endocrinology 2012; 166: 
585–592.
5  Wagenmakers MA, Netea-Maier RT, Prins JB, Dekkers T, den Heijer M, Hermus AR. 
Impaired quality of life in patients in long-term remission of Cushing’s syndrome of 
both adrenal and pituitary origin: a remaining effect of long-standing hypercorti-
solism? European Journal Endocrinology 2012; 16: 687-95.
6  Wagenmakers MA, Boogaarts HD, Roerink SH, Timmers HJ, Stikkelbroeck NM, Smit JW, 
van Lindert EJ, Netea-Maier RT, Grotenhuis JA, Hermus AR. Endoscopic transsphe-
noidal pituitary surgery: a good and safe primary treatment option for Cushing’s 
disease, even in case of macroadenomas or invasive adenomas. European Journal 
Endocrinology 2013; 169: 329-37.
7  Wagenmakers M, Roerink S, Gil L, Plantinga T, Smit J, Netea-Maier R, Hermus A. 
Persistent centripetal fat distribution and metabolic abnormalities in patients in 
long-term remission of Cushing’s syndrome. Clinical Endocrinology. 2015; 82: 180-7.
243
11
11)  Appendix - List of publications
8  Wagenmakers MA, Roerink SH, Maal TJ, Pelleboer RH, Smit JW, Hermus AR, Berge´ SJ, 
Netea-Maier RT, Xi T. Three-dimensional facial analysis in acromegaly: a novel tool 
to quantify craniofacial characteristics after long-term remission. Pituitary 2015; 
18: 126-34.
9  Roerink SH, Wagenmakers MA, Wessels JF, Sterenborg RB, Smit JW, Hermus AR, Ne-
tea-Maier RT. Persistent self-consciousness about facial appearance, measured 
with the Derriford appearance scale 59, in patients after long-term biochemical 
remission of acromegaly. Pituitary 2015; 18: 366-75/
10  Roerink SH, Wagenmakers MA, Smit JW, van Rossum EF, Netea-Maier RT, Plantinga 
TS, Hermus AR. Glucocorticoid receptor polymorphisms modulate cardiometabolic 
risk factors in patients in long-term remission of Cushing’s syndrome. Endocrine; 
2016 Feb 13. [Epub ahead of print].
244
Dankwoord
Na jarenlang promotieonderzoek is nu eindelijk het moment aangebroken dat ik het 
laatste en meest gelezen hoofdstuk mag schrijven: het dankwoord.
Het is een cliché, maar waar: promoveren doe je niet alleen. Een groot aantal mensen 
heeft bijgedragen aan dit boekje, zowel direct als indirect. Ik wil iedereen daarvoor heel 
hartelijk bedanken! Zonder volledig te willen en kunnen zijn wil ik een aantal mensen in 
het bijzonder noemen. 
Allereerst wil ik alle patiënten bedanken die, vaak meerdere malen, mee hebben gedaan 
aan onze onderzoeken, zonder dat daar iets tegenover stond. Zonder jullie was dit proef-
schrift niet tot stand gekomen! Ik heb met velen van jullie, tussen de onderzoeken door, 
veel tijd doorgebracht en veel gepraat. Door die gesprekken ben ik des te meer gaan 
beseffen hoe belangrijk het is dat hulpverleners echt naar patiënten luisteren en daar 
ook de tijd voor nemen. Dit is een waardevolle les geweest die ik beloof nooit te vergeten. 
Jullie hebben me ook overtuigd dat de endocrinologie het mooiste vak is dat er bestaat, 
en dat goede zorg zeker niet ophoudt als de ziekte is “genezen”. Hartelijk dank daarvoor.
Als vertegenwoordigers van de patiënten wil ik de Stichting Bijnierfonds (voorheen Stich-
ting Vrienden NVACP) en de Bijniervereniging NVACP bedanken. Met name wil ik graag 
Johan Beun en Alida Noordzij noemen: ik ben heel blij dat ik zoveel met jullie heb mogen 
samenwerken. Ik ken weinig mensen die zo bezield zijn in wat ze doen en er zoveel vrije 
tijd voor opofferen. Heel erg bedankt voor jullie grote inzet voor het Cushingonderzoek. 
Verder wil ik de familie Leppink zeer hartelijk bedanken voor hun bijzondere gift aan het 
bijnierfonds, waardoor de sponsoring van ons Cushingonderzoek mogelijk was. Het is 
heel bijzonder dat patiënten zelf op deze manier onderzoek mogelijk maken! 
Prof. dr. Hermus, beste Ad, je nam me aan als arts-onderzoeker toen ik net uit de school-
banken kwam. Ik was nog zeer onervaren, kon nog niet zo goed prioriteiten stellen en 
mijn onderzoek ging in die eerste 9 maanden dan ook alle kanten op. Toch zag je potentie 
in me en bood me een promotietraject aan, wat geresulteerd heeft in dit boekje. Ik wil je 
bedanken voor deze mogelijkheid en het vertrouwen dat je in me stelde. De afgelopen 
jaren heb je me met zeer veel enthousiasme begeleid. Je was er altijd als ik advies nodig 
had, maar je hebt me ook erg vrijgelaten om zelf de verdere lijn van mijn onderzoek te 
bepalen. Hierdoor heb ik kunnen groeien als onderzoeker en weet ik ondertussen dat ik 
heel graag verder wil in de wetenschap. Heel erg bedankt!
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Prof. dr. Smit, beste Jan, je kwam pas halverwege mijn promotietraject van Leiden naar 
Nijmegen en bent sindsdien bezield afdelingshoofd en plaatsvervangend opleider Alge-
mene Interne Geneeskunde. Ondanks dat dit een heel drukke baan is ben je meteen 
intensief betrokken geraakt bij mijn promotietraject. Je bent een ervaren weten-
schapper en ik heb inhoudelijk veel aan de discussies met jou gehad. Maar verder vind ik 
je ook een erg prettig persoon en zeer betrokken arts. Ik ben dan ook heel blij dat jij mijn 
tweede promotor geworden bent. Bedankt voor alles!
Dr. Netea-Maier, beste Romana, toen jij als beoogd copromotor bij mijn onderzoek 
betrokken raakte, was je zelf nog maar net internist-endocrinoloog. Je was opgeleid 
door Ad en in het begin nog duidelijk aan het zoeken naar jouw rol in het onderzoek. 
Ik heb je in de afgelopen jaren, zowel inhoudelijk als qua leiding nemen, enorm zien 
groeien als wetenschapper. Je hebt nu prachtige eigen onderzoekslijnen lopen op het 
gebied van schildkliercarcinoom en acromegalie, en een duidelijke toekomstvisie. Je 
bent daarmee een groot voorbeeld voor mij. Maar ook met hoe je alle drukte op het werk 
en privé combineert, waarbij enige quality time met je gezin heilig is. Dank voor de bege-
leiding de afgelopen jaren!
Prof. dr. Wagenmakers, lieve papa, normaal wordt familie aan het eind van het dank-
woord bedankt. Maar behalve dat jij natuurlijk een geweldige vader bent, ben jij ook 
mijn mentor in de wetenschap. Ik vind daarom dat je achter mijn promotoren en copro-
motor hoort te staan. Van jongs af aan heb ik je met collega’s zoals Dave Halliday uren-
lang, vaak onder het genot van een goede maaltijd en een glas wijn, horen discussiëren 
bij ons aan de keukentafel. Ik was dan niet bij jullie weg te slaan en als het enigszins 
kon stelde ik honderden vragen. Ik ben ervan overtuigd dat in die jaren mijn liefde voor 
endocrinologie, metabolisme en wetenschap is geboren. Jarenlang heb ik het proberen 
te ontkennen, want hoeveel bewondering ik ook voor jouw baan en kennis had, zo hard 
werken als jij altijd deed wilde ik niet. Maar de appel valt niet ver van de boom en ik kon 
het niet laten om, toen jullie in Birmingham woonden, een wetenschappelijke stage 
bij prof. Paul Stewart te gaan volgen. Tot mijn grote verrassing bleek jij mijn dagelijkse 
begeleider…. En dat ging eigenlijk buiten verwachting goed! Sindsdien hebben wij regel-
matig discussies aan de keukentafel, met resultaat: we hebben nu al meerdere geza-
menlijke studies lopen! Jouw grote fysiologische kennis en vermogen om verbanden te 
leggen, aangevuld met mijn klinische ervaring in de endocrinologie is volgens mij een 
goede combinatie, en ik kan heel veel van je leren. Lieve papa, bedankt voor alles en ik 
hoop in de toekomst, naast ons intensieve liefdevolle gezinsleven, nog heel veel met 
je samen te werken! 
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Beste leden van de manuscriptcommissie (prof. dr. N.P. Riksen, prof. dr. J.H.W. de Wilt 
en prof. dr. A.M. Pereira), hartelijk dank dat jullie mijn manuscript wilden beoordelen. 
Prof. dr. Pereira, beste Alberto, ook hartelijk dank voor het inhoudelijk meedenken met 
ons fase 3 Cushingonderzoek en het zoeken naar de laatste zeldzame patiënten die 
geschikt waren voor het vaatartikel.
Mijn ex-kamergenoten, Sean Roerink en Theo Plantinga (de endomaffia). Sean, het is 
natuurlijk vanzelfsprekend dat jij vandaag mijn paranimf bent. Wat ben ik ongelooflijk 
blij dat ze jou hebben aangenomen om mijn onderzoek voort te zetten. We hebben de 
afgelopen jaren heel intensief samengewerkt en dat is me heel goed bevallen. Samen 
met Theo hebben we op onze kamer heel wat afgediscussieerd over wetenschappe-
lijke, maatschappelijke en persoonlijke kwesties, en zijn er veel mooie nieuwe ideeën 
ontstaan. En ook niet onbelangrijk, er is heel wat afgelachen (al kan ik het filmpje van de 
Miami Dolphins nog steeds niet uitstaan). Ik hoop van harte dat onze samenwerking en 
vriendschap nog lang mogen duren! Theo, je hebt ons onderzoek als postdoc op basaal 
niveau naar een veel hoger plan getrokken. Je dacht altijd mee en was nooit te beroerd 
om te helpen. Ik heb veel van je geleerd. Bedankt! 
De neurochirurgen, prof. dr. Grotenhuis, dr. Van Lindert en dr. Boogaarts; beste André, 
Erik en Jeroen, bedankt voor de mooie samenwerking! Ik vond het bijzonder dat jullie 
de gehele analyse van jullie operatieresultaten aan mij overlieten zonder die ook maar 
enigszins te sturen. De kelders met jullie oude archief zal ik niet snel vergeten! Erik en 
Jeroen, bedankt voor het reviseren van alle preoperatieve MRI-scans. 
Mannen van het 3D-lab van de Mond-, Kaak- en Aangezichtschirurgie, en met name 
Thomas Maal en Tong Xi, bedankt voor de prettige samenwerking. 
Prof. dr. Thijssen, beste Dick, ik ben heel blij dat je bent gaan meewerken aan ons onder-
zoek, zowel praktisch met het verrichten van de FMD-metingen, als inhoudelijk. Jouw 
grote fysiologische kennis heeft het Cushingonderzoek veel meer diepgang gegeven. 
Prof. Rongen, beste Gerard, ook jij dacht meteen enthousiast mee over de plethysmo-
grafiemethode waar jij zelf veel ervaring mee hebt. Bedankt dat je onze back-up was 
voor het inbrengen van de arterielijnen, en voor je inhoudelijke bijdrage.
Suzanne Holewijn, bedankt voor het verrichten van alle niet-invasieve vaatmetingen. 
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Alle studenten die met hun wetenschappelijke stage hebben meegedaan aan ons 
onderzoek: bedankt! Tanja, jouw bijdrage aan het QoLCushing-artikel is echt substan-
tieel geweest! En ondertussen ga je bijna zelf ook promoveren op bijnierziekten. Ik ben 
blij dat we collega’s zijn geworden. Linda, jij heb zelfs een half jaar vrijwillig onderzoek 
bij ons gedaan en ik kon veel aan je overlaten. Ik ben blij dat ik na die zes maanden een 
aanbevelingsbrief voor de opleiding tot internist voor je kon schrijven. En binnenkort ben 
je al infectioloog, nog eerder dan ik endocrinoloog. 
Ook alle andere coauteurs wil ik van harte bedanken voor hun bijdrage aan mijn onder-
zoek. 
Thalijn Wolters, wat leuk dat jij nu verder gaat met het acromegalieonderzoek! Onze 
samenwerking is nog relatief pril, maar erg prettig.
De hele afdeling Endocriene Ziekten wil ik bedanken voor de collegiale werksfeer en alle 
hulp tijdens mijn promotietraject en opleiding. Ik ben blij dat ik nog een tijdje bij jullie mag 
blijven! 
Lieve vrienden en familie, bedankt dat jullie me eraan blijven herinneren dat er ook een 
leven naast het werk en mijn gezin is. Ook al spreken we niet zo vaak af als ik zou willen, 
jullie gezelschap is enorm belangrijk voor mij. Bedankt! 
Lieve Luella, dat jij mijn tweede paranimf zou worden was voor mij ook niet meer dan 
vanzelfsprekend. We kennen elkaar al sinds het eerste jaar van onze studie in Diepen-
beek en onze vriendschap is ondertussen heel hecht geworden. Het is heerlijk om met 
jou over promotieperikelen te sparren, maar ook over de andere belangrijke zaken des 
levens. Ook hebben we samen met Onno, Erik en de kinderen veel lol. Ik kijk uit naar veel 
toekomstige skivakanties en weekendjes in Harderwijk!
Lieve Martijn, je vond het vroeger vaak moeilijk als ik met papa weer eens over het werk 
praatte en jij ons niet kon volgen. Dat moet ook erg irritant geweest zijn. Sorry daarvoor! 
De laatste jaren zijn we elkaar over en weer steeds beter gaan begrijpen en ik ben heel 
blij dat jij mijn broertje bent. Ik vind het dan ook extra speciaal dat jij de samenvatting 
voor niet-medici hebt gereviewd! 
Lieve opa, ook al zal je op de dag zelf waarschijnlijk niet bij de verdediging kunnen zijn, 
ik vind het heel bijzonder dat je zo met mijn hele promotie hebt meegeleefd! Lieve oma, 
je maakte je vaak zorgen of ik mijn promotie nog wel af zou ronden nu ik moeder was 
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geworden. Dat kon toch niet allemaal tegelijk? Ik ben heel blij dat ik je nog heb mogen 
vertellen dat het manuscript was ingeleverd. Ik mis je!
Lieve Elly, een betere schoonmoeder had ik me niet kunnen wensen. Heel erg bedankt 
voor je praktische en morele steun in moeilijke en drukke tijden. Lieve Wim, bedankt dat 
je me hebt gestimuleerd om dit promotieonderzoek te gaan doen. Wat zou het mooi zijn 
geweest als we nog veel meer met je hadden mogen delen. 
Lieve mama, zonder jou was ik nooit geworden wie ik nu ben. Jij bent de meest sociale, 
energieke en lieve persoon die ik ken en je staat altijd voor me klaar. Ik hoop dat je nu wat 
meer tijd voor jezelf krijgt, dat heb je heel erg verdiend. Ik hou van je.
Lieve Veerle en Joris, jullie maken mijn leven compleet. Door jullie kan ik opeens wel prio-
riteiten stellen, omdat ik nu pas besef wat echt belangrijk is. De wereld is door jullie ogen 
zoveel mooier en magischer. Ik kijk uit naar alle avonturen die we samen gaan beleven. 
Bedankt dat ik jullie moeder mag zijn!
Lieve Erik, bedankt voor je grote steun, zowel emotioneel als inhoudelijk, tijdens mijn 
hele promotietraject, en voor alle spellingcontroles. Je bent mijn maatje en de liefde van 
mijn leven. Wij halen het beste in elkaar naar boven. Dank je wel dat je me altijd aanmoe-
digt om mijn dromen achterna te gaan, ook als dat niet de makkelijkste weg is. Ik kan 
wel zeggen dat er nu meer tijd voor ons samen komt, maar dat zal gezien onze ambities 
wel weer tegenvallen. Maar dat geeft niet, want de tijd die we samen hebben maakt alles 
goed. Ik hou ongelooflijk veel van je en kijk uit naar een heel mooie toekomst met jou en 
de kinderen.
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